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ABSTRACT 
  Trans-cyclobutane-containing meroterpenoids are a structurally intriguing class of 
natural products with a diverse array of pharmacologically interesting properties. Herein, 
the development of a synthetic strategy for de novo construction of the trans-cyclobutane 
motif is described, which has enabled the first enantioselective total synthesis of the 
cytotoxic natural product, (+)-psiguadial B. Specifically, we have developed a 
photochemical Wolff rearrangement with tandem catalytic, asymmetric addition to a 
ketene generated in situ. To our knowledge, this work represents the first example of this 
methodology used to prepare enantioenriched amides. A palladium-catalyzed, directed 
C(sp3)–H alkenylation reaction is used to quickly build molecular complexity, and two 
distinct epimerization strategies permit access to either enantiomer of the natural product 
from a single enantiomer of organocatalyst. 
  In the course of this work, three different synthetic routes toward (+)-psiguadial B 
were investigated and each is discussed. These studies have led to the execution of 
several challenging key transformations, including an ortho-quinone methide hetero–
Diels–Alder cycloaddition with a cyclohexanone-derived enol ether, a vinyl sulfide-
mediated Prins cyclization, and a modified Norrish–Yang cyclization. Ultimately, the 
successful synthetic strategy was realized by employing a ring-closing metathesis to form 
the strained, 7-membered terpene framework, and a late-stage benzylic 
oxidation/arylation strategy to complete the core of the natural product.  
  Finally, in an effort to apply these key strategy concepts in the context of other 
bioactive trans-cyclobutane-containing natural products, initial results toward a concise 
total synthesis of (+)-rumphellaone A are presented. 
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Chapter 1 
(+)-Psiguadial B and Structurally-Related Natural Products 
 
1.1 INTRODUCTION 
Natural products are a large and diverse class of bioactive molecules that hold 
tremendous potential as medicinal agents. To date, natural products and their derivatives 
rank among the most successful lead compounds that have been developed into drug 
candidates and evaluated in clinical trials.1 Although 33% of approved drugs are derived 
from natural products,2 the pharmaceutical industry has shifted away from natural-
product based discovery programs over the last two decades,3 due in part to prohibitively 
difficult synthetic challenges associated with accessing architecturally complex 
molecules. Moreover, chemical derivatization of natural product-based scaffolds is often 
non-trivial, hindering the systematic study of structure activity relationships (SAR).  
To the synthetic chemist, it is precisely these challenges that drive the pursuit of 
natural product total synthesis. The intriguing structural frameworks of these molecules 
provide a platform to inspire the invention of new chemical methods that facilitate rapid 
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construction of particularly formidable synthetic targets. In this regard, we strive for 
creativity as well as efficiency when designing new synthetic strategies, unencumbered 
by the notion that we may only utilize the tools that are already at our disposal. From this 
ideal perspective, only the limits of imagination preclude us from advancing the frontiers 
of chemical science. To the extent that we are successful in developing novel 
transformations with the goal of improving synthetic efficiency, there is no better venue 
to showcase the versatility of a new method than in the context of total synthesis.  
 
1.2 DIFORMYL PHLOROGLUCINOL MEROTERPENOID NATURAL 
PRODUCTS 
 
As their name suggests, meroterpenoids are classified as hybrid natural products 
that are partially derived from terpene biosynthesis pathways. The term “phloroglucinol” 
refers to a 1,3,5-trihydroxybenzene unit, which arises in nature from malonyl-CoA by a 
series of condensation and cyclization events facilitated by polyketide synthases. 4 
Specifically, diformyl phloroglucinol constitutes a highly oxidized arene containing two 
aldehydes and three phenols in an alternating arrangement (see Figure 1.1). Diformyl 
phloroglucinol meroterpenoids therefore possess two distinct sets of physiochemical 
properties: the terpene portion is often stereochemically-rich, largely hydrophophic, and 
chemically inert, while the diformyl phloroglucinol motif is flat, aromatic, reactive, and 
has great capacity for multiple hydrogen-bonding interactions. The fusion of these 
disparate features in one molecule makes this class of natural products particularly 
fascinating and has captivated the interest of chemists and biologists alike for decades.  
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1.2.1 Biological Activity and Medicinal Properties 
Phloroglucinol-containing natural products are a large class of bioactive 
molecules, comprising over 700 compounds known to date.5 Diformyl phloroglucinol 
meroterpenoids are a subset of this family whose diverse medicinal properties5,6 are 
exemplified by molecules such as euglobal-In-3 (1),7 robustadial A (2),8 sideroxylonal B 
(3),9 and marcocarpal C (4, Figure 1.1),10 which exhibit anti-cancer, anti-malarial, anti-
bacterial, and anti-viral bioactivity, respectively. Owing to their therapeutic potential, 
there is growing interest in preparing various derivatives of these natural products, which 
have recently appeared in patents describing their utility as neurotransmitter-reuptake 
inhibitors for the treatment of a variety of neurological disorders such as depression, 
obesity, addiction, and Alzheimer’s disease.11 Given the intriguing bioactivity of diformyl 
phloroglucinol meroterpenoids, many research groups continue to pursue the isolation 
and characterization of new molecules in this family that are derived from natural 
sources.12 In particular, the extracts of plants used in traditional folk medicine have long 
served as rich sources of bioactive natural meroterpenoids with novel structures. 
Figure 1.1. Bioactive diformyl phloroglucinol terpenes 
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1.2.2 Synthetic Aspects: Hetero-Diels–Alder Strategies 
Decades of synthetic studies have led to a variety of chemical tools for the 
construction of diformyl phloroglucinol meroterpenoids.5 In particular, those containing 
central pyran rings prompt a hetero-Diels–Alder (HDA) cycloaddition as an obvious 
retrosynthetic disconnection. Such transformations commonly proceed with hetero-dienes 
known as ortho-quinone methides (o-QM, i.e. 7 and 17, Scheme 1.1). These highly 
reactive species can be generated in situ using a variety of methods,13 often involving loss 
of a stable molecule, such as thiophenol or water. Notable examples of concise, 
biomimetic syntheses using this strategy to rapidly assemble the frameworks of several 
prototypical diformyl phloroglucinol meroterpenoid natural products include early work 
by Chiba,14 Tatsuta,15 and Singh.16  
Scheme 1.1. Synthesis of diformyl phloroglucinol meroterpenoids via o-QMHDA 
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1.3 TRANS-CYCLOBUTANE-CONTAINING NATURAL PRODUCTS 
1.3.1 Natural Products Derived from β-Caryophyllene 
Cyclobutane-containing natural products are a structurally intriguing class of 
metabolites produced by a variety of organisms, with over 210 compounds in this family 
displaying a wide range of interesting bioactive properties.17 While 4-membered rings are 
relatively common among natural products, trans-fused cyclobutanes are rare due to the 
strain associated with this stereochemical arrangement, and almost exclusively found in 
molecules derived from β-caryophyllene (21). First isolated in 1834, 21 is an optically 
active, naturally abundant sesquiterpenoid from which a multitude of polycyclic natural 
products originate.18 Biosynthetically, 21 is proposed to arise by caryophyllene synthase-
mediated intramolecular cyclization of farnesyl pyrophosphate (18, Figure 1.2a) to   
Figure 1.2. Trans-cyclobutane natural products derived from β-caryophyllene 
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generate humulyl cation 19,19 which undergoes subsequent ring closure to produce the 4-
membered ring. This enzymatic process is proposed to guide the stereoselective 
formation of the unusual trans-fused cyclobutane in 21. Further cationic, enzyme-
mediated rearrangement of 21 leads to divergent biosyntheses of many complex 
terpenoid scaffolds.18,20 Indeed, the structural hallmarks of caryophyllene are clearly 
evident in a diverse array of natural products, especially those displaying the trans-
cyclobutane motif (22–29, Figure 1.2b).21 Unsurprisingly, the unique structural features 
of β-caryophyllene and related natural products have generated much interest from the 
synthetic community in the last 50 years. 
 
1.3.2 Seminal Synthetic Approaches Toward Natural Products 
Containing Trans-Fused Cyclobutanes  
In 1963, Corey and coworkers reported the first landmark total synthesis of β-
caryophyllene (21, Scheme 1.2). 22  Construction of the cyclobutane ring was 
accomplished at the outset via a regioselective, photochemical [2+2] cycloaddition 
Scheme 1.2. Corey’s total synthesis of β-caryophyllene via [2+2] and fragmentation 
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between isobutylene (30) and 2-cyclohexenone (31). Interestingly, the reaction produced 
unstable trans-fused cyclobutane 32 as the major diastereomer,23 which was subsequently 
epimerized to the more stable cis cyclobutane 33 upon treatment with KOH in methanol. 
Elaboration to a diastereomeric mixture of tosylates 34 and 35 then enabled formation of 
the 9-membered ring by a Grob fragmentation, forming either the E or Z olefin through 
the antiperiplanar transition states 34' and 35', respectively. Addition of tert-butanol then 
facilitated base-mediated epimerization at C9 over the course of 15 hours to produce 
penultimate ketone 36. A final Wittig methylenation reaction proceeded smoothly to 
furnish the natural product in 13 steps.  
 Twenty years after Corey’s initial disclosure, Oishi and coworkers reported a 
markedly different strategy toward 21 (Scheme 1.3).24 Cyclobutene 39 was accessed 
using Brannock’s method for enamine-promoted formal [2+2] cycloaddition between 37 
and 38 under thermal conditions. 25  Base-mediated conjugate addition of ethyl 2-
(phenylsulfonyl)acetate established the thermodynamically preferred trans-
stereochemistry across the cyclobutane ring, and following selective decarboxylation and  
Scheme 1.3. Oishi’s total synthesis of β-caryophyllene via intramolecular alkylation 
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 re-esterification, provided phenylsulfone 40 in 62% over the 4-step sequence. Exposure 
of nitrile 41 to KOt-Bu triggered formation of a thiolate anion (not shown), which 
underwent intramolecular alkylation to give 13-membered macrocycle 42 after oxidation 
to the corresponding sulfoxide. In a key step, ring contraction was achieved via acyl 
transfer reaction upon treatment of 42 with LDA in the presence of HMPA. With the 9-
membered ring secured, reductive cleavage of the aryl sulfoxide and Wittig 
methylenation then delivered β-caryophyllene in a total of 22 steps.   
 Shortly after Oishi’s report, Paquette and Sugimura described the first asymmetric 
synthesis of a related β-caryophyllene-derived natural product, (–)-punctatin A (22, 
Scheme 1.4).26 Enantioenriched Hajos–Parrish ketone (44)27 was advanced to bicyclic 
ketone 45, which was conformationally poised to undergo stereoselective Norrish–Yang 
cyclization28 upon irradiation with 254 nm light. This elegantly employed transformation 
is known to proceed by excitation of the carbonyl π system to the photoexcited triplet 
state, which exhibits diradical character29 (i.e. 46). The oxygen-centered radical then 
abstracted a proximal hydrogen atom (highlighted in red), which resulted in two carbon-
centered radicals (i.e. 47) that recombined to furnish cyclobutanol 48. This intermediate 
Scheme 1.4. Paquette’s total synthesis of punctatin A via Norrish–Yang cyclization 
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was then converted to the natural product in a further 8 steps.  
 These early reports exemplify some common synthetic strategies to construct 
cyclobutanes in natural product total synthesis. Moreover, the challenges associated with 
building this motif with the requisite trans-fused arrangement, in high yield and 
stereoselectivity, are apparent. Although many lessons have been learned through the 
synthetic efforts aimed at accessing terpenes such as β-caryophyllene (21) through total 
synthesis, others have exploited the natural abundance of 21 by utilizing it as a starting 
material in the semi-synthesis of other biosynthetically related natural products. 
 
1.3.3 Biomimetic Strategies for Semi-Synthesis 
Caryolanemagnolol (23) is a sesquiterpene-neolignan isolated from the bark of 
Magnolina obovata that exhibits striking neurological activity,30 as well as demonstrated 
in vivo efficacy for improving motor function in patients with Huntington’s disease.31 In 
2010, Siegel and coworkers reported a concise semi-synthesis of 23, proceeding in just 2 
steps from 21, according to the biosynthetic proposal for its origin (Scheme 1.5).32 
Selective epoxidation of the more electron-rich, trisubstituted olefin in 21 was 
accomplished to afford 49 with moderate diastereoselectivity. Notably, Shi’s catalyst was 
used to override the substrate’s inherent preference to produce the undesired α-epoxide. 
Scheme 1.5. Siegel’s semi-synthesis of caryolanemagnolol 
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Transannular epoxide opening was effected with diphenyl phosphate, thus generating 
bridgehead carbocation 50, which was trapped by magnolol to provide direct access to 
the natural product, albeit in a modest 15% yield.33  
 Concurrent with these studies, Lee and coworkers explored a three-component, 
one-pot assembly of the diformyl phloroglucinol meroterpenoids, guajadial (24) and 
psidial A (25).34 Knoevenagel condensation between benzaldehyde (51) and diformyl 
phloroglucinol 16 produced 2-hydroxybenzyl alcohol 52, which can extrude water to 
generate ortho-quinone methide (o-QM) 53 in situ (Scheme 1.6). This reactive hetero-
diene then underwent [4+2] cycloaddition with the most stable βα-configuration of 2135 
through either of the two transition states depicted below to yield 24 as the major 
diastereomer isolated from the reaction. Alternative approach of either cis or trans-53 
accounts for the complementary stereochemical outcome observed in 25, while the 
formation of 54 may arise via cycloaddition with the diastereomeric ββ-conformation of 
21. As in Siegel’s case, although this biomimetic cycloaddition (vide infra) proceeds in 
low overall yield, semi-synthesis from 21 benefits from exceptionally expedient access to 
caryophyllene-derived trans-cyclobutane-containing natural products. 
Scheme 1.6. Lee’s semi-syntheses of guajuadial and psidial A 
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1.4 THE PSIGUADIAL FAMILY OF NATURAL PRODUCTS 
1.4.1 Isolation of Psiguadials A–D 
In 2010, Shao and coworkers reported the discovery of psiguadials A (55) and B 
(56), two new phloroglucinol meroterpenoids (Figure 1.3)36 isolated from the leaves of 
Psidium guajava, a plant that has been used in traditional Chinese medicine for centuries 
to treat a variety of ailments, including diabetes and hypertension.37 Two years later, the 
same group disclosed additional members of this family, psiguadials C (57) and D (58).38 
From a structural standpoint, the psiguadials are characterized by a polycyclic terpene 
unit featuring a 3- or 4- membered ring, which is fused to a diformyl phloroglucinol arene 
through a cyclic ether bearing a phenyl substituent at C1'. 
Figure 1.3. Structures and biological activity of psiguadials A–D 
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In addition to its biological significance, 56 is also notable as the only member of 
the psiguadial family to possess a trans-cyclobutane ring, which is fused to a bridging 7-6 
strained polycyclic terpene that includes an all-carbon quaternary center at C1. Coupled 
with the presence of six stereogenic centers throughout the molecule, we became 
interested in pursuing a total synthesis of 56 to address the synthetic challenges presented 
by these unique structural features. While we ultimately sought to develop a novel 
synthetic strategy toward trans-cyclobutane containing natural products, it is instructive 
to consider nature’s unified approach toward construction of the psiguadial family. 
 
1.4.2 Proposed Biosynthesis of the Psiguadial Family 
In their isolation report of psiguadials C and D, Shao et al. provided an extensive 
and detailed proposal for the biosynthetic origins of the broader natural product family.38 
Beginning with benzoyl-CoA (59), a plausible series of condensation, cyclization, and 
enolization events result in the formation of 61,4,39 a compound that has also been 
extracted from Psidium guajava previously (Scheme 1.7). Oxidation and loss of water 
from a protonated species results in benzylic cation 62. This highly electrophilic species 
can engage one of the two olefins in the bicyclogermacrene (64), a terpene that like β-
caryophyllene, is also derived from farnesyl pyrophosphate (18). Reaction between 64 
and 62 produces cyclopropylcarbinyl cation E-65, which triggers either of two cationic 
cyclization pathways; C-C bond formation forges the 7-5 ring system that leads to 55, 
while 58 arises by isomerization of the olefin, followed by trapping of carbocation in Z-
65 with the pendant phenol. Finally, 57 may be produced by oxidation of the 
trisubstituted olefin in 58.  
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Scheme 1.7. Proposed biosynthesis of psiguadials A, C, and D 
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employing a modified Corey–Winter protocol41 for installation of the trisubstituted olefin 
with the requisite E-configuration.  
With 64 in hand, the authors validate the notion that this terpene is indeed a 
plausible biosynthetic precursor to 55, 57, and 58 by applying Lee’s strategy to access 53 
in situ, which engages with 64 according to Shao’s proposal (Scheme 1.8b).38 However, 
64 proved quite sensitive under Lee’s previously established thermal reaction conditions, 
leading to the development of a milder protocol to effect the biomimetic cationic cascade 
cyclization, which provided 58 and 55 in a modest 7% and 1% yield, respectively. 
Alternatively, it was found that reaction with a more reactive o-QM precursor (71) 
allowed psiguadial D (58) to be isolated in an improved 26% yield. Psiguadial C (57) was 
then obtained by epoxidation of 58 using trifluoroperacetic acid in near quantitative yield.  
Scheme 1.8. Cramer’s biomimetic synthesis of psiguadials A, C, and D 
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 In the same year, an analogous semi-synthesis of psiguadial B (56) appeared in 
the author’s thesis,42 utilizing the same reaction conditions with β-caryophyllene (21) in 
place of 64 to furnish the natural product in 10% yield (Scheme 1.9a). As with their 
published biomimetic syntheses of the other members of the psiguadial family, this study 
lends support for Shao’s biosynthetic proposal (Scheme 1.9b),38 which is initiated by 
ring- opening of the related natural products, guajadial (24)37a and psidial A43 (25). The 
resulting carbocation 72 can isomerize to 73 through a series of hydride shifts, and suffer 
transannular attack by the exo-olefin to generate bridgehead cation 74. As demonstrated 
by Seigel (see Scheme 1.5), this species can then be trapped by the pendant phenol to 
form the central pyran ring and furnish 56. 
Scheme 1.9. Cramer’s biomimetic semi-synthesis of psiguadial B 
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It is interesting to note that this cationic cascade cyclization stands in contrast to a 
hypothetical, concerted hetero-Diels–Alder cycloaddition with 53 from the convex face 
of anti-Bredt olefin 7544 (Figure 1.4). If such a reaction were possible, it would be 
expected to provide the corresponding product 76 with the incorrect relative 
stereochemistry between C8, C9, and C1'. Thus, the three-dimensional profile of the 
natural product also provides some evidence for the cationic pathway outlined above.  
Figure 1.4. Hypothetical “biomimetic” concerted hetero-Diels–Alder cycloaddition 
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leave, thus generating tertiary carbocation 82. This species underwent intramolecular 
cyclization with the pendant allyl silane through a chair-like transition state (i.e. 82'). 
Cation 83 was then formed in the presence of Lewis acid 86 and attacked by the exo-
olefin, thus establishing the 7-membered ring. The reaction cascade was terminated by 
trapping of bridgehead cation 84 with an equivalent of chloride released from 86 to 
furnish bicycle 85 in quantitative yield, as a single diastereomer.  
 Scheme 1.10. Tanino’s progress toward a total synthesis of (±)-psiguadial B 
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convert the maleic anhydride in 88 into the trans-fused cyclobutane ring of 56 are 
currently ongoing.47 To the best of our knowledge, the work reviewed herein constitutes 
the only synthetic studies toward psiguadial B.  
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Chapter 2 
First Generation Synthetic Strategy Toward (+)-Psiguadial B and  
Development of a Catalytic, Asymmetric Wolff Rearrangement†  
 
2.1 INTRODUCTION 
Owing to the diverse and intriguing bioactive properties of diformyl 
phloroglucinol natural products, we became interested in pursuing (+)-psiguadial B (56) 
as a target for total synthesis. As discussed in Chapter 1, biomimetic approaches to 
phloroglucinol meroterpenoids are well precedented, and often provide direct access to β-
caryophyllene-derived natural products. 1  However, we recognized that an abiotic 
synthesis of 56 would allow us to develop new chemistry and strategy concepts that we 
hoped would be useful in broader synthetic contexts. We began by focusing on the design 
of a de novo approach to construct the trans-fused cyclobutane in 56—a task for which a 
                                                
† Portions of this chapter were adapted from the following communication: Chapman, L. 
M.; Beck, J. C.; Wu, L.; Reisman, S. E. J. Am. Chem. Soc. 2016, 138, 9803, DOI: 
10.1021/jacs.6b07229, copyright 2016 American Chemical Society. The research 
discussed in this chapter was completed in collaboration with Jordan C. Beck, a graduate 
student in the Reisman Lab. 
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practical solution was not readily apparent, particularly in the context of asymmetric 
catalysis.  
 
2.1.1 C(sp3)–H Activation: A Guiding Strategic Bond Disconnection  
From a synthetic standpoint, we reasoned that the primary challenge posed by 56 
is construction of the central bicyclo[4.3.1]decane, which is trans-fused to a cyclobutane. 
Specifically, we identified the C1−C2 bond, which links the A and C rings through 
vicinal stereogenic centers, as a strategic disconnection (Figure 2.1). On the basis of this 
analysis, we became interested in forming this bond by a Pd-catalyzed C(sp3)−H 
alkenylation reaction between cyclobutane 89 and vinyl iodide 90. Although the direct 
product of this reaction would be a cis-cyclobutane, we envisioned accessing the 
thermodynamically more stable trans-cyclobutane through an epimerization process.  
Figure 2.1. Identification of a guiding strategic bond disconnection 
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(Scheme 2.1a). While this example lent credence to our proposed C(sp3)−H alkenylation 
reaction, there was some uncertainty about whether the proximal methyl C−H bonds in 
89 would intervene unproductively. Concurrent with our own efforts, Chen and 
coworkers described a general C(sp3)−H alkylation reaction,4 including an example of a 
simple cyclobutane substrate (96, Scheme 2.1b). More recently, Yu has applied a distinct 
amide-based directing group in combination with chiral ligand 100 to access 
enantioenriched arylated cyclobutanes (Scheme 2.1c). 5  These studies highlight the 
general utility of this substrate class in C(sp3)−H activation chemistry.  
Scheme 2.1. Relevant C(sp3)–H functionalizations of cyclobutane substrates 
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2.1.2 Retrosynthetic Analysis: Precedent and Anticipated Challenges 
Mapping this strategic bond construction onto a more complete retrosynthesis of 
(+)-psiguadial B (56), we planned to construct the 7-membered ring at a late stage in the 
synthesis via intramolecular Prins cyclization of a pendant vinyl sulfide onto an 
oxocarbenium ion derived from cyclic ketal 101 (Figure 2.2). Although ring closure to 
form this strained system was expected to be challenging, the Prins reaction has been 
successfully used for the preparation of complex, polycyclic ring systems. 
Figure 2.2. Retrosynthetic analysis 
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Scheme 2.2. Examples of Prins cyclizations to form medium-sized rings 
 
functionalized 2-hydroxybenzyl alcohol derivative (e.g. 103) was expected to provide an 
E-configured ortho-quinone methide (o-QM) in situ,10 which was envisioned to undergo 
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published alongside their synthesis of (±)-alboatrin (121), which utilized an analogous o-
QMHDA strategy (Scheme 2.3b).13 Notably, both reactions required a three- to tenfold 
excess of the enol ether, and suffered from formation of unwanted spiroketal side 
products, 117 and 122, which resulted from isomerization to exocyclic enol ether 115 
under the reaction conditions. Recently, Xie and coworkers leveraged this same 
disconnection to prepare (±)-Paeoveitol (125) as a single diastereomer in just 2 steps 
from benzofuran 123.14  
Scheme 2.3. o-QMHDA reactions with cyclic enol ethers in total synthesis 
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transition state that exerts high levels of enantiocontrol in formation of the corresponding 
cyclic N,O-acetal products 128. 
 
Scheme 2.4. Enantioselective o-QM enamide cycloaddition reaction 
 
Although the feasibility of this reaction was uncertain at the time, we were 
hopeful that successful implementation of this strategy would serve to 1) quickly build 
complexity in a convergent sense, 2) provide a means to install a highly oxidized arene, 
and, 3) set two vicinal stereocenters in a single step. With respect to the relative 
stereochemistry between C9 and C1', Pochini has observed the diastereoselectivity we 
desired for elaboration to 101 with acyclic vinyl ethers, such as 132, which were found to 
react with E-configured o-QM 131 through an endo transition state (Scheme 2.5a).10 
Accordingly, it was expected that phenyl substitution of the proposed o-QM 136 would 
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Scheme 2.5. Diastereoselectivity of o-QMHDA reactions with E-enol ethers 
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 101 with the desired anti relationship of the adjacent protons (Scheme 2.5b). 
With respect to the stereochemistry about C9 and C1' in an absolute sense, the 
proposed o-QMHDA reaction could give rise to two possible endo diastereomers: 101 
and 137 (Figure 2.3). Pettus has shown that chiral enol ethers may be used to achieve 
facial selectivity in substrate-controlled cycloadditions with o-QMs.16 Conformational 
analysis of the proposed substrate reveals that the large cyclobutane substituent should 
most likely occupy an equatorial position, resulting in twist-chair conformation 135'' in 
which the axial methyl could potentially block the top face. This suggested that the o-QM 
might prefer to approach from the bottom instead, leading to 101 with the stereochemical 
arrangement found in (+)-psiguadial B (56). However, we were cognizant of the fact that 
this “blocking” methyl group is relatively small and might not impose the steric influence 
that could be required for high levels of diastereoselectivity. Moreover, the methyl group     
Figure 2.3. Analysis of facial selectivity of proposed o-QMHDA cycloaddition 
 
Me
H
H
Me
Me
OMeMe
H
OMe
SPh
Me
O
Ph
OMeH
H OR
SPh
O
Ph
Me
RL
OMe
Me
RL
OMe
OR
Me
O
Ph
OMeH
H OR
SPh
OR
Me
Me
Me
Me
Me
Me
H
HMe
Me
OR
OR
SPh
Me
OMe
SPh
135 135'
O
Ph OR
OR
o-QM approach 
from bottom face
o-QM approach 
from top face
desired product
135''
101 137
136
136
Chapter 2 – First Generation Strategy Toward (+)-Psiguadial B 32 
is situated further from the reaction center than in example substrates that exhibit good 
substrate diastereocontrol. Thus, it remained unclear whether the chiral information built 
into enol ether 135 would impart facial selectivity to give the desired endo diastereomer 
101. Nonetheless, we elected to pursue the development of this key reaction. 
 Continuing on with our retrosynthetic analysis, 102 was envisioned to be 
accessible in short order from the product of the directed C(sp3)−H alkenylation reaction, 
joining fragments 89 and 90. In turn, we expected that cyclobutamide 89 could be easily 
prepared from known diazoketone 30 via photochemical Wolff rearrangement.17  
 
2.2 FORWARD SYNTHETIC EFFORTS: RACEMIC STUDIES 
Since our immediate objective was to evaluate the practicality of the C(sp3)–H 
alkenylation reaction, a straightforward synthesis of cyclobutamide 89 was first pursued 
as a racemate (Scheme 2.6). In the forward direction, the synthesis begins with an 
adaptation of a known route to access the expensive, yet commercially available 2,2-
dimethylcyclopentanone (142).18 Alkylation of isobutyronitrile (138) with 1-bromo-3-
Scheme 2.6. Scalable, racemic route to access key cyclobutamide 
 
NC
MeMe
Cl
NC Me
Me
i-Pr2NH, n-BuLi
THF, –78 °C
NaI, acetoneBr Cl
NC
MeMe
I
reflux
(89%)
(95%)
O
NaH, Et2O, 0 °C
H
O
OEt
O
H
O
CH2Cl2, –10 °Cthen, 1M oxalic acid
t-BuLi, Et2O, –78 °C;
(94%) (95% overall)
p-ABSA, Et3NMe
Me
Me
Me
O
N2
THF/H2O
hυ, pyrex
NaHCO3
N
NH2
EDCI, CH2Cl2, rt
pyrdine
OH
O
N
H
O
N
(84%)
(74%)
Me
Me
Me
Me
Me
Me
commerically
avilable
138 140 141
104 145
146
144
(±)-89
142
139
143
Chapter 2 – First Generation Strategy Toward (+)-Psiguadial B 33 
chloropropane (139) and subsequent Finkelstein reaction proceeded smoothly to give 
alkyl iodide 141 in near quantitative yield. Next, lithium–halogen exchange, followed by 
cyclization and hydrolysis provided access to large quantities of 142. Formylation then 
allowed for a Regitz-diazo transfer reaction, furnishing diazoketone 104 in excellent 
yield.17 Finally, photolytic ring contraction of 104 in the presence of aqueous base 
afforded cyclobutane carboxylic acid 145, which was easily coupled with 8-
aminoquninoline (146) under standard conditions to deliver (±)-89 in good overall yield.  
Upon subjection of 89 to reported Pd-catalyzed C(sp3)–H functionalization 
reaction conditions, we were pleased to detect a combined 42% yield of the desired 
coupling products 147 and 148 (Table 2.1, entry 1). A brief survey of reaction parameters 
revealed that increased concentration of pivalic acid shut down the desired reaction, 
whereas omission of this additive gave a single diastereomer (entries 2 and 3). While 
alternative bases led to lower overall conversions (entries 4 and 5), solvent choice proved 
critical, with the highest yields observed in TBME (entry 8). Although most reactions 
Table 2.1. Optimization of the racemic C(sp3)–H alkenylation reaction 
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favored formation of the cis diastereomer 147, interestingly trans 148 predominated 
under certain conditions (entries 4 and 9). Analysis by mass spectrometry also suggested 
the formation of a bis-olefinated side product19 and appreciable amounts of spirocyclic 
lactam 149, which presumably arises via intramolecular aza-Michael addition of the 
corresponding imidate (not shown) into the proximal enone.20 
Since the proposed mechanism of this transformation2a,4 proceeds through 
oxidative addition of 90 to a 5-membered palladacycle (151, Figure 2.4), it is expected 
that, following reductive elimination and protonolysis, the enone should be delivered 
from the same face as the aminoquinoline directing group. Thus, we reasoned that 148 
must arise by epimerization of the initially formed cis-product (147), presumably 
facilitated by the presence of base and protic solvent. Since the trans relationship across 
the cyclobutane ring was ultimately required, reaction conditions were sought to effect 
Figure 2.4. Proposed mechanism for the C(sp3)–H alkenylation reaction 
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complete in situ epimerization and allow the direct isolation of 148.  
Additional screening revealed that reactions run under identical conditions gave 
highly variable ratios of 147 to 148, and upon scale-up, we were surprised to find that the 
product ratio switched almost entirely to favor 147. This result led us to suspect that 
adventitious water could be playing a role in the epimerization; however, control 
experiments did not support this hypothesis.21 Next, DBU was added to the crude reaction 
mixture after the C(sp3)–H alkenylation had finished in an attempt to drive the 
epimerization to completion (Scheme 2.7). Over the course of our efforts to bring 
material through on larger scale, a general observation was made: if 147 were purified 
immediately, the yields were consistently higher than if 148 were isolated after treatment 
with DBU. In these cases, the yields were comparatively poor, but with much lower 
variance, only ranging from 40 to 45%. 
Scheme 2.7. Toward a one-pot C(sp3)–H alkenylation/epimerization process 
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consistently high yields; further optimization efforts established that the epimerization 
was best accomplished by treating purified 147 with an excess of DBU in 
dichloromethane at 60 °C, which accelerated conversion to 148.  
Scheme 2.8. Determining the site of epimerization via deuteration experiments 
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with (S)-1-phenethylamine (154, Scheme 2.9)23 provided salt 155, which was formed in 
52–57% ee. We found that at least three recrystallizations were required to achieve high 
levels of enantiopurity. As is often the case with classical resolutions, this process 
reliably provided 145 in 98% ee, albeit in only 27% overall yield. As before, amide 
coupling under standard conditions furnished (+)-89 with no racemization.  
Scheme 2.9. Classical resolution of cyclobutane carboxylic acid 145 
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of stable, isolable ketenes; thus, it was not clear that Fu’s methodology would be directly 
applicable using a ketene such as 156, generated in situ under photochemical conditions. 
In this regard, Lectka’s single example of asymmetric interception of a ketene generated 
by Wolff rearrangement to form α-chloroester 165 was encouraging (Scheme 2.10c).26 
With respect to nitrogen nucleophiles engaging with ketenes generated in situ, Wang and 
Hou have prepared lactam 169 by intramolecular attack of a tethered tosyl amine onto the 
ketene in 168, which arises by Ag-mediated dediazotization of α-diazoketone 167 
(Scheme 2.10d).27 With these key reports in mind, we set out to first establish conditions 
under which the desired reactivity could be achieved in a racemic sense.  
Scheme 2.10. Enantioselective Wolff rearrangement reaction design & precedent 
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Gratifyingly, it was found that irradiation of a mixture of 104 and 146 produced 
(±)-89 in 46% yield (Table 2.2, entry 1). Interestingly, addition of 10 mol % DMAP 
diminished reactivity under otherwise identical conditions, although longer reaction time 
and heating rescued the yield somewhat (entries 2 and 3). Silver salts, such as Ag2O and 
AgOBz, failed to promote dediazotization leaving 104 intact at room temperature or 50 
°C (entries 4–8). Having established that this reaction was feasible under photolytic 
conditions, the ability of a chiral catalyst to exert enantiocontrol was explored next.  
Table 2.2. Establishing desired reactivity in tandem with Wolff rearrangement 
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‡ Optimization studies in this section were conducted in collaboration with Dr. Linglin 
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Table 2.3, entries 1–4). Based on the observation that high loadings of (+)-161 produce a 
very dark, deep purple solution, the significant drop in yield at 50 mol % (entry 5) is 
attributed to poor light penetration through the reaction mixture. Attempts to improve 
selectivity by lowering the reaction temperature, or adding 104 slowly counterintuitively 
led to lower ee’s (entries 6 and 7). A survey of different solvents also proved 
unsuccessful in providing high levels of enantioselectivity (entries 8–12). Hoping to 
identify a more efficacious structural analog to 161, 170 and 171 were examined, but 
unfortunately both catalysts returned racemic product (entries 13 and 14).   
At this juncture it was determined that use of the high wattage, heat-producing 
Hanovia lamp could be avoided by switching to irradiation with a household 254 nm 
lamp manufactured by Honeywell.28 Reactions using this lamp were performed in quartz  
Table 2.3. Initial evaluation using chiral, planar Fe-DMAP derivatives 
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tubes to maximize 254 nm light transmittance, and although this did not improve 
selectivity with 161, this convenient setup was used moving forward. 
With no leads toward an improvement in enantioselectively using Fu’s Fe-DMAP 
catalysts, we next decided to explore the cinchona alkaloids—another class of catalysts 
known to engage in catalytic, asymmetric reactions with ketenes.29 Beginning with 
stoichiometric quantities of 172–179, we were delighted to obtain ee’s exceeding 50% for 
the first time  (Table 2.4). (+)-Cinchonine (172) provided (–)-89 with the highest 
selectivity (79% ee) in 50% yield. Interestingly, (+)-quinidine (174), which only differs 
Table 2.4. Evaluation of chiral cinchona alkaloids 
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from 172 by the presence of a methoxy group on the quinoline ring, gave (–)-89 in 64% 
ee—a marked difference for such a small structural variation. The corresponding pseudo-
enantiomers, (–)-cinchonidine (173) and (–)-quinine (175), each gave lower selectivities 
in the opposite enantiomeric series. This observation was significant since the absolute 
configuration of 89 could not be determined at the time. While dimeric cinchonas 
(DHQD)2PHAL (176) and (DHQD)2PYR (177) gave high yields of 80% and 90%, 
respectively, both provided very low levels of enantioselectivity. 
Encouraged by these results, a few more known cinchona derivatives were 
evaluated. Unfortunately, epimerization of the secondary alcohol (181–184, Table 2.5)30  
Table 2.5. Cinchona-derivatives and other classes of nucleophilic catalysts 
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significantly diminished ee, while acylation (180)29f,31 abolished selectivity entirely. NHC 
precursors 185 and 18632 were moderately successful, though these results proved very 
irreproducible and therefore this catalyst class was not pursued further. Finally, 
nucleophilic chiral phosphine catalysts 188 and 189 were found to only provide small 
amounts of racemic product.  
With (+)-cinchonine (172) identified as the best catalyst, the reaction conditions 
were optimized for this particular alkaloid. Since 172 is only sparingly soluble in THF, 
the lower yield using 1 equivalent was again attributed to poor light penetration through 
the heterogeneous mixture (Table 2.6, entry 1). Reducing the loading of 172 led to 
improved yields of (–)-89 without eroding enantioselectivity (entries 2 and 3). As before, 
lowering the reaction temperature to 0 °C did not improve selectivity (entry 4). 
Irradiation through either pyrex or vycor glass gave lower yields with significant amounts 
of starting material remaining (entries 5 and 6); this confirmed that conducting the 
reactions in quartz tubes was optimal for high conversion. Screening alternative solvents 
did not prove fruitful (8–11), although dioxane gave comparable results to THF (entry 7).  
Table 2.6. Optimization of Wolff rearrangement with (+)-cinchonine 
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 The conditions in entry 3 were chosen as optimal reaction parameters, and 
attention turned toward reproducing these results on large scale.  To our dismay, we 
found that an increase in scale from 0.10 mmol to 11.0 mmol led to a drastic drop in yield 
from 66% to 37%, although the enantioselectivity observed previously was maintained 
(Table 2.7 entries 1 and 2). After confirming this result several times, we considered that 
the discrepancy in yield could be due to a difference in the large-scale reaction setup. On 
small scale (~1.0 mL solvent) the reactions were performed in sealed quartz tubes; 
however, given that the photolysis of 104 produces N2 gas, the large-scale reactions were 
conducted in a quartz flask with an outlet needle to prevent excessive pressure buildup. 
To discern whether the low yields were the result of an inherent scalability problem, or 
due to the alternative reaction setup, a small-scale reaction left open to air was conducted; 
interestingly, this experiment gave 89 in only 18% yield33 (entry 3) with no remaining 
104, indicating that a sealed reaction vessel was indeed important.  
Table 2.7. Translating the Wolff rearrangement to large scale 
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ketene 153 might decompose via photodecarbonylation (Scheme 2.11)34 to produce 
volatile side products (i.e. 195, and/or 30 and 196). This idea was corroborated upon 
detection of CO when the atmosphere of a sealed reaction was vented into a hand-held 
CO detector. Having elucidated this deleterious pathway, the reaction was run under an 
atmosphere of CO in an attempt to take advantage of the equilibrium between 193 and 
194 and funnel back toward the ketene; however, this only resulted in lower yield and ee 
(Table 2.7, entry 4).  
Scheme 2.11. Elucidation of a deleterious photodecarbonylation pathway 
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2.3.3 Efforts Toward Flow Photochemistry 
In recent years, flow chemistry has emerged as an efficient technique for enabling 
large-scale execution of photochemical reactions. 35  In order to maximize material 
throughput for this first step of our total synthesis, we became interested in developing a 
flow reactor from readily available laboratory materials. To this end, 100 ft of PFTE 
Teflon cannula tubing was wrapped around a jacketed quartz immersion well28 and 
secured on each end with tape (Figure 2.5). A 16-gauge needle was fit inside the cannula 
at the top end of the photoreactor, allowing a large syringe to be connected to the inlet. A 
prepared reaction mixture could then be taken up into the syringe and driven through the 
photoreactor at a consistent flow rate, controlled by a syringe pump.  Based on the inner 
diameter of the cannula (1.07 mm) and its volume capacity (29 mL), appropriate flow 
rates were calculated to allow the travelling reaction mixture to be irradiated for a total of 
approximately 2-4 hours. 
Figure 2.5. Syringe-pump driven flow reactor setup 
 
It is important for reaction mixtures to remain homogenous when flowing through 
a photoreactor. As discussed previously, (+)-cinchonine (172) is only sparingly soluble in 
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THF, which necessitates dilute (0.05 M) reaction concentrations to achieve a 
homogenous solution. Therefore, in order to maximize material throughput using the 
flow reactor setup, a suitable co-solvent that would help maintain homogenous mixtures 
at higher concentrations was required. Unfortunately, 172 was found to be insoluble in a 
variety of solvents, including EtOAc, CH2Cl2, THF/CH2Cl2, MeCN, DME, and even 
DMF. However, we found that both DMPU and 2-MeTHF helped to solubilize 172. Test 
reactions in quartz tubes revealed that use of these solvents alone were detrimental to the 
reaction (Table 2.8, entries 3 and 4); however the addition of a small amount of DMPU in 
THF was well tolerated and allowed a two-fold increase in concentration (entry 2).  
Table 2.8. Flow photochemistry test reactions and results 
 
Applying this solvent system in the context of syringe-pump driven flow 
photochemistry led to a disappointing 38% yield (entry 6), compared with 57% in the 
corresponding test reaction. Likewise, a flow reaction using standard conditions suffered 
the same outcome, even at a slower flow rate (entry 7). After the discovery of the ketene 
photodecarbonylation problem, the flow setup was evaluated again using 3 equivalents of 
146 and resulted in an increased 54% yield (entry 8). Although this yield was slightly 
lower than anticipated (cf: entry 1), the ability to process many grams of material through 
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a continuous flow reactor was deemed preferable to running sequential batches, and thus 
worth the tradeoff in yield.  
 To achieve a continuous flow system, we required a device capable of sending 
more volume through the flow reactor than a simple 50 mL syringe would allow. To 
accomplish this, the cannula was attached to a threaded HPLC fitting and a remote-
controlled HPLC pump was used to send the reaction mixture through the flow reactor 
(Figure 2.6). The crude product collected in the receiving flask was monitored 
periodically by TLC. Curiously, starting material was detected after ~12 hours, indicating 
that the reaction had stalled. Once the lamp was turned off, we discovered that the side of 
the cannula facing the UV lamp had become severely discolored upon prolonged 
irradiation, which precluded light from passing through to the reaction mixture. As a 
result, the attempt at a 51 mmol scale using flow photochemistry afforded 89 in only 10% 
yield (entry 9), with the unreacted starting material recovered almost entirely. While the 
cannula discoloration is unfortunate, we note that further evaluation of alternative 
materials, including other grades of Teflon, or ideally quartz tubing, may prove fruitful in 
Figure 2.6. HPLC-pump driven flow reactor setup and discolored cannula 
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mitigating this problem. Moreover, these experiments provide an important proof-of-
concept that the newly developed asymmetric Wolff rearrangement chemistry is 
inherently compatible with flow photochemistry systems.  
 
2.3.4 Mechanistic Considerations 
Experiments designed to probe the mechanism of this transformation were guided 
by two principle possibilities: First, many cinchona alkaloid-mediated asymmetric 
transformations involving ketene intermediates are proposed to proceed by addition of 
the catalyst to the ketene, forming a chiral, zwitterionic enolate complex26,29 such as 157 
(Figure 2.7a). In the context of the tandem Wolff rearrangement/asymmetric ketene 
addition, it is envisioned that 157 may undergo a diastereoselective protonation with 146, 
which serves as an achiral proton source to produce ion pair 197. Transacylation of this 
species then generates 89 and expels the catalyst, allowing it to renter the cycle.  
Figure 2.7. Two mechanistic possibilities for the asymmetric ketene addition 
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Another possibility put forth by Fu25 in the context of the ferrocenyl DMAP 
catalysts (e.g. 161) invokes an asymmetric protonation as the enantiodetermining step 
(Figure 2.7b). In this mechanism, the free catalyst first acts as a base to deprotonate an 
achiral proton source, such as 146, to generate chiral ion pair 198; in the context of their 
system, Fu and coworkers have observed an analogous ion pair by NMR spectroscopy as 
the resting state of the catalyst. The aminoquinoline anion in 198 can then add into ketene 
156, and the resulting achiral enolate undergoes protonation with a chiral Brønsted acid 
in 199 to furnish the product and regenerate the free-base form of the catalyst.  
Lectka has used computational support to show that the alkoxide of zwitterionic 
enolates like 157 are capable of forming various hydrogen bonds with the quinuclidine 
nucleus of cinchona catalysts.29e, 36  These interactions serve to rigidify the three-
dimensional conformation of 157, thus leading to predictable levels of enantioselectivity. 
Based on this, and the fact that significant drops in asymmetric induction are observed 
using cinchona alkaloids without free hydroxyl groups (e.g. 176–180), a possible scenario 
can be envisioned in which the enolate alkoxide in 157 forms a stabilizing hydrogen bond 
with the free C9 hydroxyl on the catalyst (Figure 2.8). Notably, examination of molecular 
models reveals that, with this key interaction in place, the quinolone ring in 172 folds 
down alongside the re face of the enolate in 157, leaving the other side of the complex 
exposed for preferential protonation from the si face. Although somewhat crude, this 
analysis correctly predicts the absolute stereochemistry of the major enantiomer that is 
obtained experimentally. Moreover, models built of the pseudoenantiomeric enolate 
complex derived from 173 shows that the si face is blocked with lower efficiency, which 
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could explain the diminished levels of enantioinduction that are observed with the 
diastereomeric series of cinchona catalysts.  
Figure 2.8. A possible model for diastereoselective protonation 
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hours in THF-d8 and transferred directly to a dry NMR tube. Spectroscopic analysis by 
NMR revealed complete and relatively clean conversion of 104 to 153, exhibiting 
signature 1H and 13C NMR shifts consistent with a ketene (Scheme 2.12a). Subsequent 
addition of a 1 equiv 146 to this solution did not result in any evidence of 89, most likely 
due to decomposition of the sensitive ketene during subsequent manipulation. 
On the other hand, irradiation of 104 in the presence of 1 equiv 172 in THF-d8 for 
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characteristics of the cyclobutyl-geminal dimethyl pattern (Figure 2.12b). On the other 
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active catalyst, as in the enantioselective protonation mechanism.25  
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Scheme 2.12. Attempts to identify critical intermediates/reactive species.  
 
Lastly, to confirm that the proposed zwitterionic complex 157 is capable of 
forming ion pair 197 and undergoing subsequent transacylation, 1 equiv 146 was added 
to the reaction mixture following irradiation of 104 and 172 for 4 hours. The expected 
product 89 was obtained from this experiment, albeit in only 9% yield and 26% ee.37 
While it is unclear why the yield is so low in this case, we attribute the low levels of 
enantioselectivity to a higher rate of background reaction in the presence of excess ketene 
153, which was observed by 1H NMR analysis of the crude reaction mixture. Taken 
together with recent computational studies,38 we believe these preliminary results lend 
some support for the diastereoselective protonation mechanism outlined in Figure 2.7a. 
However, more experiments are required to fully elucidate the operative mechanism.    
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2.3.5 Efforts Toward Expansion of Substrate Scope§ 
In tandem with ongoing work to learn more about the mechanism of the 
asymmetric Wolff rearrangement, efforts to explore the generality of the substrate scope 
for this transformation have been initiated.39 A preliminary summary of our findings is 
summarized in Table 2.9. In moving away from 104, simple, systematic changes were 
made to new substrates tested (200–203); therefore, it was surprising to find that both 
yield and enantioselectivity dropped dramatically for α-diazoindanone 200. On the other 
hand, α-diazotetralone 202 performed very well in the presence of (DHQD)2PYR (177), 
providing the corresponding product in 61% yield and 75% ee. Notably, this substrate 
was the first identified to give high levels of selectivity using a dimeric cinchona catalyst; 
interestingly, the optimal catalyst for 104 afforded only 48% yield and 34% ee in this 
system. Whereas the epimeric cinchona alkaloids 182 and 181 performed poorly with 
Table 2.9. Summary of optimal catalysts for alternative substrates 
 
                                                
§ Exploration of the substrate scope for the tandem Wolff rearrangement/asymmetric 
ketene addition reaction is currently underway in collaboration with Caitlin Lacker, a 
graduate student in the Reisman Lab. 
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104, these catalysts afforded the best results for 201, a strikingly close 6-membered 
analog of 104. Although the dimeric and epimeric cinchona catalysts gave the highest ee 
for substrates 200–202, this trend did not hold for 7-membered diazoketone 203. In this 
case, (+)-quinidine (174) was determined as the optimal catalyst, furnishing the 
corresponding Wolff product in 65% yield and 69% ee. At present, a generally optimal 
catalyst has not been identified for the preparation of enantioenriched amides using this 
method, though mechanistic investigations may inform efforts to improve the substrate 
scope of this transformation. Future work will also be directed at exploring a variety of 
different nucleophiles as alternatives to 146. 
 
2.4 FORWARD SYNTHETIC EFFORTS: ASYMMETRIC ROUTE 
With rapid access to multigram quantities of 89 in enantiopure form, the C(sp3)–H 
alkenylation reaction was conducted on gram scale to give (+)-147 in 75% yield (Scheme 
2.13). The requisite trans-cyclobutane was obtained with no erosion of ee by selective 
epimerization at C2, as determined by earlier deuterium-labeling studies. It was at this 
stage that we were able to obtain single crystals of trans-cyclobutane 148 suitable for X-
ray diffraction. Unfortunately, 148 was found to be in the incorrect enantiomeric series 
for elaboration to natural 56. To our dismay, this problem could not be circumvented by 
simply employing (−)-cinchonidine (173) in the tandem Wolff rearrangement/asymmetric 
ketene addition, as this diastereomeric catalyst afforded (+)-89 in lower yield with only 
57% ee (see Table 2.4). Nevertheless, (–)-148 was advanced in the interest of validating 
the key reactions in our retrosynthetic analysis as soon as possible. 
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Scheme 2.13. Alkenylation/epimerization using enantiopure cyclobutamide 
 
 
2.4.1 Quaternary Center Formation via Conjugate Addition 
The next task focused on installing the methyl group to form the C1 quaternary 
center. Subjection of cis-cyclobutane 147 to a number of standard conjugate addition 
conditions provided only trace yields of the desired product 208, presumably due to steric 
crowding by the proximal large aminoquinoline group (Scheme 2.14). On the other hand, 
treatment of trans-cyclobutane 148 with excess Gilman’s reagent smoothly furnished 209 
and 210 in near quantitative yield as a 5:2 mixture of diastereomers, respectively. 
Separation of the diastereomers by HPLC purification allowed single crystals of 210 to 
be obtained for X-ray diffraction analysis, which unambiguously confirmed that the 
minor diastereomer possessed the undesired configuration of the methyl group at the C1 
quaternary center.   
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Scheme 2.14. Initial foray into conjugate addition to set the C1 quaternary center 
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copper sources did not prove fruitful (entry 7), this set of reaction conditions was chosen 
to move forward with.   
Table 2.10. Copper-catalyzed conjugate addition 
 
Upon scale-up, an exotherm was observed when Me3Al was added to the reaction 
mixture, which was mitigated by adding the reagent more slowly. Using this protocol, 
209 was obtained in an improved 62% yield and 30:1 dr on a 0.6 mmol scale (Scheme 
2.15). With the correct configuration at the quaternary center secured, this ketone was 
converted to the corresponding ketal 213, which could be used directly in the planned o-
QMHDA reaction (vide infra, see Scheme 2.17). 
Scheme 2.15. Optimal conjugate addition conditions and ketal protection 
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system to study the reactivity of each. Interestingly, phloroglucinol derivatives lacking 
carbonyl functionality (see 103, Figure 2.2) were generally unreactive with 1-
methoxycyclohex-1-ene (214, Scheme 2.16a). Conversely, we were gratified to find that 
use of aryl ester 215 afforded the desired cycloaddition products as a mixture of three 
diastereomers, in a combined 75% yield. Stereochemical analysis of 217–219 was aided 
by the signature 1H NMR coupling patterns of the vicinal protons at C1' and C9; the 
signal of the doubly benzylic proton at δ 3.95 ppm in 217 corresponds to a singlet that is 
characteristic of a 90° dihedral angle (J = 0 Hz) with the adjacent proton at C9. On the 
other hand, thermal equilibration of the ketal leads to a trans fusion across C8–C9 in 218, 
thus placing these protons at a 180° dihedral angle, which is consistent with the observed 
J = 11 Hz coupling also present in (+)-psiguadial B (56). Integration of these key signals 
in the crude reaction mixture revealed that products with the desired relative 
stereochemistry, 217 and 219, predominated in an overall endo/exo ratio of 4:1.  
Scheme 2.16. Model [4+2] and synthesis of fully oxidized o-QM precursor 
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The aryl ester in 215 is proposed to form a key hydrogen bond to the neighboring 
phenol, thus orienting the proton away from the co-planar phenyl group in o-QM 216. 
This interaction accounts for the successful thermolysis of 215 vs. other o-QM 
precursors, as well as the observed regioselectivity of the cycloaddition. Given the 
apparent necessity of this H-bonding assistance, a fully functionalized o-QM precursor 
was sought, which would obviate the need for arene oxidation at a later stage.  
Unfortunately, subjection of 221 41  to the same phenolic aldol conditions used to 
synthesize 21542 did not result in any productive reaction (Scheme 2.16b). On the other 
hand, generation of a more electrophilic imine, derived from benzaldehyde (51) and 
morpholine (220) engaged readily with 221 to provide 222 in 69% yield. Access to 2-
hydroxy benzyl alcohol 223 was then realized by leveraging Wilson’s tactic to access o-
QMs from morpholine derivatives;43 222 was activated with p-TsOH, and in the presence 
of water, gave 223 in 49% yield after 4 hours. Notably, 223 proved sensitive under the 
acidic reaction conditions and would slowly revert back to 221 and 51, presumably via 
protonation and retrol aldol processes.  
 
2.4.2 Evaluation of the Key o-QMHDA Cycloaddition Reaction 
 With both cycloaddition partners finally in hand, the proposed o-QMHDA 
reaction was investigated. After some experimentation, it was found that 213 could be 
used directly to afford a 1:1 equilibrating mixture of enol ethers (102) upon thermal 
extrusion of methanol at 170 °C (Scheme 2.17a).44 Concurrently, 2-hydroxy benzyl 
alcohol 223 underwent thermolysis to generate the corresponding o-QM 224. We were 
pleased to observe a remarkably efficient cycloaddition between these two in situ-
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generated species furnishing a 68% total yield of the fused tricycle products, albeit as a 
complex mixture of diastereomers that proved inseparable by standard silica gel column 
chromatography. Fortunately, analytically pure samples of each of the four diastereomers 
formed in highest abundance (Peaks 1–4) were obtained by subsequent HPLC 
purification to assess the stereochemical outcome of the reaction.  
Scheme 2.17. Realization of the o-QMHDA reaction 
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signals between the newly formed methine at C9, the methoxy ketal, and an ortho-proton 
on the phenyl ring—all of which correlate to each other—establish that these three 
substituents reside on the same face of the molecule (Scheme 2.17b). Furthermore, the 1H 
NMR signal at C1' corresponds to a characteristic singlet that is indicative of a 90° 
dihedral angle (J = 0 Hz) with the adjacent proton at C9. Whereas the methyl group at the 
C1 quaternary center does not exhibit any discerning signals in the 2D NOESY spectrum 
of 225, the C1 methyl in 226 does show a key correlation with the methoxy ketal. In turn, 
226’s methoxy ketal also shares an NOE with the C9 methine and a small, but 
discernable signal is observed with an ortho-phenyl proton, indicating that these groups 
are all oriented in the same direction. Notably, 226 appears to adopt a boat conformation, 
as evidenced by the NOE correlation between the C9 methine and axial proton on C11. 
Spectroscopic characterization of the minor products revealed that peak 3 
corresponds to 227, which displays some analogous features to 225, except that the 
methoxy ketal now correlates to the C1' methine, and the coupling constant (J = 7.3 Hz) 
between vicinal protons at C1' and C9 suggests a cis-orientation, as drawn. Interestingly, 
this same coupling constant in 228 (corresponding to peak 4) is 11 Hz, which is most 
consistent with a 180 ° dihedral angle between C9 and C1', and thus a trans-fusion across 
the newly formed ring. This assignment is further supported by characteristically 
prominent NOEs shared between all the axial protons indicated, as well as correlations 
from the methoxy ketal to both the C1 methyl group and the benzylic proton at C1'.  
Analysis of the diastereomeric mixture by mass spectrometry confirms that many 
of the minor constituents apparent in the chromatogram shown in Scheme 2.17a possess 
the same molecular weight as 225–228. These minor components likely represent the 
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remainder of the expected diastereomers, namely, the exo product complementary to 226, 
as well as trans-fused isomers resulting from thermal equilibration of the ketal, as 
observed in 228. 
With these stereochemical assignments in-hand, we were pleased to observe that 
endo products, 225 and 226, were in fact produced in the highest abundance as predicted. 
However, given the near 1:1 ratio of these intermediates, it was clear that the C1 methyl 
group did not serve to block o-QM approach from the bottom face of enol ether 102.45 
Rather, isolation of minor products, 227 and 228, suggest that cycloaddition from the 
bottom face of 102 is actually preferred. With regard to endo/exo selectivity, 227 may 
arise by one of two possibilities: either E- or Z-224 can react with 102 through an exo or 
endo transition state, respectively, to yield the same stereochemical outcome (Figure 2.9). 
Although formation of E-configured o-QMs is typically favored in order to avoid steric 
clashing with the lone pairs on oxygen,11 this interaction is unavoidable in the case of 
fully oxidized o-QM 224. Thus, without a clear steric bias to favor one configuration over 
the other, the precise nature of how 227 arises remains unclear at this time. 
Figure 2.9. Possibilities for o-QM configuration and approach to form 227 
 
Disappointed by the overall low yield of 226, a potential solution was conceived 
to improve the facial selectivity of this transformation by leveraging the auxiliary in 102 
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to direct the approach of the o-QM. Drawing inspiration from Evans’ highly selective 
Cu-catalyzed inverse-demand hetero-Diels–Alder chemistry (Scheme 2.18a),46 it was 
envisioned that the Cu-chelating aminoquinoline could engage 224 in a similar two-point 
binding mode, which would deliver the o-QM from the top face of enol ether 102 and set 
the desired stereochemistry at C9 and C1' (Scheme 2.18b). Formation of 224 would be 
triggered at room temperature by the equivalent of triflic acid generated via complexation 
of Cu(OTf)2 with aminoquinoline.15,47  
Scheme 2.18. Toward an aminoquinoline-directed o-QMHDA reaction 
 
To test this hypothesis, enol ether 102 was prepared by thermal heating in PhMe, 
and after replacing the solvent with CH2Cl2, 113 was added in the presence of Cu(OTf)2. 
Analysis of the crude mixture by 1H NMR revealed that although the ratio of 226:225 had 
improved relative to the thermal reaction, formation of undesired products, 227 and 228, 
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now predominated overall. Moreover, this reaction suffered from rapid hydrolysis of 102 
to ketone 209 and formation of retro aldol product 221—an unsurprising consequence of 
triflic acid generation. At this stage, it was clear that implementation of this strategy 
would require a significant investment in reaction optimization and we felt that such an 
effort would only be warranted if the proposed late-stage Prins reaction were proved 
feasible. Thus, attention turned to assessing this key reaction in a model system.  
 
2.4.3 Model Studies Toward a Vinyl Sulfide Prins Cyclization 
Reductive cleavage of the aminoquinoline auxiliary in 213 was accomplished 
with Schwartz’s reagent to furnish aldehyde 233, which was smoothly homologated to 
alkyne 234 using an Ohira–Bestmann reaction (Scheme 2.19). Nickel-catalyzed 
hydrothiolation48 proceeded with complete regioselectivity to give vinyl sulfide 236 in 
low yield, mainly due to the facile conversion of this intermediate to a mixture of enol 
ethers 235 during the course of the reaction. Nonetheless, having arrived at a substrate 
capable of validating the desired Prins reactivity, ketal 236 was subjected to a variety of 
Lewis acids, and in nearly all cases simple deprotection to the corresponding ketone 238 
was observed. Gratifyingly however, the use of InCl39b delivered the desired Prins 
product 237, representing successful assembly of the bridging bicyclic terpene 
framework for the first time. Formation of the 7-membered ring was confirmed by a key 
HMBC correlation between the C12 axial proton and the distinct sp2 C7 signal at δ 140 
ppm. Although the realization of a successful Prins cyclization was promising, our 
excitement was tempered by the fact that 237 was obtained in poor yield and 
unfortunately, this initial result proved irreproducible. Taken together with the significant 
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diastereoselectivity issues plaguing the o-QMHDA reaction, these setbacks ultimately 
motivated the decision to revise our retrosynthetic analysis.  
Scheme 2.19. Evaluating the feasibility of Prins cyclization in a model system 
 
 
2.5 CONCLUDING  REMARKS 
In conclusion, a first-generation route to (+)-psiguadial B (56) was investigated, 
which led to several key discoveries. First, the synthetic challenge posed by de novo 
construction of the trans-fused cyclobutane ring in 56 inspired the development of a 
photochemical Wolff rearrangement with tandem asymmetric ketene addition to provide 
direct access to enantioenriched amides in good yield and selectivity. This novel 
transformation provided the foundation for the ability to access optically active advanced 
intermediates, which were rapidly assembled using a key Pd-catalyzed C(sp3)−H 
alkenylation reaction. 
In addition, a remarkably efficient o-QMHDA cycloaddition was successfully 
achieved between a highly functionalized cyclohexanone-derived enol ether used as the 
limiting reagent and a fully oxidized o-QM under thermal conditions. Elucidation of the 
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stereochemical outcome of the reaction led to the conclusion that the presence of the C1 
methyl group was insufficient to enforce the desired facial selectivity in o-QM approach.  
Lastly, exploratory efforts aimed at realizing the proposed Prins cyclization in a model 
system were met with limited success. Having completed the evaluation of our key 
retrosynthetic disconnections, attention ultimately turned to the development of a second-
generation synthetic strategy, as described in Chapter 3.  
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2.6 EXPERIMENTAL SECTION 
2.6.1 Materials and Methods 
General Procedures. Unless otherwise stated, reactions were performed under a 
nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene 
chloride (CH2Cl2), acetonitrile (MeCN), tert-butyl methyl ether (TBME), benzene (PhH), 
and toluene (PhMe) were dried by passing through activated alumina columns. 
Triethylamine (Et3N), N,N-diisopropylethylamine (DIPEA), and methanol (MeOH) were 
distilled over calcium hydride prior to use. Unless otherwise stated, chemicals and 
reagents were used as received. All reactions were monitored by thin-layer 
chromatography using EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and 
were visualized by UV, p-anisaldehyde, or 2,4-dinitrophenylhydrazine staining. Flash 
column chromatography was performed either as described by Still et al.49 using silica gel 
(particle size 0.032-0.063) purchased from Silicycle or using pre-packaged RediSep®Rf 
columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical rotations were 
measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. 1H 
and 13C NMR spectra were recorded on a Bruker Avance III HD with Prodigy cryoprobe 
(at 400 MHz and 101 MHz respectively), a Varian 400 MR (at 400 MHz and 101 MHz, 
respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, respectively), or a Varian 
Inova 600 (at 600 MHz and 150 MHz, respectively), and are reported relative to internal 
CHCl3 (1H, δ = 7.26) and CDCl3 (13C, δ = 77.1), THF (1H, δ = 3.58) and THF-d8 (13C, δ = 
67.6), or C6H5 (1H, δ = 7.16), and C6D6 (13C, δ = 128). Data for 1H NMR spectra are 
reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicity and qualifier abbreviations are as follows: s = singlet, d = 
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doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were 
recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in frequency of 
absorption (cm–1). HRMS were acquired using an Agilent 6200 Series TOF with an 
Agilent G1978A Multimode source in electrospray ionization (ESI), or mixed (MM) 
ionization mode, or obtained from the Caltech Mass Spectral Facility in fast-atom 
bombardment mode (FAB). Analytical SFC was performed with a Mettler SFC 
supercritical CO2 analytical chromatography system with a Chiralcel AD-H column (4.6 
mm x 25 cm).  
 
2.6.2 Preparative Procedures and Spectroscopic Data 
Preparation of diazoketone 104.17 
 
 To each of two flame-dried 1 L round-bottom flasks was added NaH (60% 
dispersion in mineral oil, 3.17 g, 79.2 mmol, 1.20 equiv) and the atmosphere was 
exchanged for N2 one time. Dry Et2O (30.0 mL) was then added via syringe and the 
suspension cooled to 0 °C. Ethyl formate (12.4 mL, 152 mmol, 2.30 equiv) was then 
added, followed by 2,2-dimethylcyclopentanone 14218 (7.40 g, 66.0 mmol) either neat, or 
as a 3.0 M solution in Et2O. A catalytic amount of wet methanol (~100 μL) was then 
added and the reaction left to stir at 0 °C.50 Upon completion, the reaction solidifies to a 
chunky, white solid that dissolved readily upon the addition of DI H2O. At this point, 
both reaction mixtures were combined for workup: after dilution with Et2O, the layers 
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were separated and the aqueous layer was washed with Et2O 3x to remove organic 
impurities and a small amount of unreacted starting material. The aqueous layer was then 
cooled to 0 °C and acidified to pH = 3 using 5 M HCl. Et2O was then added and the 
acidified aqueous layer was extracted 6x. The combined organics were then dried over 
Mg2SO4, filtered, and concentrated in vacuo into a 500 mL round-bottom flask.  
The crude formyl ketone 144 was taken up in CH2Cl2 (132 mL) and the solution 
cooled to –10 °C. Triethylamine (55.2 mL, 396 mmol, 5.00 equiv) was added, followed 
by solid p-ABSA51 (31.8 g, 132 mmol, 1.00 equiv) in three portions. The reaction was 
stirred for 3 hours and allowed to gradually reach 10 °C, at which point an aqueous 
solution of KOH (55.0 mL, 4 M) was added. Additional CH2Cl2 and H2O were added, the 
layers were separated and the aqueous layer extracted with CH2Cl2 until no product 
remains by TLC. The combined organics were dried over Mg2SO4, filtered, and 
concentrated in vacuo. The crude residue was purified by silica gel flash chromatography 
(20–30% Et2O/pentane) to afford 104 (17.4 g, 95% yield) as a bright yellow oil.  
 
1H NMR (400 MHz, CDCl3) δ 2.88 (t, J = 7.0 Hz, 2H), 1.77 (t, J = 7.2 Hz, 2H), 1.04 (d, 
J = 1.0 Hz, 6H).; 1H NMR (400 MHz, THF-d8) δ 2.94 (t, J = 7.0 Hz, 2H), 1.79 (t, J = 7.2 
Hz, 2H), 1.04 (s, 6H). 
 
13C NMR (101 MHz, CDCl3) δ 204.8, 56.6, 46.3, 35.7, 24.1, 21.2.; 13C NMR (101 MHz, 
THF-d8) δ 203.6, 56.1, 46.9, 36.6, 24.5, 21.9. 
FTIR (NaCl, thin film) 3754, 3414, 3332, 2962, 2934, 2892, 2869, 2672, 2642, 2578, 
2510, 2080, 1981, 1673, 1581, 1471, 1460, 1382, 1362, 1339, 1309, 1267, 1245, 1204, 
1133, 1110, 1058, 1030, 994, 977, 948, 919, 893, 780, 726, 697 cm.-1  
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HRMS (MM) calc’d for C7H11N2O [M+H]+ 139.0866, found 139.0860. 
 
Preparation of racemic cyclobutamide (±)-89. 
 
To a flame-dried 200 mL flask were added carboxylic acid 14517 (806 mg, 6.29 
mmol), 8-aminoquinoline 146 (952 mg, 6.60 mmol, 1.05 equiv), and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (1.45 g, 7.56 mmol, 1.20 
equiv). The dry reagents were dissolved in CH2Cl2 (60 mL) and pyridine (610 μL, 7.56 
mmol, 1.20 equiv) was then added quickly via syringe. The reaction was stirred at room 
temperature for 18 hours, then diluted with H2O and extracted with CH2Cl2 (2 x 50 mL). 
The combined organics were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude residue was purified by silica gel flash chromatography (isocratic: 5% 
EtOAc/Hexane) to give (±)-89 (1.19 g, 74% yield) as a thick, pale yellow oil that 
solidified to a solid upon standing at –20 °C. For spectroscopic characterization data, see 
large-scale preparation detailed below.  
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Large-scale preparation of enantioenriched cyclobutamide (–)-89. 
 
To a flame-dried, 1 L quartz flask were added 8-aminoquinoline (146) (12.9 g, 
89.5 mmol, 3.00 equiv) and (+)-cinchonine (172) (879 mg, 2.99 mmol, 0.100 equiv). The 
flask was evacuated and backfilled with N2 three times and dry THF (600 mL) was then 
added via cannula. Diazoketone 104 (4.12 g, 29.8 mmol, 1.00 equiv) was added last via 
syringe and the reaction was irradiated with stirring using a Honeywell 254 nm lamp at 
room temperature. Reaction progress was 
monitored by TLC (72-168 hours are typically 
required for complete conversion on this scale, 
and rotation of the flask every day provided 
faster conversion). 52  Upon completion, the 
reaction mixture was concentrated in vacuo, the 
solids (172) were taken up in CH2Cl2, and the 
suspension filtered. The filter cake was washed 
with CH2Cl2 three times and the filtrate was 
concentrated in vacuo to give a crude residue that 
was purified by silica gel flash chromatography (isocratic: 6% EtOAc/hexane) to provide 
89 (4.69 g, 62% yield) as a pale-yellow solid. The enantiomeric excess was determined to 
be 79% by chiral SFC analysis (AD-H, 2.5 mL/min, 20% IPA in CO2, λ = 254 nm): tR 
(major) = 4.23 min, tR (minor) = 5.64 min. [𝛼]!!".! = –66.0° (c = 0.560, CHCl3). 
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Recrystallization procedure: 
Enantioenriched cyclobutane 89 was 
dissolved in a minimal amount of CH2Cl2in a 100 
mL round-bottom flask. An equal amount of 
hexanes was carefully layered on top of the 
CH2Cl2to form a biphasic mixture. The layers 
were allowed to diffuse overnight to provide (–)-89 as white needles. The supernatant 
was concentrated under reduced pressure and this process was repeated again to provide 
additional (–)-89 (3.50 g total, 83% recovery of theoretical total of the desired 
enantiomer, 46% overall yield from 104): [𝛼]!!".! = –109° (c = 0.720, CHCl3).  
1H NMR (400 MHz, CDCl3) δ 9.68 (s, 1H), 8.80 (t, J = 1.8 Hz, 1H), 8.79 (dd, J = 13.6, 
1.6 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.52 (q, J = 8.2, 7.5 Hz, 1H), 7.48 (dd, J = 
8.3, 1.6 Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 3.07 (ddd, J = 9.1, 8.2, 0.9 Hz, 1H), 2.48 
(dq, J = 11.4, 9.4 Hz, 1H), 2.06 (dtd, J = 11.6, 8.6, 3.3 Hz, 1H), 1.85 (dt, J = 10.8, 9.1 Hz, 
1H), 1.74 (dddd, J = 10.7, 9.5, 3.3, 0.9 Hz, 1H), 1.39 (s, 3H), 1.14 (s, 3H). 
13C NMR δ 171.8, 148.3, 138.6, 136.4, 134.7, 128.1, 127.6, 121.7, 121.3, 116.4, 51.0, 
40.4, 32.3, 30.9, 23.4, 17.4.  
FTIR (NaCl, thin film) 3353, 3047, 2952, 2861, 1685, 1595, 1577, 1526, 1485, 1460, 
1424, 1385, 1324, 1261, 1239, 1187, 1169, 1153, 825, 791,756 cm.-1  
HRMS (MM) calc’d for C16H19N2O [M+H]+ 255.1492, found 255.1501. 
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SFC data for racemic 89: 
 
 
Enantioenriched 89 isolated directly from reaction:  
 
 
 
Enantiopure (–)-89 after a single recrystallization:  
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General small-scale protocol for the asymmetric Wolff rearrangement. 
 Inside a N2-filled glovebox, six oven-dried 13 x 100 quartz test tubes were each 
charged with aminoquinoline 146 (14.4 mg, 0.100 mmol, 1.00 equiv) and the specified 
catalyst (typically, 20–50 mol %). Diazoketone 104 (13.8 mg, 0.100 mmol) was then 
added to each as a solution in 1.00 mL THF and the reactions fitted with a 19/38 rubber 
septum around the outside of each tube and sealed with electrical tape. The reactions 
were brought out of the glovebox and placed in a bottomless test tube rack in front of a 
Honeywell 254 nm lamp. The reactions were irradiated with stirring at room temperature 
for the indicated length of time (typically 18-24 hours). The reactions were then 
concentrated in vacuo and the crude reactions 
mixtures either analyzed by 1H NMR with an 
added internal standard, or purified by silica 
gel flash chromatography (isocratic: 6% 
EtOAc/hexane) to provide 89 in varying 
yields and enantiopurities.   
 
 
In situ generation of ketene 156.  
 
Inside a N2-filled glovebox, an oven-dried quartz tube was charged with 
diazoketone 104 (13.8 mg, 0.100 mmol) and dissolved in THF-d8 (750 μL). The reaction 
was fitted with a 19/38 rubber septum around the outside of the tube and sealed with 
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electrical tape. The reaction was brought out of the glovebox and irradiated for 4 hours in 
front of a Honeywell 254 nm lamp, as described above. The reaction mixture was then 
opened to air and pipetted directly into a dry NMR tube for immediate spectroscopic 
analysis.53   
 
1H NMR (400 MHz, THF-d8) δ 2.20 (t, J = 7.9 Hz, 2H), 1.66 (t, J = 8.1 Hz, 2H), 1.19 (s, 
6H).  
 
13C NMR (101 MHz, THF-d8) δ 209.1, 78.8, 45.9, 30.9, 25.9, 22.0. 
 
 
Spectroscopic observation of zwitterion 157.  
 
 
Inside a N2-filled glovebox, an oven-dried quartz tube was charged with (+)-
cinchonine (172) (29.4 mg, 0.100 mmol, 1.00 equiv) and suspended in THF-d8 (750 μL). 
Diazoketone 104 (13.8 mg, 0.100 mmol) was then added, and the reaction was fitted with 
a 19/38 rubber septum around the outside of the tube and sealed with electrical tape. The 
reaction was brought out of the glovebox and irradiated for 4 hours in front of a 
Honeywell 254 nm lamp, as described above. The reaction mixture was then opened to 
air and excess 172 was removed by rapid filtration through a 0.45 μm Whatman syringe 
filter. The filtrate was added directly to a dry NMR tube for immediate spectroscopic 
analysis and compared against the 1H for spectrum for 172: 
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Key signals in (+)-cinchonine (172) are bolded below:  
 
1H NMR (400 MHz, THF-d8) δ 8.78 (d, J = 4.4 Hz, 1H), 8.17 (dd, J = 8.5, 1.3 Hz, 1H), 
8.02 (dd, J = 8.5, 1.4 Hz, 1H), 7.62 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.54 (d, J = 4.5 Hz, 
1H), 7.50 (ddd, J = 8.3, 6.8, 1.5 Hz, 1H), 6.15 (ddd, J = 17.2, 10.3, 7.9 Hz, 1H), 5.49 
(C9: d, J = 4.3 Hz, 1H), 5.10 – 4.96 (m, 2H), 4.90 (d, J = 3.9 Hz, 1H), 3.25 (C2: ddd, J 
= 13.7, 7.7, 2.4 Hz, 1H), 3.02 (C8: td, J = 9.0, 5.1 Hz, 1H), 2.82 – 2.70 (m, 2H), 2.67 – 
2.61 (m, 1H), 2.19 (q, J = 8.4 Hz, 1H), 2.10 (ddd, J = 13.0, 8.7, 2.0 Hz, 1H), 1.68 (t, J = 
2.4 Hz, 1H), 1.50 – 1.43 (m, 2H), 1.27 (dddd, J = 13.8, 9.4, 4.7, 1.7 Hz, 1H). 
 
Key signals in 157 that have shifted or appeared are bolded below:  
 
1H NMR (400 MHz, THF-d8) δ 8.78 (d, J = 4.5 Hz, 1H), 8.18 (dd, J = 8.5, 1.3 Hz, 1H), 
8.07 – 7.98 (m, 1H), 7.63 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.55 (dd, J = 4.5, 0.7 Hz, 1H), 
7.50 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 6.15 (ddd, J = 17.2, 10.3, 7.9 Hz, 1H), 5.55 (C9: d, J 
= 5.1 Hz, 1H), 5.09 – 4.96 (m, 2H), 3.31 (C2: ddd, J = 13.7, 7.7, 2.4 Hz, 1H), 3.05 (C8: 
td, J = 8.7, 4.3 Hz, 1H), 2.96 (dddd, J = 9.2, 8.2, 5.6, 1.0 Hz, 1H), 2.85 – 2.71 (m, 3H), 
2.66 (dt, J = 13.2, 8.7 Hz, 1H), 2.17 – 2.04 (m, 2H), 1.96 – 1.77 (m, 3H), 1.48 (dddd, J = 
8.9, 4.7, 3.6, 1.8 Hz, 3H), 1.23 (s, 3H), 1.14 (s, 3H). 
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Stepwise preparation of 89 by discrete formation of zwitterion 157.  
 
  
Inside a N2-filled glovebox, an oven-dried quartz tube was charged with (+)-
cinchonine (172) (29.4 mg, 0.100 mmol, 1.00 equiv) and suspended in THF-d8 (750 μL). 
Diazoketone 104 (13.8 mg, 0.100 mmol) was then added, and the reaction was fitted with 
a 19/38 rubber septum around the outside of the tube and sealed with electrical tape. The 
reaction was brought out of the glovebox and irradiated for 4 hours in front of a 
Honeywell 254 nm lamp, as described above. The reaction mixture was then opened to 
air and solid aminoquinoline 146 (14.4 mg, 0.100 mmol, 1.00 equiv) was added in one 
portion. The reaction was stirred at room temperature (without irradiation) overnight. The 
reaction mixture was concentrated in vacuo and the crude residue purified by preparative 
thin-layer chromatography (20% EtOAc/Hexane) to afford 89 (2.20 mg, 8.7% yield). The 
enantiomeric excess was determined to be 26% by chiral SFC analysis (AD-H, 2.5 
mL/min, 20% IPA in CO2, λ = 254 nm): tR (major) = 4.23 min, tR (minor) = 5.64 min. 
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Preparation of cis-cyclobutane 147. 
 
To a flame-dried 150 mL pressure vessel were added cyclobutane 89 (2.87 g, 11.3 
mmol), vinyl iodide 9054 (7.50 g, 33.8 mmol, 3.00 equiv), Pd(OAc)2 (379 mg, 1.69 mmol, 
0.150 equiv), and Ag2CO3 (3.11 g, 11.3 mmol, 1.00 equiv). The reagents were suspended 
in TBME (56.0 mL) and the vessel sealed under ambient conditions. The reaction was 
heated to 90 °C for 16 hours, then cooled to room temperature and filtered over a pad of 
celite. The filtrate was concentrated directly onto celite and purified by silica gel flash 
chromatography (20–40% EtOAc/hexane) to afford cis-cyclobutane 147 (2.95 g, 75% 
yield) as a pale yellow foam: [𝛼]!!".! = +84.4° (c = 0.350, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 9.73 (s, 1H), 8.78 (dd, J = 12.4, 2.1 Hz, 1H), 8.78 (t, J = 
1.8 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.51 (dd, J = 8.3, 5.0 Hz, 1H), 7.50 (d, J = 0.9 
Hz, 1H), 7.45 (dd, J = 8.3, 4.2 Hz, 1H), 6.00 (q, J = 1.6 Hz, 1H), 3.45 (ddddd, J = 10.8, 
8.5, 7.6, 2.1, 1.0 Hz, 1H), 3.27 (ddd, J = 8.8, 2.8, 0.8 Hz, 1H), 2.48 (t, J = 10.8 Hz, 1H), 
2.31 (ddd, J = 7.5, 5.7, 3.5 Hz, 2H), 2.20 (qd, J = 6.0, 5.5, 1.1 Hz, 2H), 2.01 (ddd, J = 
11.0, 8.3, 2.8 Hz, 1H), 1.95 – 1.84 (m, 2H), 1.46 (s, 3H), 1.13 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 199.5, 170.2, 166.5, 148.3, 138.4, 136.3, 134.4, 127.9, 
127.4, 124.9, 121.6, 121.5, 116.5, 56.9, 37.5, 37.5, 36.8, 35.7, 29.9, 27.8, 24.9, 22.6. 
FTIR (NaCl, thin film) 3348, 2929, 2865, 1662, 1623, 1595, 1576, 1522, 1485, 1424, 
1386, 1347, 1322, 1258, 1191, 1165, 1132, 827, 793 cm.-1 
I
O
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HRMS (MM) calc’d for C22H25N2O2 [M+H]+ 349.1911, found 349.1910. 
Preparation of trans-cyclobutane 148 and spirolactam 149. 
 
To a 150 mL pressure vessel were added cis-cyclobutane 148 (2.74 g, 7.86 mmol) 
and wet CH2Cl2 (27.5 mL). The colorless solution was treated with DBU (11.7 mL, 78.6 
mmol, 10.0 equiv) and a bright yellow color was observed immediately. The vessel was 
sealed under ambient conditions and heated to 60 °C for 20 hours. The reaction mixture 
was diluted with 100 mL of water and 100 mL of CH2Cl2. The layers were separated, and 
the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel flash chromatography (isocratic: 40% EtOAc/hexane until 148 
eluted completely, then 10% MeOH/CH2Cl2) to afford 148 (1.74 g, 64% yield) and 149 
(367 mg, 14% yield), each as a pale yellow solid.  
 
Data for trans-cyclobutane 148: [𝛼]!!".! = –129.0° (c = 1.43, CHCl3). 
 
1H NMR (500 MHz, CDCl3) δ 9.68 (s, 1H), 8.79 (dd, J = 4.2, 1.7 Hz, 1H), 8.73 (dd, J = 
7.2, 1.8 Hz, 1H), 8.15 (dd, J = 8.3, 1.7 Hz, 1H), 7.52 (dd, J = 8.3, 7.2 Hz, 1H), 7.49 (dd, J 
= 8.3, 1.8 Hz, 1H), 7.44 (dd, J = 8.3, 4.2 Hz, 1H), 5.92 (q, J = 1.5 Hz, 1H), 3.58 (ddq, J = 
18.5, 8.7, 1.6, 0.8, 0.8 Hz, 1H), 2.97 (dd, J = 9.8, 0.7 Hz, 1H), 2.41 – 2.29 (m, 4H), 2.05 – 
1.92 (m, 3H), 1.85 (t, J = 10.4 Hz, 1H), 1.40 (s, 3H), 1.19 (s, 3H). 
147 149
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13C NMR (126 MHz, CDCl3) δ 199.8, 169.6, 167.5, 148.3, 138.3, 136.3, 134.2, 127.9, 
127.3, 123.9, 121.7, 121.5, 116.3, 55.5, 37.5, 36.8, 36.4, 36.3, 30.7, 27.6, 23.1, 22.6. 
 
FTIR (NaCl, thin film) 3344, 3046, 2952, 2865, 2246, 1669, 1623, 1595, 1577, 1526, 
1485, 1461, 1424, 1323, 1346, 1326, 1292, 1253, 1191, 1161, 1133, 915, 884, 827, 792, 
757,731 cm.-1  
 
HRMS (MM) calc’d for C22H25N2O2 [M+H]+ 349.1911, found 349.1919. 
 
For X-Ray crystallographic analysis of 148, see Appendix 2.  
 
Data for spirolactam 149, 2.5:1 mixture of diastereomers: [𝛼]!!".! = –56.5° (c = 1.085, 
CHCl3). 
1H NMR (asterisk denotes minor diast., 400 MHz, CDCl3) δ 8.92 (dd, J = 4.1, 1.8 Hz, 
1H), 8.85* (dd, J = 4.1, 1.8 Hz, 1H), 8.17 (dd, J = 8.3, 1.8 Hz, 1H), 8.13* (dd, J = 8.3, 
1.8 Hz, 1H), 7.87 (dd, J = 8.3, 1.5 Hz, 1H), 7.63 – 7.53 (m, 2H), 7.49 (dd, J = 7.2, 1.5 Hz, 
1H), 7.42 (dd, J = 8.3, 4.1 Hz, 1H), 7.37* (dd, J = 8.3, 4.1 Hz, 1H), 3.07* (ddd, J = 7.3, 
3.2, 0.9 Hz, 1H), 2.93 (dd, J = 6.0, 3.3 Hz, 1H), 2.86 (d, J = 13.2 Hz, 1H), 2.83 – 2.73 (m, 
1H), 2.53 (dt, J = 13.1, 2.4 Hz, 1H), 2.41 – 2.33 (m, 1H), 2.27 (ddq, J = 15.1, 11.3, 2.1 
Hz, 1H), 2.15 – 1.94 (m, 2H), 1.94 – 1.83 (m, 1H), 1.71 (dtd, J = 13.2, 8.6, 7.6, 3.0 Hz, 
1H), 1.52 – 1.38* (m, 1H), 1.35 (s, 3H), 1.34* (s, 3H), 1.31 (s, 3H), 1.14* (s, 3H), 1.03 
(td, J = 13.7, 4.0 Hz, 1H). 
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13C NMR (major diastereomer, 101 MHz, CDCl3) δ 209.2, 175.5, 150.7, 146.3, 136.1, 
134.2, 130.7, 129.6, 129.1, 126.2, 121.9, 69.2, 53.2, 49.9, 40.7, 35.8, 34.8, 34.1, 30.2, 
29.0, 25.6, 20.1.  
13C NMR (minor diastereomer, 101 MHz, CDCl3) δ 210.0, 175.5, 150.7, 145.6, 136.0, 
134.2, 131.5, 129.6, 129.2, 126.0, 121.7, 68.9, 52.9, 49.8, 40.4, 35.0, 34.8, 34.6, 31.3, 
30.0, 26.1, 20.1. 
FTIR (NaCl, thin film) 3356, 3039, 2953, 2933, 2866, 1705, 1687, 1616, 1596, 1574, 
1525, 1496, 1472, 1426, 1391, 1341, 1312, 1279, 1250, 1223, 1134, 1124, 1038, 1027, 
905, 831, 795, 753, 664, 643 cm.-1 
HRMS (MM) calc’d for C22H25N2O2 [M+H]+ 349.1911, found 349.1916. 
 
Preparation of ketones 209 and 210 using Gilman’s reagent.  
 
To a flame-dried 100 mL flask was added copper (I) iodide (1.48 g, 7.75 mmol, 
5.00 equiv) and Et2O (15.5 mL). The resulting suspension was cooled to –40 °C and 
methyllithium (1.6 M in Et2O; 9.68 mL, 15.5 mmol, 10 equiv) was added dropwise. The 
reaction mixture was stirred at –40 °C for 2 hours before 148 (540 mg, 1.55 mmol) was 
added dropwise as a solution in 5:2 CH2Cl2/Et2O. The reaction mixture was gradually 
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warmed to 0 °C over 4 hours, then quenched with saturated aqueous NH4Cl (10 mL) and 
diluted with EtOAc. NH4OH was added until all of the solid copper salts were 
sequestered and two homogenous layers remained. The aqueous layer was extracted with 
EtOAc (3 x 20 mL) and the combined organics dried over MgSO4, filtered, and 
concentrated in vacuo. The crude residue was purified by silica gel flash chromatography 
(isocratic: 20% EtOAc/Hexane) to afford a 5:2 mixture of 209 and 210 (543 mg, 96% 
yield), respectively as a white amorphous solid. Subsequent purification by reverse-phase 
HPLC using two Agilent Eclipse XDB-C8 5um 9.4 x 250 mm columns connected in 
series (gradient: 77–85%MeCN/H2O) afforded analytically pure samples of each 
diastereomer, from which 210 was crystallized (for X-Ray analysis, see Appendix 2). 
 
Data for minor diastereomer 210: [𝛼]!!".! = –25.5° (c = 1.50, CHCl3). 
 
1H NMR (500 MHz, CDCl3) δ 9.64 (s, 1H), 8.82 (dd, J = 4.2, 1.7 Hz, 1H), 8.75 (dd, J = 
7.4, 1.6 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.56 – 7.48 (m, 2H), 7.46 (dd, J = 8.2, 
4.2 Hz, 1H), 2.89 – 2.77 (m, 2H), 2.35 – 2.26 (m, 2H), 2.24 (d, J = 13.3 Hz, 1H), 2.09 (d, 
J = 13.4 Hz, 1H), 2.07 – 1.99 (m, 1H), 1.88 – 1.77 (m, 1H), 1.72 – 1.61 (m, 3H), 1.55 – 
1.48 (m, 1H), 1.35 (s, 3H), 1.13 (s, 3H), 0.92 (s, 3H). 
 
13C NMR (126 MHz, CDCl3) δ 212.4, 170.6, 148.4, 138.5, 136.5, 134.6, 128.1, 127.6, 
121.7, 121.4, 116.4, 51.5, 50.8, 41.2, 39.8, 39.6, 35.2, 34.1, 33.0, 30.8, 23.7, 22.2, 21.3. 
 
FTIR (NaCl, thin film) 3349, 3044, 2952, 2863, 1706, 1687, 1595, 1577, 1523, 1484, 
1460, 1424, 1383, 1325, 1238, 1228, 1163, 827, 792 cm.-1 
 
HRMS (MM) calc’d for C23H29N2O2 [M+H]+ 365.2224, found 365.2261. 
Chapter 2 – First Generation Strategy Toward (+)-Psiguadial B 83 
Selective preparation of ketone 209 using copper-catalyzed conjugate addition. 
 
Inside a N2-filled glovebox, [Cu(OTf)]2•PhMe (72.4 mg, 0.140 mmol, 0.25 equiv) 
and (S,R,R) ligand 21155 (302 mg, 0.560 mmol, 1.00 equiv) were added to a 25 mL flask. 
The reagents were suspended in Et2O (5.60 mL) and stirred at room temperature for 30 
mins before trans-enone 148 (195 mg, 0.560 mmol) was added as a solid, in one portion. 
The reaction was sealed under N2, removed from the glovebox and cooled to –30 °C 
under argon using a cryocool unit to control the temperature. Me3Al (2.0 M in heptane; 
560 μL, 1.12 mmol, 2.00 equiv) was then added dropwise, taking care to avoid an 
exotherm and the reaction mixture stirred vigorously at –30 °C for 16 hours. MeOH (1.00 
mL) was then added to quench excess Me3Al and then the reaction was warmed to room 
temperature. The mixture was diluted with EtOAc and H2O, then the organic layer was 
separated. The aqueous layer was extracted with EtOAc (3 x 5 mL) and the combined 
organics dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel flash chromatography (2% Et2O/CH2Cl2 until ligand/impurities 
elute, then 4% Et2O/CH2Cl2) to afford a 30:1 mixture of 209 and 210 (126 mg, 62% 
yield), respectively as a white solid: [𝛼]!!".! = –84.7° (c = 0.600, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 9.64 (s, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.75 (dd, J = 
7.2, 1.8 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.56 – 7.47 (m, 2H), 7.45 (dd, J = 8.3, 
4.2 Hz, 1H), 2.89 – 2.76 (m, 2H), 2.36 – 2.28 (m, 2H), 2.25 (ddd, J = 12.5, 6.6, 1.1 Hz, 
 [Cu(OTf)]2•PhMe 
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1H), 2.04 (dt, J = 13.4, 2.0 Hz, 1H), 1.96 (ddq, J = 13.7, 7.0, 3.6 Hz, 1H), 1.81 (dtt, J = 
13.7, 12.0, 5.0 Hz, 1H), 1.68 – 1.62 (m, 2H), 1.62 – 1.51 (m, 2H), 1.35 (s, 3H), 1.13 (s, 
3H), 0.89 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 212.4, 170.6, 148.3, 138.5, 136.5, 134.6, 128.1, 127.5, 
121.7, 121.4, 116.4, 51.5, 50.4, 41.3, 40.9, 39.5, 35.2, 33.8, 32.6, 30.8, 23.7, 22.1, 20.8. 
 
FTIR (NaCl, thin film) 3351, 3047, 2954, 2870, 1708, 1688, 1524, 1485, 1460, 1424, 
1384, 1325, 1281, 1259, 1240, 1228, 1163, 919, 827, 792, 757, 732 cm.-1 
 
HRMS (MM) calc’d for C23H29N2O2 [M+H]+ 365.2224, found 365.2228 
 
Preparation of dimethyl ketal 213.  
 
To a flame-dried 15 mL flask was added ketone 209 (100 mg, 0.274 mmol) and 
dissolved in freshly distilled MeOH (2.7 mL). Trimethylorthoformate (150 μL, 1.37 
mmol, 5.00 equiv) was then added, followed by p-toluenesulfonic acid monohydrate 
(2.60 mg, 0.014 mmol, 0.05 equiv). The reaction was topped with a reflux condenser and 
heated to 65 °C for 1 hour, then quenched with saturated aqueous NaHCO3. The aqueous 
layer was extracted with EtOAc (3 x 5 mL), and the combined organics were dried over 
MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by Florisil ® 
O
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flash chromatography (isocratic: 10% EtOAc/Hexane) to afford 213 (106 mg, 94% yield) 
as a white, foamy solid: [𝛼]!!".! = –83.3° (c = 1.60, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 9.66 (s, 1H), 8.81 (dd, J = 4.3, 1.7 Hz, 1H), 8.78 (dd, J = 
7.4, 1.6 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.44 (dd, J = 8.3, 
4.2 Hz, 1H), 3.16 (s, 3H), 3.13 (s, 3H), 2.80 (d, J = 10.0 Hz, 1H), 2.69 (q, J = 9.7 Hz, 
1H), 2.01 (ddd, J = 13.2, 3.5, 1.6 Hz, 1H), 1.74 (dt, J = 14.0, 2.4 Hz, 1H), 1.70 – 1.50 (m, 
4H), 1.31 (s, 3H), 1.28 – 1.13 (m, 4H), 1.11 (s, 3H), 1.01 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 171.0, 148.3, 138.5, 136.4, 134.7, 128.0, 127.6, 121.6, 
121.2, 116.4, 100.8, 51.3, 47.9, 47.3, 42.3, 38.6, 34.8, 34.7, 34.0, 33.3, 32.5, 30.7, 23.9, 
21.4, 18.8. 
 
FTIR (NaCl, thin film) 3356, 3048, 2950, 2867, 2828, 1690, 1525, 1485, 1460, 1424, 
1384, 1368, 1325, 1288, 1276, 1261, 1242, 1155, 1108, 1096, 1048, 946, 927, 826, 792, 
756, 690, 666 cm.-1 
 
HRMS (MM) calc’d for C24H31N2O2 [M–OCH3]+ 379.2380, found 379.2376.  
 
 
 
 
 
 
 
Chapter 2 – First Generation Strategy Toward (+)-Psiguadial B 86 
Preparation of methyl enol ether 102. 
 
To a 15 mL thick-walled, screw top pressure vessel were added dimethyl ketal 
213 (59.8 mg, 0.146 mmol) and PhMe (5.0 mL). The tube sealed under a stream of N2. 
The reaction was heated to 170 °C in a preheated oil bath for 3.5 hours. The reaction was 
then cooled to room temperature and concentrated in vacuo to afford 102 (55.1 mg, 
quantitative yield), an inseparable ~1:1 mixture of enol ether isomers, as a foamy 
colorless gum: [𝛼]!!".! = –78.8° (c = 1.25, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 9.70 (s, 1H), 8.90 – 8.72 (m, 2H), 8.15 (dd, J = 8.2, 1.5 
Hz, 1H), 7.57 – 7.40 (m, 3H), 4.48 (s, 1H), 3.48 (s, 3H), 2.87 – 2.74 (m, 2H), 2.12 – 1.93 
(m, 2H), 1.74 – 1.57 (m, 4H), 1.48 – 1.36 (m, 1H), 1.33 (s, 3H), 1.31 – 1.27 (m, 1H), 1.12 
(s, 3H), 0.97 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 171.6, 171.0, 156.3, 154.3, 148.3, 148.3, 138.6, 138.5, 
136.4, 136.4, 134.8, 134.7, 128.5, 128.1, 128.1, 127.6, 126.9, 126.8, 121.7, 121.6, 121.2, 
121.2, 116.4, 116.3, 99.4, 92.1, 54.1, 53.9, 52.6, 51.5, 40.9, 40.1, 36.4, 35.4, 35.2, 34.0, 
33.5, 33.0, 32.6, 30.9, 30.8, 30.7, 29.9, 28.2, 26.1, 25.1, 24.1, 23.9, 21.2, 20.7, 19.5. 
 
FTIR (NaCl, thin film) 3354, 3051, 2949, 2930, 2862, 1690, 1668, 1524, 1484, 1461, 
1424, 1384, 1368, 1326, 1238, 1215, 1162, 1147, 1026, 826, 791, 756, 694 cm.-1 
 
HRMS (MM) calc’d for C24H31N2O2 [M+H]+ 379.2380, found 379.2395. 
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Preparation of model methoxy ketals 217–219.   
 
To a flame-dried 50 mL thick-walled, screw top pressure vessel were added o-
QM precursor 21542 (308 mg, 1.12 mmol), enol ether 21456 (756 mg, 6.74 mmol, 6.00 
equiv) and PhMe (19.0 mL). The vessel was sealed under a stream of N2 and heated to 
170 °C for 18 hours. The reaction mixture was concentrated in vacuo and the crude 
residue was purified by silica gel flash chromatography (2 – 10% Et2O/Hexane) to afford 
a 4:1 inseparable mixture of 217 and 218 (238 mg total, 46% and 12% yield, 
respectively), and 219 (69.8 mg, 17% yield), each as white solids.  
 
Data for 217 and 218:  
 
1H NMR (4:1 dr, asterisk denotes minor diastereomer, 400 MHz, CDCl3) δ 11.15 (s, 1H), 
δ 10.91* (s, 1H), 7.77 (dd, J = 8.9, 0.6 Hz, 1H), 7.68* (dd, J = 8.8, 0.7 Hz, 1H), 7.26 – 
7.20 (m, 2H), 7.14 (t, J = 7.3 Hz, 1H), 7.08 (d, J = 6.9 Hz, 2H), 6.57 (d, J = 8.8 Hz, 1H), 
6.49* (d, J = 8.8 Hz, 1H), 3.95 (s, 1H), 3.90 (s, 3H), 3.83* (s, 3H), 3.74* (d, J = 10.9 Hz, 
1H), 3.17* (s, 3H), 3.04 (s, 3H), 2.42 – 2.35* (m, 1H), 2.35 – 2.22 (m, 2H), 1.90 – 1.82 
(m, 1H), 1.80* (ddd, J = 12.1, 10.9, 3.9 Hz, 1H), 1.77 – 1.68 (m, 2H), 1.72 – 1.64* (m, 
2H), 1.64 – 1.58* (m, 1H), 1.52 – 1.43 (m, 1H), 1.45* (ddt, J = 11.2, 7.3, 3.0 Hz, 2H), 
1.42 – 1.32* (m, 1H), 1.36 (ddd, J = 9.9, 8.2, 2.5 Hz, 3H), 1.11* (tdd, J = 13.3, 8.3, 4.0 
Hz, 1H). 
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13C NMR (217, major diastereomer, 101 MHz, CDCl3) δ 170.8, 162.1, 158.2, 145.6, 
129.3, 127.7, 127.5, 125.6, 110.7, 109.1, 105.5, 101.0, 52.1, 47.5, 45.4, 42.1, 32.8, 31.5, 
25.3, 22.9. 
 
13C NMR (218, minor diastereomer 101 MHz, CDCl3) δ 170.7, 161.5, 158.3, 145.5, 
129.2, 128.0, 127.7, 125.8, 115.5, 109.1, 106.0, 100.2, 52.0, 48.8, 48.4, 41.7, 30.9, 26.9, 
25.4, 22.6. 
 
FTIR (NaCl, thin film) 3138 (br), 3085, 3061, 3025, 3002, 2937, 2858, 2832, 1666, 
1621, 1590, 1492, 1438, 1368, 1340, 1295, 1251, 1217, 1198, 1140, 1100, 1082, 1058, 
1014, 979, 936, 924, 885, 827, 816, 787, 753, 699 cm.-1 
 
HRMS (ESI) calc’d for C22H25O5 [M+H]+ 369.1697, found 369.1704. 
 
Data for 219:  
 
1H NMR (400 MHz, CDCl3) δ 11.14 (s, 1H), 7.72 (dd, J = 8.8, 0.9 Hz, 1H), 7.43 – 7.24 
(br m, 2H), 7.20 (t, J = 7.1 Hz, 2H), 7.12 – 6.76 (br m, 1H), 6.51 (d, J = 8.8 Hz, 1H), 4.68 
(d, J = 6.9 Hz, 1H), 3.87 (s, 3H), 3.24 (s, 3H), 2.51 – 2.39 (m, 1H), 1.99 (ddd, J = 12.5, 
6.9, 4.3 Hz, 1H), 1.77 – 1.65 (m, 1H), 1.60 (dd, J = 6.7, 4.3 Hz, 1H), 1.52 (tt, J = 12.9, 
3.8 Hz, 1H), 1.37 (td, J = 13.2, 4.5 Hz, 1H), 1.07 – 0.97 (m, 2H), 0.92 – 0.84 (m, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 170.9, 162.1, 158.9, 141.8, 129.2, 128.3, 125.8, 111.9, 
109.3, 105.9, 100.9, 52.1, 48.6, 43.6, 39.2, 32.6, 25.7, 25.3, 22.7. 
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FTIR (NaCl, thin film) 3134 (br), 3061, 3085, 3024, 3006, 2952, 2938, 1667, 1618, 
1588, 1490, 1438, 1422, 1341, 1292, 1256, 1242, 1219, 1200, 1174, 1142, 1120, 1098, 
1054, 1033, 1014, 976, 923, 886, 869, 806, 782, 761, 702, 632 cm.-1 
 
HRMS (ESI) calc’d for C21H21O4 [M–OCH3]+ 337.1434, found 337.1443. 
 
Preparation of benzhydryl morpholine 222. 
 
 To a flame-dried 100 mL round-bottom flask were added phloroglucinol 221 
(1.00g, 4.13 mmol), followed by freshly distilled MeOH (41.0 mL). Benzaldehyde (421 
μL, 4.13 mmol, 1.00 equiv), morpholine (361 μL, 4.13 mmol ,1.00 equiv), and 
triethylamine (576 μL, 4.13 mmol, 1.00 equiv) were then added successively via syringe 
and the reaction stirred at room temperature for 24 hours. The precipitate thus formed 
was collected by vacuum filtration and washed with MeOH (20 mL) and dried under high 
vacuum to afford analytically pure 222 (1.19 g, 69% yield) as a white powder.  
 
1H NMR (400 MHz, CDCl3) δ 15.34 (s, 1H), 13.16 (s, 1H), 12.53 (s, 1H), 7.45 (d, J = 
7.2 Hz, 2H), 7.34 – 7.20 (m, 3H), 4.88 (s, 1H), 3.99 (s, 3H), 3.91 (s, 3H), 3.90 – 3.40 (br 
m, 4H), 3.08 (br s, 1H), 2.46 (ddd, J = 11.9, 6.2, 3.1 Hz, 2H), 2.18 (br s, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 171.7, 166.2, 165.6, 165.1, 138.2, 128.9, 128.4, 103.8, 
96.5, 94.2, 69.0, 66.6, 52.7, 52.6. 
 
HO
OH
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CO2Me
CO2Me
Ph
HO
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O
OH
OH
CO2Me
CO2Me
N
Ph
O HO
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rt, 24 h
(69% yield)
220
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FTIR (NaCl, thin film) 3404 (br), 3062, 3030, 2955, 2894, 2854, 2716, 2562 (br), 2252, 
1953 (br), 1731, 1654, 1603, 1494, 1454, 1431, 1403, 1326, 1290, 1250, 1205, 1169, 
1121, 1080, 1029, 1006, 986, 942, 915, 878, 843, 825, 808, 761, 732, 700, 648 cm.-1 
 
HRMS (MM) calc’d for C21H24NO8 [M+H]+  418.1496, found 418.1515. 
 
Preparation of fully oxidized o-QM precursor 223. 
 
To a 50 mL round-bottom flask was added benzhydryl morpholine 222 (200 mg, 
0.479 mmol), followed by a 1:1 mixture of THF/H2O (9.6 mL). p-toluenesulfonic acid 
monohydrate (91.1 mg,  0.479 mmol, 1.00 equiv) was then added in one portion and the 
reaction was heated to 60 °C for 4 hours. Note: it is best to monitor this reaction closely 
by TLC to mitigate degradation of the product via acid-mediated retro aldol. Upon 
completion, the reaction was cooled to room temperature and quenched with saturated 
aqueous NaHCO3. The reaction was diluted with EtOAc and the organic layer separated. 
The aqueous layer was extracted with EtOAc (2 x 5 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel flash chromatography (isocratic: 5% EtOAc/CH2Cl2 + 0.5% AcOH, 
necessary to avoid streaking on the column). Fractions containing pure product were 
combined, washed with saturated aqueous NaHCO3, dried over MgSO4, filtered, and 
concentrated in vacuo to afford 223 (82.0 mg, 49% yield) as a white solid.  
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O HO
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Chapter 2 – First Generation Strategy Toward (+)-Psiguadial B 91 
1H NMR (400 MHz, CDCl3) δ 11.89 (s, 2H), 11.70 (s, 1H), 7.46 – 7.39 (m, 2H), 7.31 (t, 
J = 7.4 Hz, 2H), 7.26 – 7.19 (m, 1H), 6.38 – 6.23 (m, 1H), 4.09 (d, J = 11.6 Hz, 1H), 4.02 
(s, 6H). 
 
13C NMR (101 MHz, CDCl3) δ 170.9, 165.0, 164.7, 143.9, 128.2, 127.0, 125.6, 110.2, 
94.5, 68.1, 53.2. 
 
FTIR (NaCl, thin film) 3563 (br), 3357 (br), 3085, 3058, 3028, 3006, 2956, 2851, 2749 
(br), 1727, 1655, 1623, 1599, 1492, 1434, 1333, 1318, 1245, 1201, 1170, 1129, 1039, 
1026, 972, 909, 836, 816, 733, 698, 622 cm.-1 
 
HRMS (MM) calc’d for C17H15O7 [M–OH]+  331.0812, found 331.0825. 
 
Preparation of tricyclic ketals 225–228 by thermal cycloaddition. 
 
 
 To a 15 mL thick-walled, screw top pressure vessel were added dimethyl ketal 
213 (105 mg, 0.256 mmol) and o-QM precursor 223 (98.0 mg, 0.281 mmol, 1.10 equiv). 
PhMe (4.3 mL) was then added and the tube sealed under a stream of argon. The reaction 
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was heated to 170 °C in a preheated oil bath for 21 hours. The reaction was then cooled 
to room temperature and concentrated in vacuo. The crude residue was first purified by 
silica gel flash chromatography to remove separable impurities (4% EtOAc/CH2Cl2 + 
0.5% AcOH) to afford a complex mixture of diastereomers, including 225–228 (109 mg, 
68% yield). Analytically pure samples of the four diastereomers produced in greatest 
abundance (i.e. 225–228) were obtained by subsequent reverse-phase HPLC purification 
using an Agilent XDB-C18 5 μm 30 x 250 mm column (gradient: 83–100% MeCN/H2O). 
 
Chromatogram from HPLC separation:  
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Data for 225 (peak 1): [𝛼]!!".! = –13.8° (c = 0.420, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 12.22 (s, 1H), 11.68 (s, 1H), 9.65 (s, 1H), 8.81 (dd, J = 
4.2, 1.7 Hz, 1H), 8.77 (dd, J = 7.3, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.56 – 
7.48 (m, 2H), 7.46 (dd, J = 8.3, 4.2 Hz, 1H), 7.24 – 7.16 (m, 2H), 7.16 – 7.09 (m, 1H), 
7.09 – 7.02 (m, 2H), 3.96 (s, 3H), 3.93 (s, 3H), 3.91 (s, 1H), 3.05 (s, 3H), 2.82 – 2.67 (m, 
2H), 2.16 (dd, J = 12.4, 3.5 Hz, 1H), 1.98 (d, J = 13.8 Hz, 1H), 1.76 (dd, J = 13.3, 4.1 Hz, 
1H), 1.70 – 1.39 (m, 6H), 1.32 (s, 3H), 1.12 (s, 3H), 0.96 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 171.0, 170.8, 169.9, 165.0, 163.1, 157.2, 148.3, 145.6, 
138.5, 136.5, 134.7, 128.1, 127.8, 127.6, 127.3, 125.6, 121.7, 121.3, 116.4, 102.4, 102.1, 
99.0, 95.3, 52.8, 52.5, 51.3, 47.8, 45.3, 41.9, 41.4, 40.1, 34.7, 34.6, 32.7, 32.6, 30.8, 27.4, 
23.8, 22.3. 
FTIR (NaCl, thin film) 3410 (br), 3355 (br), 3055, 3021, 3000, 2950, 2864, 1734, 1686, 
1654, 1643, 1599, 1524, 1484, 1460, 1426, 1384, 1336, 1326, 1279, 1247, 1225, 1163, 
1142, 1093, 1063, 988, 973, 949, 841, 826, 791, 754, 698, 667 cm.-1 
 
HRMS (MM) calc’d for C41H45N2O9 [M+H]+  709.3120, found 709.3119. 
 
Data for 226 (peak 2): [𝛼]!!".! = –32.2° (c = 0.360, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 12.81 (s, 1H), 12.08 (s, 1H), 9.65 (s, 1H), 8.78 – 8.74 (m, 
2H), 8.15 (dd, J = 8.3, 1.6 Hz, 1H), 7.53 – 7.46 (m, 2H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 
7.22 (d, J = 7.5 Hz, 2H), 7.14 – 7.07 (m, 3H), 3.93 (d, J = 0.4 Hz, 3H), 3.93 (d, J = 0.3 
Hz, 3H), 3.91 (d, J = 7.8 Hz, 1H), 3.39 (s, 3H), 2.82 – 2.76 (m, 2H), 2.12 (s, 1H), 1.86 – 
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1.73 (m, 2H), 1.69 – 1.49 (m, 5H), 1.33 (s, 3H), 1.25 (d, J = 9.6 Hz, 1H), 1.10 (s, 3H), 
1.05 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 171.4, 170.8, 169.9, 166.0, 164.7, 158.9, 148.3, 145.9, 
138.5, 136.5, 134.7, 128.1, 128.1, 127.8, 127.6, 126.0, 121.7, 121.3, 116.3, 104.2, 104.1, 
97.1, 95.7, 52.7, 52.7, 52.2, 49.0, 44.2, 41.7, 39.9, 37.7, 35.1, 35.1, 33.9, 30.8, 28.9, 24.0, 
23.5, 22.8. 
 
FTIR (NaCl, thin film) 3412 (br), 3354 (br), 3059, 3022, 3006, 2951, 2928, 2864, 1731, 
1686, 1654, 1648, 1643, 1594, 1524, 1484, 1459, 1426, 1384, 1338, 1325, 1249, 1222, 
1201, 1157, 1122, 1081, 1092, 1028, 976, 945, 936, 847, 826, 792, 755, 700, 667 cm.-1 
 
HRMS (MM) calc’d for C41H45N2O9 [M+H]+  709.3120, found 709.3141. 
 
Data for 227 (peak 3): [𝛼]!!".! = –98.4° (c = 0.206, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 12.11 (s, 1H), 11.61 (s, 1H), 9.64 (s, 1H), 8.82 (dd, J = 
4.3, 1.7 Hz, 1H), 8.76 (dd, J = 7.3, 1.7 Hz, 1H), 8.16 (dd, J = 8.2, 1.7 Hz, 1H), 7.57 – 
7.43 (m, 3H), 7.30 (dd, J = 8.6, 5.1 Hz, 2H), 7.17 (s, 2H), 6.81 (s, 1H), 4.54 (d, J = 7.3 
Hz, 1H), 3.94 (s, 3H), 3.92 (s, 3H), 3.21 (s, 3H), 2.74 (q, J = 9.8 Hz, 2H), 2.10 (d, J = 
13.7 Hz, 1H), 1.97 – 1.83 (m, 1H), 1.62 (d, J = 8.9 Hz, 2H), 1.45 (d, J = 13.8 Hz, 1H), 
1.32 (s, 3H), 1.29 – 1.24 (m, 1H), 1.18 (d, J = 13.2 Hz, 1H), 1.11 (s, 3H), 1.10 – 1.06 (m, 
1H), 1.04 (s, 3H), 0.76 (dd, J = 13.1, 3.9 Hz, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 171.0, 170.9, 169.7, 164.9, 162.7, 158.0, 148.3, 142.2, 
138.5, 136.5, 134.7, 128.5, 128.1, 127.7, 127.6, 125.9, 121.7, 121.3, 116.4, 104.2, 102.2, 
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99.3, 95.5, 52.8, 52.5, 51.3, 49.0, 43.7, 42.2, 40.3, 38.5, 34.8, 34.4, 33.0, 32.6, 30.8, 23.8, 
22.1, 21.7. 
 
FTIR (NaCl, thin film) 3408 (br), 3354 (br), 3059, 3022, 3009, 2952, 2868, 1738, 1732, 
1682, 1658, 1652, 1645, 1599, 1525, 1485, 1462, 1455, 1426, 1385, 1327, 1281, 1251, 
1225, 1165, 1133, 1090, 1077, 1031, 991, 946, 872, 826, 792, 755, 703 cm.-1 
 
HRMS (MM) calc’d for C41H45N2O9 [M+H]+  709.3120, found 709.3133. 
 
Data for 228 (peak 4): [𝛼]!!".! = –13.4° (c = 0.226, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 11.95 (s, 1H), 11.23 (s, 1H), 9.66 (s, 1H), 8.81 (dd, J = 
4.2, 1.7 Hz, 1H), 8.76 (dd, J = 7.3, 1.7 Hz, 1H), 8.16 (dd, J = 8.3, 1.7 Hz, 1H), 7.55 – 
7.42 (m, 3H), 7.22 (dd, J = 7.9, 6.5 Hz, 2H), 7.18 – 7.13 (m, 1H), 7.10 (d, J = 7.4 Hz, 
2H), 3.90 (s, 3H), 3.87 (s, 3H), 3.67 (d, J = 11.0 Hz, 1H), 3.16 (s, 3H), 2.81 – 2.66 (m, 
2H), 2.10 (dd, J = 14.2, 1.6 Hz, 1H), 1.71 (td, J = 10.8, 5.3 Hz, 1H), 1.64 (dd, J = 9.2, 2.6 
Hz, 2H), 1.56 – 1.48 (m, 2H), 1.45 (d, J = 14.3 Hz, 1H), 1.38 – 1.32 (m, 1H), 1.31 (s, 
3H), 1.21 – 1.14 (m, 1H), 1.12 (s, 3H), 1.08 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 170.8, 170.8, 169.5, 164.0, 162.4, 157.4, 148.3, 145.4, 
138.5, 136.5, 134.7, 128.1, 128.1, 127.6, 125.9, 121.7, 121.3, 116.4, 108.0, 101.7, 99.6, 
95.5, 52.7, 52.5, 51.2, 49.4, 49.0, 42.0, 41.1, 36.2, 35.3, 34.8, 33.3, 32.6, 30.8, 23.8, 22.5, 
21.1. 
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FTIR (NaCl, thin film) 3412 (br), 3354 (br), 3055, 3023, 3003, 2950, 2866, 1732, 1688, 
1656, 1598, 1524, 1484, 1453, 1426, 1384, 1327, 1277, 1248, 1225, 1165, 1062, 993, 
954, 925, 826, 792, 755, 702 cm.-1 
 
HRMS (MM) calc’d for C41H45N2O9 [M+H]+  709.3120, found 709.3139. 
 
Preparation of tricyclic ketals 225–228 by Cu(OTf)2-mediated cycloaddition. 
 
Inside a N2-filled glovebox, methyl enol ether 102 (17.0 mg, 0.045 mmol) and o-
QM precursor 223 (16.4 mg, 0.047 mmol, 1.05 equiv) were added to a 1 dram vial and 
dissolved in CH2Cl2 (400 μL). Cu(OTf)2 was then added as a solid in one portion and the 
reaction immediately turns a light green color, then yellow-brown within the first 5 
minutes. The reaction was stirred at room temperature for 1 hour, then quenched with 
saturated aqueous NaHCO3 and diluted with CHCl3. The reaction mixture was extracted 
with CHCl3 (3 x 1 mL) and the organics fitered through a plug of Na2SO4 and 
concentrated in vacuo. The crude residue was analyzed by 1H NMR and determined to 
contain 225, 226, 227, and 228 in a 1.0 : 1.8 : 2.3 : 2.5 ratio, respectively. For 
spectroscopic characterization data, see above.  
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Preparation of aldehyde 233. 
 
Inside a N2-filled glovebox, Schwartz’s reagent (119 mg, 0.462 mmol, 2.00 equiv) 
was added to a 10 mL flask and sealed under N2. The flask was removed from the 
glovebox and THF (1.2 mL) was added via syringe. To the milky-white suspension was 
added ketal 213 (94.8 mg, 0.231mmol) as a solution in THF (1.2 mL) in a quick drip. The 
reaction immediately beings to turn yellow, eventually becoming a darker orange color 
over 1 hour, at which time the reaction was quenched by the addition of saturated 
aqueous NaHCO3. The reaction was diluted with EtOAc and the organic layer separated. 
The aqueous layer was extracted with EtOAc (2 x 5 mL) and the combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The crude residue was 
purified by silica gel flash chromatography (isocratic: 5% EtOAc/hexane + 1% Et3N) to 
afford 233 (36.9 mg, 62% yield) as a pale yellow oil: [𝛼]!!".! = –33.1° (c = 0.500, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 9.70 (d, J = 3.0 Hz, 1H), 3.14 (s, 3H), 3.09 (s, 3H), 2.64 
(td, J = 9.7, 8.5 Hz, 1H), 2.58 (dd, J = 9.9, 3.0 Hz, 1H), 1.86 (ddt, J = 13.6, 4.2, 2.6 Hz, 
1H), 1.61 (t, J = 10.3 Hz, 1H), 1.57 – 1.44 (m, 4H), 1.34 – 1.18 (m, 2H), 1.16 (s, 3H), 
1.14 (s, 3H), 1.13 – 1.05 (m, 2H), 0.89 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 204.7, 100.5, 55.2, 47.6, 47.1, 39.8, 39.3, 35.7, 34.4, 
33.9, 33.0, 32.7, 31.1, 24.3, 21.7, 18.6. 
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FTIR (NaCl, thin film) 2952, 2868, 2828, 2705, 1713, 1461, 1383, 1368, 1341, 1288, 
1262, 1246, 1180, 1166, 1110, 1098, 1048, 1009, 945, 924, 823, 828 cm.-1 
 
HRMS (MM) calc’d for C15H25O2 [M–OCH3]+  237.1849, found 237.4454. 
 
Preparation of alkyne 234. 
 
To a 10 mL round bottom flask were added aldehyde 233 (36.0 mg, 0.134 mmol) 
and K2CO3 (37.0 mg, 0.268 mmol, 2.00 equiv). The flask was fitted with a septum and 
the atmosphere exchanged 2x for N2. Freshly distilled MeOH (1.5 mL) was then added 
via syringe and the solution cooled to 0 °C. Dimethyl-1-diazo-2-oxopropylphosphonate57 
(38.6 mg, 0.201 mmol, 1.50 equiv) was weighed into a tared syringe and added dropwise 
to the reaction, neat. The reaction was allowed to gradually warm to room temperature 
and stirred for 12 hours. The reaction was then diluted with Et2O, saturated aqueous 
NaHCO3 was added, and the organic layer separated. The aqueous layer was extracted 
with Et2O (3 x 5 mL) and the combined organic layers were dried over MgSO4, filtered, 
and concentrated in vacuo. The crude residue was purified by Florisil® flash 
chromatography (isocratic: 5% Et2O/pentane) to afford 234 (32.9 mg, 93% yield) as a 
pale yellow oil: [𝛼]!!".! = –43.6° (c = 0.355, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 3.17 (s, 3H), 3.13 (s, 3H), 2.43 (dd, J = 10.1, 2.4 Hz, 1H), 
2.16 – 2.05 (m, 2H), 2.04 – 1.93 (m, 1H), 1.69 (ddd, J = 13.9, 2.8, 1.8 Hz, 1H), 1.59 – 
O
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1.50 (m, 2H), 1.48 (d, J = 9.6 Hz, 2H), 1.29 – 1.17 (m, 5H), 1.16 (d, J = 2.7 Hz, 4H), 1.03 
(s, 3H), 0.97 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 100.7, 85.8, 70.5, 49.1, 47.9, 47.3, 39.1, 35.2, 35.1, 34.0, 
33.5, 33.2, 33.2, 29.9, 24.8, 21.1, 18.8. 
 
FTIR (NaCl, thin film) 3310, 3263, 2953, 2866, 2828, 1459, 1383, 1364, 1342, 1323, 
1288, 1266, 1243, 1180, 1157, 1106, 1094, 1048, 945, 926, 858, 830, 655, 621 cm.-1 
 
HRMS (MM) calc’d for C16H25O2 [M–OCH3]+  233.1900, found 233.1887. 
 
Preparation of vinyl sulfides 236 and 235. 
 
 Inside a N2-filled glovebox, THF (400 μL) was added to a 1 dram vial containing 
alkyne 234 (12.4 mg, 0.047 mmol), followed by Ni(acac)2 as a stock solution in THF 
(0.10 M, 70 μL, 0.007 mmol, 0.15 equiv). The reaction was stirred for 10 minutes at 
room temperature before thiophenol (10 μL, 0.094 mmol, 2.00 equiv) was added neat. 
The reaction was sealed with a Teflon cap and heated to 60 ° C in a preheated aluminum 
block inside the glovebox. After 3 hours, the reaction was cooled to room temperature 
and diluted with CH2Cl2. The reaction mixture was filtered over a small pad of celite, 
washed with CH2Cl2 until the filtrate runs colorless, and concentrated in vacuo. The crude 
residue was taken up in EtOAc and shaken with 5M NaOH (to remove excess 
H
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thiophenol). The organic layer was then filtered through a plug of Na2SO4, concentrated, 
and purified by preparative thin-layer chromatography (5% EtOAc/hexane + 1% Et3N) to 
afford 235 (8.50 mg, 53% yield) and 236 (2.7 mg, 15% yield) each as colorless oils.  
Data for ketal 236: [𝛼]!!".! = +12.3° (c = 0.115, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.42 (dd, J = 8.1, 1.6 Hz, 2H), 7.36 – 7.28 (m, 3H), 5.17 
(d, J = 1.3 Hz, 1H), 4.96 (s, 1H), 3.17 (s, 3H), 3.13 (s, 3H), 2.51 (d, J = 10.2 Hz, 1H), 
2.26 (q, J = 9.7 Hz, 1H), 2.04 – 1.92 (m, 1H), 1.65 (ddd, J = 13.8, 2.8, 1.6 Hz, 1H), 1.50 
(ddd, J = 9.6, 7.0, 3.7 Hz, 2H), 1.45 – 1.39 (m, 2H), 1.21 – 1.12 (m, 4H), 1.11 (s, 3H), 
0.98 (s, 3H), 0.91 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 145.9, 133.8, 133.4, 129.2, 127.9, 111.6, 100.8, 49.4, 
47.9, 47.3, 45.1, 39.7, 35.6, 34.8, 34.6, 33.2, 32.4, 30.6, 23.2, 21.7, 18.9. 
 
FTIR (NaCl, thin film) 2950, 2863, 2827, 1610, 1583, 1476, 1459, 1439, 1379, 1364, 
1322, 1274, 1260, 1247, 1178, 1145, 1130, 1100, 1083, 1049, 1024, 946, 926, 856, 831, 
822, 747, 691 cm.-1 
 
HRMS (MM) calc’d for C22H31OS [M–OCH3]+  343.2090, found 343.2073. 
 
Data for enol ether 235: [𝛼]!!".! = –11.0° (c = 0.982, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 7.46 – 7.36 (m, 2H), 7.36 – 7.27 (m, 3H), 5.23 – 4.84 (m, 
2H), 4.63 – 4.29 (m, 1H), 3.40 (s, 3H), 2.58 – 2.50 (m, 1H), 2.40 (dq, J = 34.9, 9.5 Hz, 
1H), 2.11 – 1.91 (m, 3H), 1.64 (ddd, J = 15.0, 5.9, 2.4 Hz, 2H), 1.48 – 1.40 (m, 2H), 1.39 
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– 1.30 (m, 1H), 1.11 (d, J = 9.9 Hz, 3H), 1.00 (d, J = 2.4 Hz, 3H), 0.83 (d, J = 21.0 Hz, 
4H). 
 
13C NMR (101 MHz, CDCl3) δ 155.3, 154.4, 146.0, 145.9, 133.8, 133.5, 133.4, 133.3, 
129.2, 129.1, 127.9, 127.7, 112.3, 111.1, 100.6, 92.0, 54.1, 53.9, 50.2, 49.5, 43.5, 40.9, 
37.7, 36.1, 35.1, 35.1, 34.5, 34.1, 32.9, 32.6, 31.6, 30.6, 30.5, 28.2, 25.8, 23.3, 23.2, 22.0, 
20.8, 19.4. 
 
FTIR (NaCl, thin film) 3061, 2991, 2950, 2930, 2862, 2843, 1667, 1609, 1583, 1476, 
1460, 1453, 1440, 1380, 1366, 1251, 1215, 1148, 1066, 1024, 940, 817, 747, 691 cm.-1 
 
HRMS (MM) calc’d for C22H31OS [M+H]+  343.2090, found 343.2087. 
 
Preparation of bridged bicycle 237. 
 
 Inside a N2-filled glovebox, CH2Cl2 was added to a 1 dram vial containing 236 
(9.30 mg, 0.025 mmol), followed by InCl3 (5.49 mg, 0.025 mmol, 1.00 equiv). The 
reaction was stirred at room temperature for 2 hours, then quenched with saturated 
aqueous NaHCO3 and diluted with CH2Cl2. The reaction was extracted with CH2Cl2 (3 x 
500 μL), the combined organics filtered a plug of Na2SO4, and concentrated in vacuo. 
The crude residue was purified by silica gel flash chromatography (40–60% 
H
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CH2Cl2/hexane) to afford 237 (0.900 mg, 11% yield) as a colorless oil, with the 
remaining mass balance accounted for by ketone 238, as determined by crude 1H NMR.  
Data for bridged bicycle 237: [𝛼]!!".! = +58.2° (c = 0.053, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.36 (m, 2H), 7.30 (ddd, J = 8.3, 7.1, 0.8 Hz, 2H), 
7.24 – 7.18 (m, 1H), 5.52 (dd, J = 2.8, 1.7 Hz, 1H), 3.18 (s, 3H), 2.91 – 2.81 (m, 1H), 
2.00 – 1.72 (m, 5H), 1.66 (ddd, J = 11.6, 6.8, 3.5 Hz, 1H), 1.44 – 1.37 (m, 2H), 1.35 (dd, 
J = 12.3, 1.7 Hz, 1H), 1.29 (m, 1H), 1.28 (s, 3H), 1.19 (dd, J = 14.1, 7.0 Hz, 1H), 1.00 (s, 
3H), 0.80 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 139.7, 139.6, 135.0, 131.7, 129.2, 127.2, 80.6, 52.4, 50.2, 
49.2, 48.6, 40.1, 38.3, 36.2, 33.7, 31.3, 31.2, 28.9, 22.4, 21.2. 
FTIR (NaCl, thin film) 3062, 2945, 2927, 2860, 2820, 1734, 1718, 1701, 1654, 1583, 
1560, 1476, 1458, 1438, 1370, 1294, 1254, 1232, 1151, 1086, 1066, 1024, 950, 870, 840, 
800, 743, 690 cm.-1 
 
HRMS (MM) calc’d for C22H31OS [M+H]+  343.2090, found 343.2077. 
 
Data for ketone 238: [𝛼]!!".! = +31.6° (c = 0.100, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 7.46 (dd, J = 8.1, 1.6 Hz, 2H), 7.40 – 7.32 (m, 3H), 5.13 
(d, J = 1.3 Hz, 1H), 4.98 (s, 1H), 2.53 (d, J = 10.1 Hz, 1H), 2.38 (td, J = 10.0, 8.9 Hz, 
1H), 2.32 – 2.23 (m, 2H), 2.17 (d, J = 13.6 Hz, 1H), 2.02 (dt, J = 13.4, 1.9 Hz, 1H), 1.93 
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– 1.90 (m, 1H), 1.82 (dddd, J = 9.7, 8.1, 3.9, 2.3 Hz, 1H), 1.57 (q, J = 4.4 Hz, 1H), 1.49 – 
1.44 (m, 1H), 1.44 – 1.33 (m, 2H), 1.16 (s, 3H), 1.03 (s, 3H), 0.82 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 212.6, 145.5, 134.1, 133.0, 129.3, 128.2, 111.4, 51.1, 
49.8, 43.1, 41.3, 40.3, 35.1, 34.2, 32.5, 30.6, 23.1, 22.1, 21.8. 
 
FTIR (NaCl, thin film) 3059, 2953, 2927, 2860, 1711, 1680, 1611, 1583, 1476, 1461, 
1440, 1381, 1364, 1347, 1311, 1283, 1253, 1228, 1151, 1087, 1067, 1024, 890, 855, 749, 
692 cm.-1 
 
HRMS (MM) calc’d for C21H29OS [M+H]+  329.1934, found 329.1943. 
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Appendix 2 
X-Ray Crystallography Reports Relevant to Chapter 2: 
First Generation Synthetic Strategy Toward (+)-Psiguadial B and  
Development of a Catalytic, Asymmetric Wolff Rearrangement† 
  
                                                
† The work disclosed in this appendix for the X-ray crystallographic analysis of 148 was 
completed by Dr. Allen Oliver at the University of Notre Dame in the Molecular 
Structure Facility and Dr. Nathan Schley, a postdoctoral researcher in the Fu lab. X-ray 
crystallographic analysis of 210 was completed by Dr. Michael Takase at the Caltech X-
ray crystallography lab and Julie Hofstra, a graduate student in the Reisman lab. 
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A2.1 CRYSTAL STRUCTURE ANALYSIS: TRANS-CYCLOBUTANE 148 
Figure A2.1. Rendering of trans-cyclobutane 148, used to establish the absolute 
stereochemistry across the cyclobutane ring.  
 
 
 
Table A2.1. Crystal data and structure refinement for trans-cyclobutane 148. 
Identification code  Crystal01 (or trans-cyclobutane 148).  
Empirical formula  C22H24N2O2 
Formula weight  348.43 
Temperature  119.98 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.3942(5) Å α = 90°. 
 b = 11.6678(9) Å β = 90 °. 
 c = 24.848(2) Å γ = 90 °. 
Volume 1853.8(3) Å3 
Z 4 
Density (calculated) 1.248 Mg/m3 
Absorption coefficient 0.636 mm-1 
F(000) 744 
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Crystal size 0.237 x 0.093 x 0.082 mm3 
Theta range for data collection 3.557 to 71.792°. 
Index ranges -7<=h<=7, -14<=k<=14, -28<=l<=30 
Reflections collected 41642 
Independent reflections 3620 [R(int) = 0.0313] 
Completeness to theta = 67.679° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9883 and 0.8875 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3620 / 0 / 237 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0292, wR2 = 0.0782 
R indices (all data) R1 = 0.0294, wR2 = 0.0785 
Absolute structure parameter -0.04(4) 
Largest diff. peak and hole 0.255 and -0.181 e/Å-3 
 
 
Crystallographic Analysis and Refinement Details: 
A suitable crystal of C22H24N2O2 was selected for analysis. All measurements were made on a 
Bruker APEX-II CCD with filtered Cu-Kα radiation at a temperature of 120 K. Using Olex2,1 the structure 
was solved with the ShelXS2 structure solution program using Direct Methods and refined with the ShelXL 
refinement package using Least Squares minimization. The absolute stereochemistry was determined on the 
basis of the absolute structure parameter. Graphical representation of the structure with 50% probability 
thermal ellipsoids was generated using Mercury visualization software.3  
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Table A2.2. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for trans-cyclobutane 148.  U(eq) is defined as one third of 
the trace of the orthogonalized Uij tensor.  
________________________________________________________________________________  
 x y z U(eq) 
_______________________________________________________________________________  
O(1) -4024(2) 4325(1) 3741(1) 30(1) 
O(2) 5981(2) 5004(1) 2361(1) 34(1) 
N(1) -3297(2) 4719(1) 4622(1) 22(1) 
N(2) -3330(2) 4949(1) 5683(1) 23(1) 
C(1) -2893(2) 4755(1) 4081(1) 21(1)  
C(2) -944(2) 5426(1) 3950(1) 19(1) 
C(3) -1002(3) 6755(1) 4055(1) 24(1) 
C(4) -3194(3) 7259(2) 3999(1) 31(1) 
C(5) 36(3) 7135(2) 4574(1) 33(1) 
C(6) 286(3) 6893(1) 3529(1) 26(1) 
C(7) -388(3) 5674(1) 3354(1) 22(1) 
C(8) 1149(3) 4904(1) 3080(1) 22(1) 
C(9) 2914(3) 5310(1) 2858(1) 23(1) 
C(10) 4426(3) 4596(2) 2574(1) 26(1) 
C(11) 3943(3) 3338(2) 2530(1) 38(1) 
C(12) 2522(3) 2898(2) 2970(1) 40(1) 
C(13) 612(3) 3648(2) 3047(1) 30(1) 
C(14) -5080(2) 4317(1) 4886(1) 20(1) 
C(15) -6783(3) 3820(1) 4640(1) 22(1) 
C(16) -8492(3) 3441(1) 4955(1) 24(1) 
C(17) -8509(3) 3560(1) 5503(1) 27(1) 
C(18) -6795(3) 4077(1) 5768(1) 24(1) 
C(19) -5062(2) 4456(1) 5460(1) 20(1) 
C(20) -3303(3) 5073(2) 6212(1) 27(1) 
C(21) -4952(3) 4734(2) 6553(1) 29(1) 
C(22) -6681(3) 4240(2) 6333(1) 29(1)  
________________________________________________________________________________ 
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Table A2.3. Bond lengths [Å] and angles [°]for trans-cyclobutane 148. 
_____________________________________________________  
O(1)-C(1)  1.219(2) 
O(2)-C(10)  1.224(2) 
N(1)-C(1)  1.369(2) 
N(1)-C(14)  1.397(2) 
N(2)-C(19)  1.365(2) 
N(2)-C(20)  1.320(2) 
C(1)-C(2)  1.507(2) 
C(2)-C(3)  1.574(2) 
C(3)-C(4)  1.526(2) 
C(3)-C(6)  1.554(2) 
C(5)-C(3)  1.516(2) 
C(7)-C(2)  1.551(2) 
C(7)-C(6)  1.549(2) 
C(7)-C(8)  1.495(2) 
C(8)-C(13)  1.508(2) 
C(8)-C(9)  1.342(2) 
C(10)-C(11)  1.504(3) 
C(10)-C(9)  1.459(2) 
C(11)-C(12)  1.511(3) 
C(13)-C(12)  1.515(3) 
C(14)-C(15)  1.377(2) 
C(14)-C(19)  1.436(2) 
C(15)-C(16)  1.414(2) 
C(17)-C(16)  1.369(2) 
C(18)-C(17)  1.415(2) 
C(18)-C(19)  1.417(2) 
C(18)-C(22)  1.417(2) 
C(20)-C(21)  1.410(3) 
C(21)-C(22)  1.362(3) 
  
O(1)-C(1)-C(2) 123.68(14) 
O(1)-C(1)-N(1) 123.69(14) 
O(2)-C(10)-C(11) 121.04(16) 
O(2)-C(10)-C(9) 121.70(16) 
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N(1)-C(1)-C(2) 112.58(13) 
N(1)-C(14)-C(19) 115.04(14) 
N(2)-C(19)-C(14) 117.20(14) 
N(2)-C(19)-C(18) 123.12(14) 
N(2)-C(20)-C(21) 123.85(16) 
C(1)-C(2)-C(3) 117.15(13) 
C(1)-C(2)-C(7) 119.57(13) 
C(1)-N(1)-C(14) 128.75(13) 
C(4)-C(3)-C(2) 112.66(14) 
C(4)-C(3)-C(6) 111.66(14) 
C(5)-C(3)-C(2) 114.81(13) 
C(5)-C(3)-C(4) 111.60(14) 
C(5)-C(3)-C(6) 116.97(15) 
C(6)-C(3)-C(2) 87.09(11) 
C(6)-C(7)-C(2) 88.10(12) 
C(7)-C(2)-C(3) 88.86(11) 
C(7)-C(6)-C(3) 89.69(12) 
C(7)-C(8)-C(13) 117.31(14) 
C(8)-C(13)-C(12) 112.61(15) 
C(8)-C(7)-C(2) 118.23(13) 
C(8)-C(7)-C(6) 119.83(14) 
C(8)-C(9)-C(10) 123.62(15) 
C(9)-C(10)-C(11) 117.19(15) 
C(9)-C(8)-C(13) 120.87(15) 
C(9)-C(8)-C(7) 121.80(15) 
C(10)-C(11)-C(12) 113.71(15) 
C(11)-C(12)-C(13) 112.36(17) 
C(14)-C(15)-C(16) 119.81(14) 
C(15)-C(14)-C(19) 119.65(14) 
C(15)-C(14)-N(1) 125.31(14) 
C(16)-C(17)-C(18) 120.05(16) 
C(17)-C(16)-C(15) 121.66(16) 
C(17)-C(18)-C(19) 119.14(14) 
C(17)-C(18)-C(22) 123.96(16) 
C(18)-C(19)-C(14) 119.67(14) 
C(20)-N(2)-C(19) 117.41(15) 
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C(21)-C(22)-C(18) 119.72(16) 
C(22)-C(18)-C(19) 116.89(15) 
C(22)-C(21)-C(20) 119.00(15) 
_____________________________________________________________  
 
 
Table A2.4. Anisotropic displacement parameters (Å2x 104) for trans-cyclobutane 
148. The anisotropic displacement factor exponent takes the form: -2π2[ h2 
a*2U11 + ... + 2 h k a* b* U12 ]  
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 28(1)  43(1) 19(1)  1(1) -2(1)  -12(1) 
O(2) 28(1)  46(1) 27(1)  0(1) 8(1)  -4(1) 
N(1) 20(1)  28(1) 18(1)  0(1) 0(1)  -4(1) 
N(2) 24(1)  25(1) 21(1)  1(1) -1(1)  1(1) 
C(1) 20(1)  22(1) 20(1)  2(1) -1(1)  0(1) 
C(2) 19(1)  22(1) 17(1)  1(1) -1(1)  -1(1) 
C(3) 26(1)  23(1) 23(1)  0(1) 4(1)  -2(1) 
C(4) 34(1)  28(1) 32(1)  4(1) 7(1)  8(1) 
C(5) 38(1)  31(1) 29(1)  -6(1) 2(1)  -8(1) 
C(6) 29(1)  23(1) 27(1)  2(1) 5(1)  -2(1) 
C(7) 22(1)  26(1) 18(1)  4(1) 0(1)  -2(1) 
C(8) 22(1)  26(1) 16(1)  -1(1) -2(1)  -2(1) 
C(9) 26(1)  25(1) 19(1)  1(1) 0(1)  -4(1)  
C(10) 24(1)  37(1) 16(1)  -1(1) 0(1)  -3(1) 
C(11) 36(1)  39(1) 40(1)  -16(1) 10(1)  -3(1) 
C(12) 45(1)  27(1) 48(1)  -8(1) 12(1)  -4(1) 
C(13) 31(1)  28(1) 32(1)  -6(1) 8(1)  -8(1) 
C(14) 21(1)  18(1) 21(1)  3(1) 1(1)  3(1) 
C(15) 24(1)  20(1) 21(1)  2(1) -1(1)  2(1) 
C(16) 21(1)  22(1) 31(1)  3(1) 0(1)  -1(1) 
C(17) 24(1)  26(1) 31(1)  5(1) 7(1)  -1(1) 
C(18) 26(1)  20(1) 24(1)  3(1) 3(1)  4(1) 
C(19) 22(1)  17(1) 21(1)  2(1) 0(1)  3(1) 
C(20) 32(1)  28(1) 22(1)  -1(1) -3(1)  2(1) 
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C(21) 38(1)  30(1) 20(1)  1(1) 2(1)  6(1) 
C(22) 34(1)  28(1) 25(1)  4(1) 8(1)  4(1) 
______________________________________________________________________________ 
 
 
 
 
Table A2.5. Hydrogen coordinates ( x 104) and isotropic displacement parameters 
(Å2x 103) for trans-cyclobutane 148. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1) -2298 4985 4831 26 
H(2) 286 5078 4137 23 
H(4A) -3840 6972 3667 47 
H(4B) -3104 8096 3983 47 
H(4C) -4046 7031 4309 47 
H(5A) -803 6878 4881 49 
H(5B) 144 7973 4579 49 
H(5C) 1438 6799 4597 49 
H(6A) -237 7508 3290 31 
H(6B) 1809 6972 3590 31 
H(7) -1698 5721 3135 26 
H(9) 3195 6107 2889 28 
H(11A) 5272 2902 2541 46 
H(11B) 3277 3190 2177 46 
H(12A) 3314 2863 3312 48 
H(12B) 2067 2110 2880 48 
H(13A) -363 3523 2743 36 
H(13B) -114 3417 3382 36 
H(15) -6811 3732 4260 26 
H(16) -9656 3096 4781 29 
H(17) -9674 3295 5705 32 
H(20) -2101 5411 6371 33 
H(21) -4858 4849 6930 35 
H(22) -7806 4005 6557 35 
________________________________________________________________________________ 
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A2.2  CRYSTAL STRUCTURE ANALYSIS: MINOR KETONE 210 
Figure A2.2. Rendering of minor ketone 210, used to establish the relative 
stereochemistry of the methyl group at the C1 quaternary center.  
  
 
 
Table A2.6. Crystal data and structure refinement for minor ketone 210. 
Identification code  LMC-04-038 or minor ketone 210.  
Empirical formula  C23H28N2O2 
Formula weight  364.47 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.5496(4) Å a= 90°. 
 b = 10.8428(6) Å b= 90°. 
 c = 27.6666(15) Å g = 90°. 
Volume 1964.77(19) Å3 
Z 4 
Density (calculated) 1.232 Mg/m3 
Absorption coefficient 0.619 mm-1 
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F(000) 784 
Crystal size 0.25 x 0.15 x 0.1 mm3 
Theta range for data collection 3.195 to 79.392°. 
Index ranges -8<=h<=8, -13<=k<=13, -35<=l<=34 
Reflections collected 24424 
Independent reflections 4179 [R(int) = 0.0414] 
Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7542 and 0.7017 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4179 / 0 / 251 
Goodness-of-fit on F2 1.021 
Final R indices [I>2sigma(I)] R1 = 0.0272, wR2 = 0.0655 
R indices (all data) R1 = 0.0300, wR2 = 0.0672 
Absolute structure parameter 0.08(9) 
Extinction coefficient 0.0031(3) 
Largest diff. peak and hole 0.187 and -0.154 e.Å-3 
 
Crystallographic Analysis and Refinement Details: 
Low-temperature diffraction data (φ- and ω-scans) were collected on a Bruker AXS D8 
VENTURE KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with Cu-Kα radiation (λ = 
1.54178 Å) from a IµS HB micro-focus sealed X-ray tube. All diffractometer manipulations, including data 
collection, integration, and scaling were carried out using the Bruker APEXII software.4 Absorption 
corrections were applied using SADABS.5 The structure was solved by intrinsic phasing using SHELXT14 
and refined against F2 on all data by full-matrix least squares with SHELXL-20142 using established 
refinement techniques.6 All non-hydrogen atoms were refined anisotropically. The coordinates for the 
hydrogen atom bound to N1 were located in the difference Fourier synthesis and refined using a riding 
model. All other hydrogen atoms were included into the model at geometrically calculated positions and 
refined using a riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups and hydroxyl groups). 
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Compound 210 crystallizes in the monoclinic space group P212121 with one molecule in the asymmetric 
unit. Absolute configuration was determined by anomalous dispersion (Flack = 0.08(9)).7 Graphical 
representation of the structure with 50% probability thermal ellipsoids was generated using Mercury 
visualization software.3 
 
Table A2.7. Atomic coordinates ( x 104) and equivalent isotropic displacement 
parameters (Å2x 103) for minor ketone 210.  U(eq) is defined as one third of the 
trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(2) 1276(2) 7506(1) 2689(1) 28(1) 
O(1) 8526(2) 4834(1) 3832(1) 28(1) 
N(1) 6907(2) 5042(1) 4555(1) 17(1) 
N(2) 6036(2) 5230(1) 5486(1) 17(1) 
C(1) 6977(2) 4762(1) 4073(1) 17(1) 
C(19) 9262(2) 6260(1) 5671(1) 18(1) 
C(8) 4149(2) 4860(1) 2948(1) 15(1) 
C(23) 7898(2) 5670(1) 5348(1) 15(1) 
C(15) 8440(2) 5545(1) 4849(1) 16(1) 
C(7) 4752(2) 3938(1) 3343(1) 16(1) 
C(2) 4949(2) 4328(1) 3880(1) 16(1) 
C(17) 11684(2) 6499(1) 5023(1) 21(1) 
C(18) 11180(2) 6672(1) 5498(1) 21(1) 
C(16) 10309(2) 5955(1) 4692(1) 19(1) 
C(3) 4183(2) 3002(1) 4028(1) 19(1) 
C(22) 5507(2) 5373(2) 5942(1) 21(1) 
C(10) 1519(2) 6401(2) 2662(1) 19(1) 
C(14) 5948(2) 5744(2) 2867(1) 22(1) 
C(21) 6728(3) 5976(2) 6290(1) 24(1) 
C(9) 2231(2) 5619(1) 3083(1) 18(1) 
C(6) 3268(3) 2907(1) 3511(1) 20(1) 
C(13) 3699(2) 4120(2) 2484(1) 19(1) 
C(20) 8601(3) 6410(2) 6153(1) 22(1) 
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C(12) 2998(2) 4916(2) 2060(1) 22(1) 
C(4) 2696(3) 2947(2) 4449(1) 25(1) 
C(5) 5955(3) 2106(2) 4103(1) 26(1) 
C(11) 1133(3) 5697(2) 2200(1) 24(1) 
________________________________________________________________________________  
 
 
 
Table A2.8. Bond lengths [Å] and angles [°] for minor ketone 210. 
_____________________________________________________  
O(2)-C(10)  1.211(2) 
O(1)-C(1)  1.2176(18) 
N(1)-C(1)  1.3676(19) 
N(1)-C(15)  1.402(2) 
N(1)-H(1)  0.90(2) 
N(2)-C(23)  1.364(2) 
N(2)-C(22)  1.319(2) 
C(1)-C(2)  1.507(2) 
C(19)-C(23)  1.417(2) 
C(19)-C(18)  1.416(2) 
C(19)-C(20)  1.412(2) 
C(8)-C(7)  1.534(2) 
C(8)-C(14)  1.535(2) 
C(8)-C(9)  1.548(2) 
C(8)-C(13)  1.540(2) 
C(23)-C(15)  1.431(2) 
C(15)-C(16)  1.373(2) 
C(7)-H(7)  1.0000 
C(7)-C(2)  1.5486(19) 
C(7)-C(6)  1.552(2) 
C(2)-H(2)  1.0000 
C(2)-C(3)  1.577(2) 
C(17)-H(17)  0.9500 
C(17)-C(18)  1.369(2) 
C(17)-C(16)  1.414(2) 
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C(18)-H(18)  0.9500 
C(16)-H(16)  0.9500 
C(3)-C(6)  1.555(2) 
C(3)-C(4)  1.520(2) 
C(3)-C(5)  1.527(2) 
C(22)-H(22)  0.9500 
C(22)-C(21)  1.410(2) 
C(10)-C(9)  1.514(2) 
C(10)-C(11)  1.511(2) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
C(14)-H(14C)  0.9800 
C(21)-H(21)  0.9500 
C(21)-C(20)  1.367(2) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(6)-H(6A)  0.9900 
C(6)-H(6B)  0.9900 
C(13)-H(13A)  0.9900 
C(13)-H(13B)  0.9900 
C(13)-C(12)  1.527(2) 
C(20)-H(20)  0.9500 
C(12)-H(12A)  0.9900 
C(12)-H(12B)  0.9900 
C(12)-C(11)  1.535(2) 
C(4)-H(4A)  0.9800 
C(4)-H(4B)  0.9800 
C(4)-H(4C)  0.9800 
C(5)-H(5A)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5C)  0.9800 
C(11)-H(11A)  0.9900 
C(11)-H(11B)  0.9900 
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C(1)-N(1)-C(15) 128.85(13) 
C(1)-N(1)-H(1) 119.7(13) 
C(15)-N(1)-H(1) 111.4(13) 
C(22)-N(2)-C(23) 117.51(13) 
O(1)-C(1)-N(1) 123.29(14) 
O(1)-C(1)-C(2) 124.01(13) 
N(1)-C(1)-C(2) 112.68(12) 
C(18)-C(19)-C(23) 119.31(14) 
C(20)-C(19)-C(23) 117.04(14) 
C(20)-C(19)-C(18) 123.65(15) 
C(7)-C(8)-C(14) 108.23(12) 
C(7)-C(8)-C(9) 112.51(12) 
C(7)-C(8)-C(13) 107.68(12) 
C(14)-C(8)-C(9) 109.05(13) 
C(14)-C(8)-C(13) 110.57(12) 
C(13)-C(8)-C(9) 108.79(12) 
N(2)-C(23)-C(19) 123.01(13) 
N(2)-C(23)-C(15) 117.29(13) 
C(19)-C(23)-C(15) 119.68(14) 
N(1)-C(15)-C(23) 114.75(13) 
C(16)-C(15)-N(1) 125.50(14) 
C(16)-C(15)-C(23) 119.69(14) 
C(8)-C(7)-H(7) 107.9 
C(8)-C(7)-C(2) 121.88(12) 
C(8)-C(7)-C(6) 121.41(13) 
C(2)-C(7)-H(7) 107.9 
C(2)-C(7)-C(6) 87.86(11) 
C(6)-C(7)-H(7) 107.9 
C(1)-C(2)-C(7) 119.93(12) 
C(1)-C(2)-H(2) 109.5 
C(1)-C(2)-C(3) 118.23(13) 
C(7)-C(2)-H(2) 109.5 
C(7)-C(2)-C(3) 88.51(11) 
C(3)-C(2)-H(2) 109.5 
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C(18)-C(17)-H(17) 119.1 
C(18)-C(17)-C(16) 121.76(15) 
C(16)-C(17)-H(17) 119.1 
C(19)-C(18)-H(18) 120.2 
C(17)-C(18)-C(19) 119.62(15) 
C(17)-C(18)-H(18) 120.2 
C(15)-C(16)-C(17) 119.85(14) 
C(15)-C(16)-H(16) 120.1 
C(17)-C(16)-H(16) 120.1 
C(6)-C(3)-C(2) 86.77(11) 
C(4)-C(3)-C(2) 116.02(12) 
C(4)-C(3)-C(6) 117.16(14) 
C(4)-C(3)-C(5) 110.98(13) 
C(5)-C(3)-C(2) 111.89(13) 
C(5)-C(3)-C(6) 112.06(13) 
N(2)-C(22)-H(22) 118.0 
N(2)-C(22)-C(21) 123.90(15) 
C(21)-C(22)-H(22) 118.0 
O(2)-C(10)-C(9) 123.15(15) 
O(2)-C(10)-C(11) 122.04(15) 
C(11)-C(10)-C(9) 114.80(14) 
C(8)-C(14)-H(14A) 109.5 
C(8)-C(14)-H(14B) 109.5 
C(8)-C(14)-H(14C) 109.5 
H(14A)-C(14)-H(14B) 109.5 
H(14A)-C(14)-H(14C) 109.5 
H(14B)-C(14)-H(14C) 109.5 
C(22)-C(21)-H(21) 120.7 
C(20)-C(21)-C(22) 118.69(15) 
C(20)-C(21)-H(21) 120.7 
C(8)-C(9)-H(9A) 109.4 
C(8)-C(9)-H(9B) 109.4 
C(10)-C(9)-C(8) 111.24(12) 
C(10)-C(9)-H(9A) 109.4 
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C(10)-C(9)-H(9B) 109.4 
H(9A)-C(9)-H(9B) 108.0 
C(7)-C(6)-C(3) 89.19(11) 
C(7)-C(6)-H(6A) 113.8 
C(7)-C(6)-H(6B) 113.8 
C(3)-C(6)-H(6A) 113.8 
C(3)-C(6)-H(6B) 113.8 
H(6A)-C(6)-H(6B) 111.0 
C(8)-C(13)-H(13A) 108.8 
C(8)-C(13)-H(13B) 108.8 
H(13A)-C(13)-H(13B) 107.7 
C(12)-C(13)-C(8) 113.71(13) 
C(12)-C(13)-H(13A) 108.8 
C(12)-C(13)-H(13B) 108.8 
C(19)-C(20)-H(20) 120.1 
C(21)-C(20)-C(19) 119.80(15) 
C(21)-C(20)-H(20) 120.1 
C(13)-C(12)-H(12A) 109.4 
C(13)-C(12)-H(12B) 109.4 
C(13)-C(12)-C(11) 111.00(13) 
H(12A)-C(12)-H(12B) 108.0 
C(11)-C(12)-H(12A) 109.4 
C(11)-C(12)-H(12B) 109.4 
C(3)-C(4)-H(4A) 109.5 
C(3)-C(4)-H(4B) 109.5 
C(3)-C(4)-H(4C) 109.5 
H(4A)-C(4)-H(4B) 109.5 
H(4A)-C(4)-H(4C) 109.5 
H(4B)-C(4)-H(4C) 109.5 
C(3)-C(5)-H(5A) 109.5 
C(3)-C(5)-H(5B) 109.5 
C(3)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5C) 109.5 
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H(5B)-C(5)-H(5C) 109.5 
C(10)-C(11)-C(12) 110.96(13) 
C(10)-C(11)-H(11A) 109.4 
C(10)-C(11)-H(11B) 109.4 
C(12)-C(11)-H(11A) 109.4 
C(12)-C(11)-H(11B) 109.4 
H(11A)-C(11)-H(11B) 108.0 
_____________________________________________________________  
 
 
 
Table A2.9. Anisotropic displacement parameters (Å2x 104) for minor ketone 210. 
The anisotropic displacement factor exponent takes the form: -2π2[ h2 a*2U11 + ... 
+ 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(2) 36(1)  22(1) 27(1)  0(1) -3(1)  8(1) 
O(1) 19(1)  47(1) 18(1)  -3(1) 4(1)  -2(1) 
N(1) 15(1)  21(1) 16(1)  -2(1) 3(1)  -3(1) 
N(2) 18(1)  17(1) 17(1)  1(1) 1(1)  1(1) 
C(1) 20(1)  16(1) 16(1)  1(1) 2(1)  2(1) 
C(19) 20(1)  12(1) 21(1)  2(1) -6(1)  2(1) 
C(8) 17(1)  16(1) 14(1)  1(1) 2(1)  0(1) 
C(23) 16(1)  12(1) 17(1)  1(1) -1(1)  2(1) 
C(15) 17(1)  13(1) 18(1)  0(1) -1(1)  2(1) 
C(7) 19(1)  15(1) 14(1)  0(1) 1(1)  1(1) 
C(2) 18(1)  15(1) 14(1)  0(1) 3(1)  0(1) 
C(17) 14(1)  16(1) 33(1)  5(1) -1(1)  -1(1) 
C(18) 20(1)  16(1) 28(1)  2(1) -9(1)  -2(1) 
C(16) 18(1)  16(1) 22(1)  2(1) 2(1)  2(1) 
C(3) 26(1)  14(1) 16(1)  1(1) 3(1)  -2(1) 
C(22) 23(1)  23(1) 18(1)  2(1) 1(1)  0(1) 
C(10) 16(1)  22(1) 19(1)  -1(1) 2(1)  4(1) 
C(14) 19(1)  23(1) 25(1)  6(1) -1(1)  -3(1) 
Appendix 2 – X-Ray Crystallography Reports Relevant to Chapter 2  
 
 
188 
C(21) 32(1)  24(1) 15(1)  0(1) -1(1)  2(1) 
C(9) 20(1)  18(1) 15(1)  -1(1) 2(1)  1(1) 
C(6) 25(1)  14(1) 19(1)  -1(1) 1(1)  -3(1) 
C(13) 21(1)  20(1) 15(1)  -2(1) 2(1)  3(1) 
C(20) 29(1)  17(1) 19(1)  -1(1) -8(1)  2(1) 
C(12) 24(1)  29(1) 15(1)  -3(1) 1(1)  7(1) 
C(4) 34(1)  21(1) 21(1)  1(1) 8(1)  -6(1) 
C(5) 36(1)  18(1) 22(1)  3(1) 0(1)  4(1) 
C(11) 24(1)  30(1) 18(1)  -3(1) -3(1)  7(1) 
______________________________________________________________________________ 
 
 
 
Table A2.10.  Hydrogen coordinates ( x 104) and isotropic displacement 
parameters (Å2x 103) for minor ketone 210. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(7) 6064 3539 3245 19 
H(2) 3872 4950 3959 19 
H(17) 12993 6751 4913 25 
H(18) 12112 7066 5712 25 
H(16) 10677 5874 4361 22 
H(22) 4228 5051 6044 25 
H(14A) 6225 6198 3166 34 
H(14B) 5607 6327 2609 34 
H(14C) 7162 5270 2775 34 
H(21) 6258 6078 6612 28 
H(9A) 1121 5052 3180 21 
H(9B) 2548 6159 3361 21 
H(6A) 3511 2101 3353 23 
H(6B) 1810 3142 3492 23 
H(13A) 4948 3668 2389 22 
H(13B) 2627 3502 2556 22 
H(20) 9454 6811 6382 26 
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H(12A) 2645 4379 1783 27 
H(12B) 4127 5466 1959 27 
H(4A) 3400 3189 4747 38 
H(4B) 2174 2105 4483 38 
H(4C) 1557 3513 4389 38 
H(5A) 6918 2181 3833 38 
H(5B) 5430 1261 4117 38 
H(5C) 6654 2302 4406 38 
H(11A) 825 6286 1936 29 
H(11B) -67 5153 2242 29 
H(1) 5760(30) 4900(20) 4724(7) 29 
________________________________________________________________________________ 
 
 
 
Table A2.11.  Torsion angles [°] for minor ketone 210. 
_____________________________________________________________  
O(2)-C(10)-C(9)-C(8) -125.20(17) 
O(2)-C(10)-C(11)-C(12) 127.00(17) 
O(1)-C(1)-C(2)-C(7) 0.1(2) 
O(1)-C(1)-C(2)-C(3) 106.07(18) 
N(1)-C(1)-C(2)-C(7) -178.49(13) 
N(1)-C(1)-C(2)-C(3) -72.53(17) 
N(1)-C(15)-C(16)-C(17) 176.96(14) 
N(2)-C(23)-C(15)-N(1) 3.66(19) 
N(2)-C(23)-C(15)-C(16) -179.03(13) 
N(2)-C(22)-C(21)-C(20) -2.0(3) 
C(1)-N(1)-C(15)-C(23) -177.11(14) 
C(1)-N(1)-C(15)-C(16) 5.8(3) 
C(1)-C(2)-C(3)-C(6) -144.20(13) 
C(1)-C(2)-C(3)-C(4) 97.03(17) 
C(1)-C(2)-C(3)-C(5) -31.70(18) 
C(19)-C(23)-C(15)-N(1) -174.83(13) 
C(19)-C(23)-C(15)-C(16) 2.5(2) 
C(8)-C(7)-C(2)-C(1) -91.02(17) 
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C(8)-C(7)-C(2)-C(3) 146.90(14) 
C(8)-C(7)-C(6)-C(3) -147.60(13) 
C(8)-C(13)-C(12)-C(11) -55.22(18) 
C(23)-N(2)-C(22)-C(21) 1.6(2) 
C(23)-C(19)-C(18)-C(17) 0.3(2) 
C(23)-C(19)-C(20)-C(21) 0.9(2) 
C(23)-C(15)-C(16)-C(17) 0.0(2) 
C(15)-N(1)-C(1)-O(1) 6.0(3) 
C(15)-N(1)-C(1)-C(2) -175.39(14) 
C(7)-C(8)-C(9)-C(10) -172.85(13) 
C(7)-C(8)-C(13)-C(12) 177.89(13) 
C(7)-C(2)-C(3)-C(6) -20.67(11) 
C(7)-C(2)-C(3)-C(4) -139.44(14) 
C(7)-C(2)-C(3)-C(5) 91.84(14) 
C(2)-C(7)-C(6)-C(3) -20.99(11) 
C(2)-C(3)-C(6)-C(7) 20.61(11) 
C(18)-C(19)-C(23)-N(2) 179.01(14) 
C(18)-C(19)-C(23)-C(15) -2.6(2) 
C(18)-C(19)-C(20)-C(21) -179.54(15) 
C(18)-C(17)-C(16)-C(15) -2.4(2) 
C(16)-C(17)-C(18)-C(19) 2.3(2) 
C(22)-N(2)-C(23)-C(19) 0.2(2) 
C(22)-N(2)-C(23)-C(15) -178.22(14) 
C(22)-C(21)-C(20)-C(19) 0.7(2) 
C(14)-C(8)-C(7)-C(2) 71.18(17) 
C(14)-C(8)-C(7)-C(6) -179.66(13) 
C(14)-C(8)-C(9)-C(10) 67.06(16) 
C(14)-C(8)-C(13)-C(12) -64.05(17) 
C(9)-C(8)-C(7)-C(2) -49.38(18) 
C(9)-C(8)-C(7)-C(6) 59.77(18) 
C(9)-C(8)-C(13)-C(12) 55.69(16) 
C(9)-C(10)-C(11)-C(12) -52.89(19) 
C(6)-C(7)-C(2)-C(1) 142.76(14) 
C(6)-C(7)-C(2)-C(3) 20.68(11) 
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C(13)-C(8)-C(7)-C(2) -169.26(13) 
C(13)-C(8)-C(7)-C(6) -60.10(17) 
C(13)-C(8)-C(9)-C(10) -53.62(16) 
C(13)-C(12)-C(11)-C(10) 51.44(19) 
C(20)-C(19)-C(23)-N(2) -1.4(2) 
C(20)-C(19)-C(23)-C(15) 176.96(13) 
C(20)-C(19)-C(18)-C(17) -179.26(15) 
C(4)-C(3)-C(6)-C(7) 138.32(14) 
C(5)-C(3)-C(6)-C(7) -91.73(14) 
C(11)-C(10)-C(9)-C(8) 54.70(18) 
________________________________________________________________  
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Chapter 3 
Revised Strategies for the Enantioselective Synthesis of (+)-Psiguadial B† 
 
3.1 INTRODUCTION 
Having evaluated the key reactions proposed in our original retrosynthetic plan, 
we learned that the substrate employed in the o-QMHDA reaction (102, see chapter 2) 
was unfortunately incapable of inducing a synthetically useful level of inherent 
diastereoselectivity. Moreover, initial efforts to effect a directed o-QMHDA reaction 
revealed a number of additional challenges that precluded implementation of such an 
approach. Since the Lewis acid-promoted Prins cyclization proved capricious in a model 
system, a more reliable and robust method was sought to secure the 7-membered ring 
central to the terpene core of (+)-psiguadial B (56). With the successful development of 
an asymmetric Wolff rearrangement and application of C(sp3)–H functionalization to 
                                                
† Portions of this chapter were adapted from the following communication: Chapman, L. 
M.; Beck, J. C.; Wu, L.; Reisman, S. E. J. Am. Chem. Soc. 2016, 138, 9803, DOI: 
10.1021/jacs.6b07229, copyright 2016 American Chemical Society. Studies toward the 
synthesis of 241 were conducted in collaboration with Jordan C. Beck, a graduate student 
in the Reisman Lab. 
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rapidly build the trans-cyclobutane, a new synthetic route was devised that preserved the 
ability to leverage these early strategic reactions. 
  
3.1.1 Revised Retrosynthetic Analysis 
 
In our revised retrosynthesis, we imagined that the chroman substructure could be 
constructed via a modified Norrish–Yang cyclization,1 revealing benzophenone 239 as a 
key intermediate (Figure 3.1). Scission of the aryl C−O bond in 239 led to tertiary alcohol 
240, which would be used in the forward sense to assemble 239 via an intermolecular O-
arylation reaction.2 We reasoned that the strained 7-membered ring in 240 could be 
formed by a potentially challenging ring-closing metathesis, leading back to vinyl ketone 
241. In turn, it was expected that 241 should be accessible from known intermediates 
prepared through the previously established C(sp3)–H alkenylation/asymmetric Wolff 
rearrangement strategy.  
Figure 3.1. Revised retrosynthetic analysis enabled by a Norrish–Yang cyclization 
 
With respect to the first key disconnection, benzophenones (e.g. 242) are well 
known to undergo photoexcitation to the triplet state upon irradiation with UV light.3 
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Triplet benzophenones possess substantial diradical character and can undergo two types 
of subsequent fragmentation pathways (Scheme 3.1). Norrish type I fragmentation results 
in initial C–C bond cleavage, thus generating acyl radical species4 244 and stabilized 
alkyl radicals such as 245. Alternatively, Norrish type II reaction involves 1,5-hydrogen 
atom abstraction (e.g. 246), and the resulting biradical may either fragment further via C–
C bond cleavage (path A) or recombine to generate cyclobutanol 250. The latter pathway 
is often referred to as the Norrish–Yang cyclization and has been utilized in many 
synthetic contexts in since its initial discovery.1,5  
Scheme 3.1. Norrish type I and type II fragmentation pathways 
 
In the specific case of the proposed Norrish substrate 239, it was envisioned that 
the benzophenone motif could undergo photoexcitation to the triplet state upon 
irradiation with UV light (Scheme 3.2). It was hypothesized that, in the absence of any 
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from the spatially proximal site at C9 to generate diradical 252. We anticipated that the 
resulting carbon-centered radicals could then recombine to form the central chroman ring 
in 253, and thus complete the core of 56.  
Scheme 3.2. Detailed plan for our proposed modified Norrish–Yang cyclization 
 
 While 1,7-hydrogen atom abstraction processes are not particularly common, 
Breslow has established that remote C–H oxidation may be achieved by analogous 
Norrish–Yang type reactivity (Scheme 3.3a). For example, benzophenone 254 was shown 
to engage in long-range hydrogen atom abstraction predominantly at C14 of a tethered 
alkyl chain, thus producing macrocyclic alcohol 256 upon irradiation in CCl4.6 Likewise, 
Boscá and Miranda have reported the synthesis of photoadduct 259, produced by laser 
flash photolysis of benzophenone 257, which was tethered to a more rigid, steroidal 
framework (Scheme 3.3b).7 The authors of these foundational studies note that the site-
selectivity of long-range hydrogen atom abstractions is typically governed by the 
preferred conformation that the alkyl substrates adopt in solution, which is in turn heavily 
influenced by solvent effects.  
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Scheme 3.3. Precedent for long-range hydrogen atom abstraction 
 
 
 While these reports provided validation from a reactivity standpoint, we 
acknowledged that achieving the desired regioselectivity could prove challenging since 
251 also possesses two other CH2’s (highlighted in green, Scheme 3.2) within range for 
the same 1,7-H–atom abstraction. Although the regiochemical outcome of this 
transformation was uncertain, analysis of three-dimensional molecular models suggested 
that the product resulting from hydrogen atom abstraction at C9 would produce the least 
sterically encumbered chroman product. Moreover, pursuit of this strategy to access the 
core of (+)-psiguadial B was particularly appealing since it was anticipated that 239 could 
be accessed in an expedient and convergent fashion.  
 With regard to securing the terpene framework, we hoped to harness the power of 
ring-closing metathesis (RCM)—a method that has proven particularly reliable for 
accessing medium-sized carbocycles8—to form the 7-membered ring in 240. However, 
we were mindful that Vanderwal and Dowling were unable to effect a ring-closing 
metathesis with a trans-cyclobutane-containing substrate in their attempted synthesis of 
CCl4
 
(450W Hg)
O
O
14
HO
Me
(  )8
O
O
O
(  )8
Me
Me
Me
O
O
OH
Me
Me
C6H13
Me
Me
O
O
O
Me
Me
C6H13
Me
Me
O
O
Me
Me
C6H13
OH
H
O
O
14
HO
Me
(  )8
a) Breslow and Winnik, 1969:
b) Boscá and Miranda, 2011:
H
256
(56-66%)
254 255
257 258 259
Chapter 3 – Revised Strategies for the Enantioselective Synthesis (+)-Psiguadial B  197 
β-caryophyllene (Scheme 3.4).9 Unexpectedly, Vanderwal found that exposure of triene 
260 to Grubbs second-generation catalyst (Grubbs-II)10 did not furnish the desired 
penultimate intermediate 262, but rather resulted in the formation of an undesired, 
deallylated product 261 in high yield. Whereas RCM with the 1,1-disubstituted olefin in 
260 proved challenging, formation of the 7-membered ring in retrosynthetic intermediate 
240 would require reaction between two less hindered, monosubstituted vinyl groups. 
Therefore, it was anticipated that RCM with the planned trans-cyclobutane-containing 
substrate would be more feasible in the proposed context.  
Scheme 3.4. Vanderwal’s attempted RCM toward β-caryophyllene 
 
 
 
Having established this revised retrosynthetic plan, we set out to prepare vinyl 
ketone 241 from intermediates already in-hand. In so doing, we wished to develop a new 
synthetic sequence that would address two outstanding problems encountered in the 
previous route. First, a substrate for conjugate addition lacking the Cu-chelating 
aminoquinoline was required in order to reduce the high catalyst loadings. Secondly, 
given that (–)-cinchonidine (173) provided (+)-89 in lower yield and ee in the tandem 
Wolff rearrangement/asymmetric ketene addition reaction (Scheme 3.5), we sought to 
develop an alternative epimerization strategy that would allow preparation of natural (+)-
psiguadial B (56) from (–)-89.  
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Scheme 3.5. Comparison of diastereomeric catalyst performance in the tandem 
Wolff rearrangement/asymmetric ketene addition reaction 
 
 
 
3.2 FORWARD SYNTHETIC EFFORTS 
3.2.1 Development of an Alternative Epimerization Strategy 
Toward the first goal, it was found that ketalization of trans-enone 148 enabled 
clean reductive cleavage of the aminoquinoline auxiliary, and the corresponding aldehyde 
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ketalization, thus delivering 263 under a variety of canonical acidic protection conditions. 
Attempts to apply Noyori’s aprotic ketalization protocol11 caused rapid decomposition of 
147.  
Scheme 3.6. Access to vinyl enone 265 as a better substrate for conjugate addition 
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coupling partner eliminated a linear protection step and substantially improved the 
material throughput.12 Moreover, it is notable that either enantiomer of 265 can be 
prepared using a single enantiomer of organocatalyst. 
Scheme 3.7. Overview of two complementary epimerization strategies 
 
 
3.2.2 Optimization of a Catalytic Conjugate Addition Reaction 
With the desired enantiomer of vinyl enone 265 in hand, attention turned to 
installation of the methyl group at the C1 quaternary center. Reaction of 265 with 
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This model also provides a possible explanation for the low levels of diastereoselectivity; 
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Scheme 3.8. Conjugate addition on a new substrate without aminoquinoline 
 
 
Building off earlier studies, the diastereoselectivity of the conjugate addition was 
improved using Alexakis’ copper-catalyzed asymmetric method.13 A survey of all four 
possible stereochemical permutations of BINOL-based phosopramidite ligands ent-211, 
270–272 confirmed that the (R,S,S) configuration was  optimally matched for chiral 
substrate 265 to provide the highest selectivity, delivering 241 in 51% yield and 10:1 dr 
(Table 3.1). From these data, it is apparent that the configuration of the BINOL, rather 
than the bis-phenylethylamine, is the more dominant stereocontrolling factor of the 
phosopramidite ligand. 
Table 3.1. Confirming optimal ligand configuration with Alexakis’ conditions 
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 Having established ent-211 as the optimal ligand, a series of experiments was 
conducted to optimize this reaction further in terms of both yield and selectivity. 
Unfortunately, consistent with previous studies, use of a bulkier napthyl-substituted 
ligand (ent-212) resulted in lower selectivity, although the yield increased substantially 
(Table 3.2, entry 2). Interestingly, lowering the reaction temperature to –78 °C had no 
effect on dr (entry 3), and the selectivity began to erode in other ethereal solvents  (entry 
4). In the interest of increasing yield without sacrificing selectivity, the catalyst loading 
was increased. Gratifyingly, in the presence of 15 mol % CuTC, 241 was produced in 
97% yield and 12:1 dr on a 0.10 mmol scale. On larger scales, an appreciable exotherm 
was observed during the addition of trimethylaluminium, which was accompanied by 
slightly lower levels of selectivity. To mitigate this problem, the reaction temperature was 
lowered to –35 °C during the addition of trimethylaluminium, and we were pleased to 
obtain 241 in 94% yield and 19:1 dr on a 3.7 mmol scale (entry 6).  
Table 3.2. Optimization of the copper-catalyzed conjugate addition using 265 
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3.2.3 Evaluation of the Key Norrish–Yang Cyclization 
 With a reliable and scalable route to access vinyl ketone 241, the key ring-closing 
metathesis reaction was investiagted. Fortunately, vinyl Grignard addition to the ketone 
proceeded uneventfully, providing divinyl alcohol 273 in excellent yield and 
diastereoselectivity (Scheme 3.9). We were pleased to find that exposure of 273 to 
second-generation Hoveyda–Grubbs’ catalyst (HG-II) at elevated temperature effected 
smooth cyclization to bridged bicycle 240 in 93% yield. Subsequent hydrogenation under 
standard conditions led to tertiary alcohol 274, which was subjected to a challenging 
intermolecular O-arylation reaction with functionalized aryl bromide 275.14 After some 
experimentation, it was found that the combination of Pd(OAc)2 and dppf2 indeed 
produced the desired aryl ether 239, albeit in modest yield. Unfortunately, reproducibility 
issues plagued this transformation and attempts to improve the yield through optimization 
were met without success. Nevertheless, a sufficient amount of 239 was obtained to 
evaluate the feasibility of the final key Norrish–Yang cyclization.  
Scheme 3.9. Elaboration to the Norrish–Yang cyclization substrate 
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mixture of many new products. Formation of Norrish–Yang product 276 was confirmed 
by 2D NMR spectroscopy; a prominent HMBC correlation was apparent between the 
newly formed C7 methine proton and C5, in addition to key NOE signals that are 
consistent with the three dimensional structure as drawn (Scheme 3.10a). Thus, while the 
anticipated reactivity was achieved to some extent, it was disappointing to observe the 
undesired regioselectivity. Moreover, 276 was isolated in a mere 6.5% yield—a result 
that would be difficult to improve to synthetically useful yields.  
 The major product isolated from this reaction is phenol 278,15 which was obtained 
in 28% yield (Scheme 3.10b). This side product presumably arises by fragmentation of 
diradical species 252 following Norrish type II hydrogen atom abstraction (analogous to 
“path A” depicted in Scheme 3.1). This apparently facile C–O bond cleavage expels enol 
tautomer 277, and the resulting terpene-based radical species likely undergoes further 
Scheme 3.10. Evaluation of the key Norrish–Yang cyclization reaction 
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decomposition pathways, since we were unable to detect the formation of the presumably 
unstable bridgehead olefin 75 by 1H NMR. In an effort to investigate whether this 
competing pathway could be suppressed, a number of different solvents and wavelengths 
were examined in a model system, but rapid formation of phenol 278 was observed in all 
cases.  
 The remaining products formed in significant quantities were obtained as a 
mixture of three compounds in 18% combined yield (Scheme 3.10c). Notably, the 1H 
NMR spectrum of this mixture bears striking resemblance to that of 276, but definitive 
characterization was hampered by the inability to purify any of these compounds under a 
variety of separation conditions. Thus, we turned to a chemical correlation method to 
determine if some of desired product 253 were present in the mixture. To this end, the 
mixture of three compounds was subjected to a deoxygenation protocol that had 
successfully been demonstrated to work well in a simpler model system. It was expected 
that 279, a compound that was ultimately prepared by other means (vide infra), would be 
observed by 1H NMR if indeed 253 had been formed in the Norrish reaction. Although a 
deoxygenated product was obtained that appeared quite similar to 279 (as judged by TLC 
and mass spectrometry), the 1H NMR spectrum clearly did not exactly match that of 279.  
Thus, while the identity of these potential Norrish–Yang products remains uncertain, we 
believe that a diastereomer of 253—perhaps epimeric at C9—may have been formed in 
low yield. With these disappointing results in hand, an alternative strategy was sought to 
close the central chroman ring and complete the core (+)-psiguadial B (56).  
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3.3 REVISED SYNTHETIC ROUTE AND NEW ENGAME STRATEGY 
Returning to evaluate our retrosynthetic analysis, we were pleased to have 
identified a robust method for the formation the strained terpene core; however, we had 
determined that late-stage Norrish–Yang cyclization was an untenable strategy to access 
56. We therefore revised the synthetic route again, deciding to construct the C9–C1' bond 
at an earlier stage, thereby simplifying 56 to 280 (Figure 3.2). Invoking the same 
disconnection through the C–O aryl bond as before, it was anticipated that an analogous 
intramolecular ring closure would prove more reliable than the challenging 
intermolecular arylation we had struggled with earlier. This disconnection revealed aryl 
bromide 281, which would be accessed using the same ring-closing metathesis, while the 
arene functionality at C9 could be installed via aldol condensation with vinyl ketone 241.  
Figure 3.2. Comparison of revised retrosynthetic analyses 
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straightforward, accomplished by a Vilsmeier–Haack formylation according to literature 
procedures.16 To our delight, treatment of vinyl ketone 241 and 282 with potassium 
Me
H
O
Me
Me
Me
O
Ph
CHO
OH
CHO
OH
H
H
Me
Me
H
Me
O OMe
OMe
H
H
Me
Me
O Ph
Me
OH
H
H
Me
Me
(+)-psiguadial B (56)
HepG2 IC50 = 46 nm
Norrish–Yang
cyclization
intermolecular
arylation RCM
239 240
Me
O OMe
OMe
H
H
Me
Me
1'H
•
•
•
•
•
•
Me
OH
H
H
Me
Me
MeO Br
OMe
intramolecular
arylation
• •
• •
•
•
RCM
aldol
oxidation
280
281 241
Chapter 3 – Revised Strategies for the Enantioselective Synthesis (+)-Psiguadial B  207 
hydroxide in methanol at elevated temperature smoothly afforded exo-enone 283 in 92% 
yield (Scheme 3.11). Attempts to incorporate the C1' phenyl group via conjugate addition 
were met with limited success, yielding only trace amounts of 284 as an inseparable 
mixture of several diastereomers formed at both C9 and C1'. An alternative aldol 
condensation between 241 and benzophenone 27514 did not proceed under otherwise 
identical conditions; likewise, Mukaiyama aldol with a silyl enol ether derived from 241 
and various Lewis acids also gave no productive reaction. These results were not 
surprising, owing to the electron rich nature of a more hindered diaryl ketone. Despite the 
inability to introduce the C1' phenyl, we elected to reserve the task of installing this 
group at a later stage in the synthesis and moved forward with 283, since this 
intermediate was readily available in excellent yield.  
Scheme 3.11. Aldol reaction and attempts to incorporate the phenyl at C1' 
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entry 1).  While lowering the temperature to –78 °C indeed improved the dr to 4.5:1, an 
even lower overall yield of 286 was obtained (entry 2). Alternative solvents or warmer 
reaction temperatures did not alleviate this problem (entries 3–5), and thus we turned to 
Lewis acid activators known to suppress enolization of hindered ketones. 17  While 
additives such as CeCl3 and LaCl3•2LiCl indeed improved conversion, this was always 
accompanied by substantially lower dr, which unfortunately amounted to similar overall 
yields of 286 (entries 6 and 7). On the other hand, reactions with lithium salts such as 
LiCl and LiOCl4 as additives still suffered from poor conversion. 
Ultimately, allylic alcohol 286 was obtained in good yield with serviceable dr by 
employing vinyllithium in THF at −78 °C (entry 8). Addition of La(OTf)3, or lowering 
the reaction temperature to –100 °C did not improve this reaction further (entries 9 and 
10). Larger vinyllithium nucleophiles, as well as divinylzinc were also investigated; 
however, use of these reagents resulted in low conversions or no reaction, respectively. 
Table 3.3. Optimization of 1,2 addition using vinylmetal species 
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Lastly, Corey–Chaykovsky-type conditions,18 which are known to afford allylic alcohols 
in the presence of excess dimethylsulphonium methylide, led to exclusive formation of 
the undesired diastereomer 287.  
 The conformational analysis model depicted in Figure 3.3 may explain the 
diastereoselectivity trends apparent in Table 3.3. Conformer 283'' orients the large 
cyclobutane and aryl substituents in more favorable equatorial positions and is therefore 
expected to be lower in energy than 283'. Considering that a trajectory from the top face 
along the Bürgi–Dunitz angle places the incoming nucleophile in close proximity to the 
axial methyl group, it is reasonable that larger nucleophiles, such as vinylmagnesium 
bromide (ionic radius of Br— = 182 pm), engage in equatorial attack from the bottom face 
with greater preference. Conversely, smaller nucleophiles such as vinyllithium (ionic 
radius of Li+ = 90 pm) give rise to larger amounts of 287. This same logic applies to 
Lewis acid activators—large lanthanides likely coordinate to the carbonyl from the less 
hindered bottom face, thus eroding selectivity for 286.  With respect to the conformation 
Figure 3.3. Conformational analysis and selectivity model for 1,2-addition 
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of the products, 287 exhibits more pronounced adverse 1,3-diaxial interactions between 
the methyl and vinyl group (A = 1.35 kcal/mol), which may contribute to the preferred 
formation of 286, observed as the major diastereomer in all cases.  
 We were pleased to find that the results in Table 3.3, entry 8 were reproducible on 
large scale, delivering 286 in 54% isolated yield as a single diastereomer (Scheme 3.12). 
Gratifyingly, the ring-closing metathesis proceeded with equal efficiency on this new 
substrate to furnish 281 in 93% yield. With the strained sesquiterpene framework 
secured, both the di- and trisubstituted olefins in 281 were hydrogenated in the presence 
of Crabtree’s catalyst, which engaged in a hydroxyl-directed reduction19 to establish the 
C9 stereogenic center with 16:1 dr, providing 288 in excellent yield. The final ring of the 
psiguadial framework was constructed by a significantly more facile Cu-catalyzed 
intramolecular O-arylation reaction, which furnished pentacycle 280 in 75% yield.20 
Scheme 3.12. Elaboration to complete pentacyclic core of (+)-psiguadial B 
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3.3.2 Appendage of the C1' Phenyl Group and Final Functionalization 
Having succeeded in developing a scalable and high-yielding route to 280, the 
task of appending the C1' phenyl group was now at hand. Ideally, we wished to develop a 
direct arylation protocol, wherein the electron rich arene in 280 might assist in benzylic 
oxidation at C1', followed by trapping with an appropriate phenyl nucleophile. Whereas a 
number of laboratories have shown that electron rich, oxidized arenes can efficiently trap 
benzylic cations in related systems,21 an electronically neutral, unsubstituted phenyl 
group is not sufficiently reactive to engage in this type of transformation. Nonetheless, 
we investigated the possibility of sequential oxidation at C1' with reagents commonly 
used in flavonoid chemistry, such as DDQ,21a,d,22 Pb3O4,23 and Oxone/CuSO4,24 followed 
by trapping with PhMgBr, with no success (Scheme 3.13). Chloranil, a structural analog 
of DDQ, as well as other organic single-electron oxidants and hydride abstractors,25 were 
also examined to no avail. Finally, efforts to apply Shi’s FeCl2-catalyzed benzylic 
Scheme 3.13. Summary of strategies to install phenyl ring at C1' 
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dehydrogenative arylation,26 or Muramatsu’s C(sp3)–H arylation using DDQ and PIFA27 
were also unfruitful. 
Without any success in achieving a direct arylation, a stepwise protocol was 
employed for the installation of the C1' phenyl substituent. Reasoning that alcohol 253 
could be accessed by 1,2-addition of PhMgBr into chromanone 289, benzylic oxidation 
was attempted under standard conditions but only complex reaction profiles and trace 
yields were observed. On the other hand, oxidation with DDQ in the presence of primary 
alcohols22 seemed promising; although these reactions produced several side products 
suspected to result from over oxidation and elimination of the newly installed benzylic 
ether, use of ethoxyethanol afforded 290—a relatively stable product that could be 
isolated in modest yields. The possibility of accessing other benzylic ethers analogous to 
290 was also explored via radical halogenation, followed by displacement with various 
alcohols, however these protocols led exclusively to arene bromination.  
With a lead in hand, the DDQ-mediated oxidative etherification reaction was 
optimized. An extensive survey of reaction parameters revealed that adding acetonitrile 
as a co-solvent led to cleaner reaction profiles (Scheme 3.14a). Although lower 
conversion of starting material was observed, productive reactivity was much improved 
and synthetically useful yields of 290 were obtained after re-subjecting recovered 280 to 
the same reaction conditions a second time. Presumably, the presence of a high dielectric 
solvent helps to stabilize the intermediate benzylic cation (291), which can allow more 
efficient trapping with ethoxyethanol, rather than undergoing unproductive side reactions.  
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Scheme 3.14. Optimized conditions and model for observed diastereoselectivity 
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PhMgBr in PhMe30 yielded only eliminated products and messy reaction profiles (entries 
3–5). Likewise, efforts to apply Bode’s conditions for addition of aryl trifluoroborates to 
oxonium ions generated by treatment with BF3•OEt2 were met without formation of 279 
(entries 6 and 7).31 Disheartened by the apparent difficulty of this transformation, we 
were therefore delighted to obtain a near quantitative yield of 279 and 293 in a 1.7:1 ratio 
upon addition of BF3•OEt2 to a mixture of 290 and lithium diphenylcyanocuprate (entry 
8).32 After some experimentation, it was found that the diastereoselectivity could be 
slightly improved to 2:1 by holding the reaction at –45 °C (entry 9), while colder 
temperatures led to significantly lower yields (entry 10).  
Table 3.4. Attempts to displace benzylic ether using various methods 
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aldehydes were simultaneously installed using Rieche formylation conditions, 33 
delivering the (+)-psiguadial B in 50% yield. Gratifyingly, synthetic 56 was found to be 
spectroscopically identical in all respects to the natural sample reported by Shao et al.34 
Scheme 3.15. Completion of the the total synthesis of (+)-psiguadial B 
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may enable the synthesis of unnatural analogs of 56 that would be difficult to access 
through semi-synthetic methods. To that end, several late-stage intermediates and select 
analogs have been prepared for the purposes of biological evaluation. Finally, efforts to 
expand the scope of our key reactions and apply this sequence in the synthesis of other 
trans-cyclobutane-containing natural products are currently ongoing in our laboratory. 
Scheme 3.16. Overview of the final, successful route to (+)-psiguadial B 
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3.5 EXPERIMENTAL SECTION 
3.5.1 Materials and Methods 
General Procedures. Unless otherwise stated, reactions were performed under a 
nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene 
chloride (CH2Cl2), acetonitrile (MeCN), tert-butyl methyl ether (TBME), benzene (PhH), 
and toluene (PhMe) were dried by passing through activated alumina columns. 
Triethylamine (Et3N), N,N-diisopropylethylamine (DIPEA), and methanol (MeOH) were 
distilled over calcium hydride prior to use. Unless otherwise stated, chemicals and 
reagents were used as received. All reactions were monitored by thin-layer 
chromatography using EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and 
were visualized by UV, p-anisaldehyde, or 2,4-dinitrophenylhydrazine staining. Flash 
column chromatography was performed either as described by Still et al.36 using silica gel 
(particle size 0.032-0.063) purchased from Silicycle or using pre-packaged RediSep®Rf 
columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical rotations were 
measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. 1H 
and 13C NMR spectra were recorded on a Bruker Avance III HD with Prodigy cryoprobe 
(at 400 MHz and 101 MHz respectively), a Varian 400 MR (at 400 MHz and 101 MHz, 
respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, respectively), or a Varian 
Inova 600 (at 600 MHz and 150 MHz, respectively), and are reported relative to internal 
CHCl3 (1H, δ = 7.26) and CDCl3 (13C, δ = 77.1), or C6H5 (1H, δ = 7.16) and C6D6 (13C, δ 
= 128). Data for 1H NMR spectra are reported as follows: chemical shift (δ ppm) 
(multiplicity, coupling constant (Hz), integration). Multiplicity and qualifier 
abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = 
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multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin Elmer 
Paragon 1000 spectrometer and are reported in frequency of absorption (cm–1). HRMS 
were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode 
source in electrospray ionization (ESI), or mixed (MM) ionization mode, or obtained 
from the Caltech Mass Spectral Facility in fast-atom bombardment mode (FAB).  
 
3.5.2 Preparative Procedures and Spectroscopic Data 
 
Preparation of dioxolanes 263 and 295.  
 
 
To a flame-dried 200 mL round-bottom flask was added trans-cyclobutane 148 
(2.59 g, 7.43 mmol) and the atmosphere was exchanged for N2 three times. Dry PhMe (74 
mL) was then added, followed by ethylene glycol (16.6 mL, 297 mmol, 40.0 equiv) and 
trimethyl orthoformate (2.44 mL, 22.3 mmol, 3.00 equiv) via syringe. Finally, p-
toluenesulfonic acid monohydrate (141 mg, 0.743 mmol, 0.10 equiv) was added as a 
solid in one portion under a stream of N2. The reaction mixture was heated to 80 ºC for 
15 hours, at which point the reaction mixture was cooled to room temperature and 
quenched with a saturated solution of aqueous NaHCO3. The layers were separated and 
the aqueous layer was extracted with EtOAc three times. The combined organic extracts 
were dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The crude residue 
was purified by silica gel flash chromatography (isocratic: 20% EtOAc/hexane  + 1% 
148
HO
OH
CH(OMe)3, p-TsOH•H2O
    PhMe, 80 °C
(86% yield)
N
H
O
N
O
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Et3N) to afford dioxolanes 263 and 295 (2.50 g, 86% yield) as a partially separable 
mixture of inconsequential olefin isomers. An analytically pure sample of the major 
dioxlane (263) was obtained and a representative spectrum of the mixture as used in the 
next step is also provided.  
 
Data for 263 (major product, peak 1): [𝛼]!!".! = –80.5° (c = 1.40, CHCl3) 
 
1H NMR (400 MHz, CDCl3) δ 9.71 (s, 1H),  8.78 (dd, J = 11.0, 1.6 Hz, 1H), 8.78 (d, J = 
1.6 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.50 (dt, J = 15.8, 8.2, 7.5 Hz, 2H), 7.47 (dd, 
J = 8.3, 1.6 Hz, 1H), 7.43 (dd, J = 8.3, 4.2 Hz, 1H), 5.54 (dt, J = 3.6, 1.8 Hz, 1H), 3.96 (q, 
J = 4.4, 3.9 Hz, 4H), 3.30 (q, J = 9.4 Hz, 1H), 2.88 (d, J = 9.8 Hz, 1H), 2.25 (d, J = 2.8 
Hz, 4H), 1.87 (dd, J = 10.5, 8.6 Hz, 1H), 1.81 – 1.61 (m, 3H), 1.36 (s, 3H), 1.17 (s, 3H).  
 
13C NMR (101 MHz, CDCl3) δ 170.7, 148.2, 138.4, 137.3, 136.3, 134.6, 127.9, 127.4, 
121.6, 121.2, 119.1, 116.3, 108.4, 64.4, 55.2, 36.7, 36.7, 36.4, 36.1, 30.9, 30.8, 24.1, 23.4. 
 
FTIR (NaCl, thin film) 3350, 3046, 2952, 2929, 2893, 2839, 1686, 1596, 1578, 1525, 
1485, 1460, 1424, 1383, 1368, 1326, 1248, 1209, 1161, 1102, 1059, 1021, 948, 826, 792, 
756 cm.-1 
 
HRMS (MM) calc’d for C24H29N2O3 [M+H]+ 393.2173, found 393.2188. 
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Preparation of vinyl enone (–)-265. 
 
Inside a N2-filled glovebox, two flame-dried 200 mL round-bottom flasks were 
each charged with Schwartz’s reagent (1.60 g, 6.21 mmol, 2.04 equiv) and sealed under 
N2. The flasks were removed from the glovebox and THF (15.5 mL) was added to each 
via syringe. To each of the milky-white suspensions was added a mixture of dioxolanes 
263 and 295 (1.19 g, 3.04 mmol) as a solution in THF (16.0 mL) in a quick drip at room 
temperature. The mixtures immediately began to turn yellow, darkening to orange over 
the course of 1 hour, at which point the reactions were quenched with saturated aqueous 
NaHCO3 and combined together. The layers were separated and the aqueous layer was 
extracted twice with EtOAc. The combined organic layers were washed twice with 100 
mL of a 0.6M aqueous solution of CuSO4 to remove the liberated 8-aminoquinoline. The 
organic layer was then dried over MgSO4, filtered, and concentrated in vacuo. The crude 
aldehyde (264, 1.70 g) was dissolved in dry PhMe (20 mL) and treated with freshly 
prepared ylide (80 mL, 32.0 mmol, 5.26 equiv) at room temperature. The reaction was 
stirred for 2 hours and monitored by TLC. Upon complete conversion, the reaction was 
cooled to 0 °C and quenched with 5 M HCl. The layers were separated and the aqueous 
layer was extracted twice with Et2O. The combined organic layers were concentrated in 
vacuo and the solvent replaced with THF (30 mL). The dioxolane was hydrolyzed by 
stirring vigorously with 5 M HCl for 8 hours, at which time Et2O was added and the 
N
H
O
N
O
O Ph3P CH2 O
H
O
O
OCp2Zr(H)Cl
THF, rt;
then, CuSO4
PhMe, rt;
then, 5M HCl
(58% yield, 2 steps)
(–)-264 (–)-265263 + 295
(4.4:1 mixture)
Me
Me
Me
Me
Me
Me
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layers separated. The aqueous layer was extracted twice with Et2O and the combined 
organics washed with aqueous NaHCO3, dried over MgSO4 and concentrated in vacuo. 
The crude residue was purified by silica gel flash chromatography (isocratic: 30% 
Et2O/hexanes) to afford vinyl enone (–)-265 (715 mg, 58% yield over 2 steps) as a clear 
oil: [𝛼]!!".! = –100° (c = 1.02, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.84 (q, J = 1.5 Hz, 1H), 5.81 (dddt, J = 16.8, 10.6, 7.9, 
0.5, 0.5 Hz, 1H), 5.04 (qd, J = 1.9, 1.0 Hz, 1H), 5.01 (ddd, J = 10.4, 2.0, 1.1 Hz, 1H), 
2.88 (q, J = 9.7, 9.1, 9.0 Hz, 1H), 2.48 (ddq, J = 9.8, 7.9, 1.0 Hz, 1H), 2.34 (t, J = 7.0, 6.5 
Hz, 2H), 2.21 (qdd, J = 5.9, 1.5, 0.8 Hz, 2H), 1.95 (dt, J = 7.7, 6.1 Hz, 2H), 1.85 (ddd, J = 
10.7, 8.3, 0.8 Hz, 1H), 1.67 (t, J = 10.4 Hz, 1H), 1.05 (s, 3H), 1.04 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 200.1, 168.7, 137.4, 123.4, 116.1, 53.8, 41.1, 37.5, 37.3, 
36.0, 30.0, 27.9, 23.1, 22.6. 
FTIR (NaCl, thin film) 3320, 3076, 3039, 2953, 2934, 2891, 2866, 2827, 1671, 1622, 
1456, 1428, 1417, 1382, 1368, 1346, 1324, 1290, 1251, 1191, 1124, 995, 968, 942, 912, 
886, 755 cm.-1 
HRMS (MM) calc’d for C14H21O [M+H]+ 205.1587, found 205.1587.  
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Preparation of Wittig ylide. 
Inside a N2-filled glovebox, methyltriphenylphosphonium bromide (22.2 g, 62.1 
mmol) and KOt-Bu (7.36 g, 65.6 mmol, 1.06 equiv) were added to a flame-dried 500 mL 
round-bottom flask and sealed under nitrogen. The flask was brought out of the box and 
dry PhMe (155 mL) was added via syringe. The flask was fitted with a reflux condenser 
under a stream of N2 and heated to 110 °C for 4 hours, at which time the reaction was 
cooled to room temperature and the salts were allowed to settle for 3 hours before the 
bright yellow supernatant (~0.40 M salt-free ylide) was used for the methylenation of 
crude trans-aldehyde 264. 
 
Preparation of protected iodide 268.  
 
Inside a N2-filled glove box, a 250 mL round bottom flask was charged with 
TMSOTf (0.410 mL, 0.230 mmol, 0.010 equiv) and CH2Cl2 (20.0 mL). The flask was 
sealed, removed from the glove box, and placed under a N2 atmosphere. The reaction 
mixture was cooled to –78 ºC, and 1,2-bistrimethylsilyloxyethane (11.0 mL, 45.0 mmol, 
2.00 equiv) was added via syringe. (Note: best results were obtained when 1,2-
bistrimethylsilyloxyethane was sparged with argon for 30 min prior to addition). Vinyl 
iodide 90 (5.00 g, 22.5 mmol, 1.00 equiv) was added to the flask dropwise as a solution 
in CH2Cl2 (20.0 mL), via cannula transfer. An additional portion of CH2Cl2 (5.00 mL) 
was used to complete the transfer. The colorless reaction mixture was allowed to stir at –
TMSO
OTMS
O
I
90
I
268
OO
TMSOTf, CH2Cl2, –78 °C to rt
(60% yield)
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78 ºC for 1 hour, at which point the reaction mixture was warmed to 0 ºC. The reaction 
mixture became yellow immediately upon warming and was allowed to warm to room 
temperature over 16 hours. The reaction mixture became dark orange and was quenched 
with the addition of DIPEA (11.0 mL), at which point the reaction became yellow. The 
mixture was poured into a separatory funnel and diluted with saturated NaHCO3 solution. 
The aqueous layer was extracted three times with CH2Cl2. The organic layers were 
combined, dried over a 1:1 mixture of anhydrous K2CO3 and Na2SO4, filtered, and 
concentrated to provide a yellow residue that was purified by flash silica gel 
chromatography (5% EtOAc, 1% Et3N/hexane–20% EtOAc, 1% Et3N/hexane) to provide 
268 (3.61 g, 60% yield) as a 8:1 mixture of olefin isomers, as a pale yellow oil. 
1H NMR (400 MHz, CDCl3) δ 6.34 (tt, J = 4.0, 1.9 Hz, 1H), 3.98 (p, J = 1.7 Hz, 4H), 
2.72 (q, J = 2.3 Hz, 2H), 2.36 – 2.22 (m, 2H), 1.77 (t, J = 6.5 Hz, 2H). 
13C NMR (101 MHz, CDCl3) δ 136.6, 108.1, 91.1, 64.7, 49.3, 30.2, 27.5. 
FTIR (NaCl, thin film) 3040, 2955, 2934, 2881, 2836, 2684, 1637, 1474, 1443, 1429, 
1418, 1360, 1330, 1300, 1243, 1207, 1142, 1114, 1076, 1058, 1021, 970, 948, 889, 848, 
827, 776, 738, 662 cm.-1 
HRMS (FAB) calc’d for C8H11IO2 [M]+ 266.9876, found 266.9888. 
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Preparation of cis-dioxolane 266.  
 
 
A 100 mL, thick-walled pressure vessel was charged with Pd(OAc)2 (132 mg, 
0.590 mmol, 0.150 equiv), Ag2CO3 (1.08 g, 3.93 mmol, 1.00 equiv), and 89 (1.00 g, 3.93 
mmol, 1.00 equiv). Vinyl iodide 268 (2.09 g, 7.86 mmol, 2.00 equiv) was then added to 
the flask as a solution in TBME (19.7 mL). The reaction vessel was sealed with a screw 
top under ambient conditions and heated to 90 ºC in an oil bath. The heterogeneous 
reaction mixture is olive green upon addition of vinyl iodide. After heating for five 
minutes, the reaction mixture became black. After 16 hours, the flask was removed from 
the oil bath and allowed to cool to room temperature. The reaction mixture was filtered 
over a pad of celite and the filter cake was washed with CH2Cl2. The filtrate was 
concentrated, and the crude orange residue was purified by flash silica gel 
chromatography (30% EtOAc, 1% Et3N/hexane–35% EtOAc, + 1% Et3N/hexane) to 
provide 266 (1.11 g, 72% yield) as a white foam: [𝛼]!!".! = –29.3° (c = 1.95, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 8.81 (ddd, J = 24.2, 7.3, 1.5 Hz, 2H), 8.13 
(dd, J = 8.3, 1.7 Hz, 1H), 7.49 (td, J = 8.2, 7.5, 6.6 Hz, 1H), 7.45 (dd, J = 8.3, 1.6 Hz, 
1H), 7.42 (dd, J = 8.3, 4.2 Hz, 1H), 5.65 (dd, J = 17.8, 9.1 Hz, 1H), 4.03 – 3.81 (m, 2H), 
3.76 – 3.64 (m, 2H), 3.25 (q, J = 9.1, 8.2 Hz, 1H), 3.05 (dd, J = 8.7, 2.8 Hz, 1H), 2.46 (t, 
J = 10.9 Hz, 1H), 2.40 – 2.23 (m, 2H), 2.19 (dt, J = 16.5, 2.1 Hz, 1H), 2.06 – 1.97 (m, 
N
H
O
N
O
O
O
N
H N
I
Pd(OAc)2 (15 mol %)
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1H), 1.93 (ddd, J = 11.1, 8.3, 2.9 Hz, 1H), 1.71 – 1.59 (m, 1H), 1.57 – 1.48 (m, 1H), 1.40 
(s, 3H), 1.11 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.0, 147.9, 138.7, 136.3, 134.9, 134.8, 127.9, 127.5, 
121.4, 121.2, 120.8, 116.6, 108.3, 64.3, 64.1, 55.9, 37.2, 37.1, 36.7, 35.4, 30.8, 30.2, 25.1, 
24.4. 
FTIR (NaCl, thin film) 3357, 3300, 3043, 3006, 2952, 2928, 2881, 1685, 1664, 1596, 
1577, 1523, 1485, 1460, 1424, 1385, 1324, 1255, 1208, 1160, 1132, 1106, 1060, 1039, 
1020, 947, 846, 826, 792, 755, 666 cm.-1 
HRMS (MM) calc’d for C24H29N2O3 [M+H]+ 393.2173, found 393.2183. 
 
Preparation of trans-aldehyde (+)-264. 
 
Inside a N2-filled glove box, a 250 mL round bottom flask was charged with 
Schwartz’s reagent (2.30 g, 8.92 mmol, 2.06 equiv) and THF (22.3 mL). Cis-dioxolane 
266 (1.70 g, 4.32 mmol, 1.00 equiv) was added to the flask as a solution in THF (22.3 
mL). The flask was sealed, removed from the glove box and put under a N2 atmosphere. 
The flask was covered with aluminum foil and allowed to stir for one hour, at which 
point the reaction was quenched with the addition of saturated NaHCO3 solution. (Note: 
it is important that the quench be conducted very quickly to avoid decomposition of 
Cp2Zr(H)Cl
N
H
O
N
O
O
H
O
O
O
266 (+)-264
(70% yield, 2 steps)
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excess Schwartz’s reagent and formation of HCl). The reaction mixture was diluted with 
EtOAc and the organic layer separated. The aqueous layer was filtered through a pad of 
celite and sand and then extracted 5x with EtOAc. The combined organics were dried 
over anhydrous Na2SO4, filtered, and concentrated to provide a yellow residue that was 
purified by flash silica gel chromatography (15% EtOAc, 1% Et3N/hexanes) to provide 
267 (755 mg, 3.01 mmol) as a yellow oil as a 1.8:1 (cis/trans) mixture of diastereomers at 
C5. The oil was concentrated directly into a 200 mL round bottom flask and dissolved in 
wet MeOH (60.0 mL). The flask was then charged with KOH (3.36 g, 59.9 mmol, 20.0 
equiv) and the mixture allowed to stir for 1 hour at room temperature. The mixture was 
then concentrated to a volume of ~3 mL and diluted with pH 7 buffer. A pale yellow 
precipitate formed upon addition of buffer. The solution was slowly acidified using dilute 
citric acid until pH 7 was achieved. The mixture was then poured into a separatory funnel 
and extracted 3x with EtOAc. The combined organics were dried over anhydrous 
Na2SO4, filtered, and concentrated to provide trans-aldehyde (+)-264 (755 mg, 70% over 
2 steps) as a mixture of olefin isomers. The yellow oil was analytically pure and used 
directly in the next step: [𝛼]!!".! = +35.2° (c = 0.295, CHCl3). Note: it is recommended 
that the aldehyde be used immediately in the next step to avoid decomposition. 
1H NMR (400 MHz, CDCl3) δ 9.76 (t, J = 2.2 Hz, 1H), 5.37 (dt, J = 3.8, 1.9 Hz, 1H), 
3.97 (dd, J = 2.5, 1.3 Hz, 4H), 3.14 (q, J = 9.2 Hz, 1H), 2.73 (dt, J = 10.0, 2.1 Hz, 1H), 
2.22 (dp, J = 6.5, 2.1 Hz, 2H), 2.16 – 1.97 (m, 2H), 1.77 (ddd, J = 15.5, 9.4, 2.0 Hz, 2H), 
1.69 (td, J = 6.5, 2.1 Hz, 2H), 1.24 (s, 3H), 1.14 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ 203.2, 137.1, 118.8, 108.3, 64.4, 59.5, 37.3, 37.1, 36.7, 
34.3, 31.2, 30.7, 24.0, 24.0. 
FTIR (NaCl, thin film) 2954, 2929, 2896, 2873, 2707, 1712, 1670, 1577, 1522, 
1461,1449, 1434, 1420, 1383, 1367, 1340, 1312, 1297, 1249, 1209, 1179, 1103, 1059, 
1039, 1018, 948, 846, 793 cm.-1 
HRMS (MM) calc’d for C15H23O3 [M+H]+ 251.1642, found 251.1645. 
 
Preparation of vinyl enone (+)-265 
 
A 250 mL round bottom flask was charged with aldehyde, (+)-264 (720 mg, 2.88 
mmol, 1.00 equiv). The flask was evacuated and backfilled three times with N2 and 
charged with toluene (2.30 mL). The flask was then charged with freshly prepared ylide 
solution37 (36.0 mL, 0.4 M, 5.00 equiv) and the reaction mixture was allowed to stir for 
30 minutes at room temperature. The reaction was quenched with the addition of 
saturated NaHCO3 solution (10.0 mL). The organic layer was separated and the aqueous 
layer extracted 3x with Et2O. The combined organics were concentrated and dissolved in 
a 1:1 mixture of THF and 5 M HCl (28 mL.0). The reaction mixture was allowed to stir 
over 16 hours, at which point the mixture was diluted with Et2O and water. The layers 
were separated and the aqueous layer extracted 3x with Et2O. The combined organics 
were dried over anhydrous MgSO4, filtered, and concentrated. The crude yellow residue 
Ph3P CH2
O
H
O
O
O
PhMe, rt;
then, 5M HCl
(88% yield)
(+)-264 (+)-265
Me
Me
Me
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was purified by flash silica gel chromatography (20–30% Et2O/pentane) to provide (+)-
265 (520 mg, 88%) as a pale yellow oil: [𝛼]!!".! = +102° (c = 0.705, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 5.84 (q, J = 1.6 Hz, 1H), 5.81 (dddt, J = 16.8, 10.6, 7.9, 
0.5, 0.5 Hz, 1H), 5.04 (qd, J = 1.9, 1.0 Hz, 1H), 5.01 (ddd, J = 10.8, 1.9, 1.1 Hz, 1H), 
2.88 (q, J = 9.7, 9.1, 9.0 Hz, 1H), 2.48 (ddq, J = 9.8, 7.9, 1.0 Hz, 1H), 2.34 (t, J = 7.0, 6.5 
Hz, 2H), 2.20 (qdd, J = 6.0, 1.5, 0.8 Hz, 2H), 1.95 (dt, J = 7.7, 6.1 Hz, 2H), 1.85 (ddd, J = 
10.8, 8.3, 0.8 Hz, 1H), 1.67 (t, J = 10.3 Hz, 1H), 1.05 (s, 3H), 1.04 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 200.1, 168.8, 137.4, 123.4, 116.1, 53.8, 41.1, 37.5, 37.3, 
36.0, 30.0, 27.9, 23.1, 22.6. 
FTIR (NaCl, thin film) 3320, 3076, 3039, 2953, 2934, 2891, 2866, 2827, 1671, 1622, 
1456, 1428, 1417, 1382, 1368, 1346, 1324, 1290, 1251, 1191, 1124, 995, 968, 942, 912, 
886, 755 cm.-1 
HRMS (MM) calc’d for C14H21O [M+H]+ 205.1587, found 205.1587.  
 
 
 
 
 
 
 
 
Chapter 3 – Revised Strategies for the Enantioselective Synthesis (+)-Psiguadial B  229 
Preparation of vinyl ketone 241.  
 
 
Inside a N2-filled glovebox, CuTC (105 mg, 0.551 mmol, 0.150 equiv) and 
(R,S,S)-ligand ent-21138 (594 mg, 1.10 mmol, 0.30 equiv) were added to a flame dried 
100 mL round-bottom flask. The reagents were suspended in Et2O (18.0 mL) and stirred 
at room temperature for 30 minutes before vinyl enone (+)-265 (750 mg, 3.67 mmol) was 
added as a solution in Et2O (18.0 mL). The reaction was sealed under N2, removed from 
the glovebox and placed under a balloon atmosphere of argon. The reaction mixture was 
allowed to equilibrate to –35 °C for 5 minutes using a cryocool unit to maintain the 
temperature. Me3Al (2.0 M in heptane; 3.67 mL, 7.34 mmol, 2.00 equiv) was then added 
dropwise and the reaction stirred at  –35 °C for 17 hours, at which point wet MeOH (5 
mL) was slowly added to quench excess Me3Al. The mixture was warmed to room 
temperature, filtered over a plug of silica gel and washed thoroughly with Et2O and 
CH2Cl2 (until no product remained in eluent). The filtrate was concentrated in vacuo and 
the crude residue purified by silica gel flash chromatography (isocratic: 20% hexane/ 
CH2Cl2) to afford vinyl ketone 241 (760 mg, 94% yield) as a 19:1 mixture of inseparable 
diastereomers at C1, colorless oil. Note: this 19:1 mixture is carried through the next 
three reactions, and a single diastereomer at C1 is isolable after the ring-closing 
metathesis: [𝛼]!!".! = +37.6° (c = 1.05, CHCl3).  
O
CuTC (15 mol %)
ent-211 (30 mol %)
1Me
H
O
Me3Al, 
Et2O –35 °C
(94% yield, 19:1 dr)
O
O
P N
Ph
Ph
Me
Me
ent-211 (R,S,S)241(+)-265
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1H NMR (400 MHz, C6D6) δ 5.68 (ddd, J = 16.9, 10.5, 8.6 Hz, 1H), 4.96 (qd, J = 2.2, 0.8 
Hz, 1H), 4.93 (ddd, J = 11.3, 2.2, 0.8 Hz, 1H), 2.20 (ddt, J = 9.6, 8.6, 0.9 Hz, 1H), 2.11 
(dtt, J = 13.9, 4.8, 1.4 Hz, 1H), 1.92 (dd, J = 3.3, 1.7 Hz, 2H), 1.90 – 1.79 (m, 2H), 1.50 – 
1.40 (m, 2H), 1.31 – 1.21 (m, 2H), 1.21 – 1.13 (m, 1H), 0.99 (dtt, J = 13.4, 4.7, 4.5, 1.5, 
1.1 Hz, 1H), 0.94 (s, 3H), 0.93 (s, 3H), 0.66 (s, 3H). 
1H NMR (400 MHz, CDCl3) δ 5.74 (ddd, J = 17.1, 10.3, 8.7 Hz, 1H), 5.08 – 4.81 (m, 
2H), 2.33 (ddd, J = 9.6, 8.7, 0.9 Hz, 1H), 2.30 – 2.19 (m, 2H), 2.16 (d, J = 13.5 Hz, 1H), 
2.07 (td, J = 10.1, 8.5 Hz, 1H), 1.99 (dt, J = 13.4, 1.8 Hz, 1H), 1.90 (ddq, J = 14.0, 6.2, 
4.7 Hz, 1H), 1.85 – 1.72 (m, 1H), 1.56 (ddd, J = 13.6, 11.1, 4.4 Hz, 1H), 1.51 – 1.34 (m, 
3H), 0.98 (s, 3H), 0.97 (s, 3H), 0.83 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 212.8, 139.6, 115.3, 51.2, 49.5, 45.2, 41.3, 40.1, 34.8, 
34.0, 33.0, 30.1, 23.7, 22.1, 21.8. 
13C NMR (101 MHz, C6D6) δ 209.3, 139.9, 115.3, 51.0, 49.5, 45.2, 41.2, 39.7, 34.7, 33.9, 
32.9, 30.1, 23.7, 22.1, 21.8. 
FTIR (NaCl, thin film) 3075, 2953, 2873, 1713, 1633, 1460, 1422, 1382, 1368, 1312, 
1285, 1253, 1228, 1172, 1049, 995, 910 cm.-1  
HRMS (FAB) calc’d for C15H24O [M]+ 221.1900, found 221.1897. 
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Preparation of divinyl alcohol 273.  
 
 To a 15 mL round-bottom flask was added vinyl ketone 241 (91.0 mg, 0.413 
mmol) and the atmosphere was exchanged 3x for N2. Dry THF (4.10 mL) was then added 
via syringe and the reaction cooled to –30 °C using a closely monitored acetone/CO2 
bath. Vinylmagnesium bromide (2.06 mL, 1.0 M in THF, 2.06 mmol, 5.00 equiv) was 
then added dropwise. The reaction was maintained at –30 °C for 30 minutes, then 
quenched at that temperature with saturated aqueous NaH2PO4. The reaction mixture was 
diluted with Et2O and the layers separated. The aqueous layer was extracted with Et2O (2 
x 5 mL) and the combined organics were dried over Mg2SO4, filtered, and concentrated in 
vacuo. The crude residue was purified by silica gel flash chromatography (10% 
EtOAc/hexane) to afford 273 (92.7 mg, 91% yield) as a colorless oil: [𝛼]!!".! = +54.4° (c 
= 1.75, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 5.88 (dd, J = 17.3, 10.6 Hz, 1H), 5.75 (ddd, J = 17.1, 
10.2, 8.7 Hz, 1H), 5.18 (dd, J = 17.3, 1.3 Hz, 1H), 5.01 – 4.85 (m, 3H), 2.32 (t, J = 9.3 
Hz, 1H), 1.92 (q, J = 9.6 Hz, 1H), 1.82 (qt, J = 13.5, 3.4 Hz, 1H), 1.55 (dddd, J = 14.0, 
5.3, 3.5, 1.9 Hz, 1H), 1.48 (dq, J = 13.8, 3.5 Hz, 1H), 1.45 – 1.39 (m, 2H), 1.35 (dd, J = 
13.5, 4.0 Hz, 1H), 1.31 – 1.22 (m, 3H), 1.16 – 1.11 (m, 1H), 1.11 (s, 1H), 1.06 (s, 3H), 
0.97 (s, 3H), 0.97 (s, 3H). 
 
Me
H
O
Me
Me
Me
H
OH
MgBr, THF
–30 to –20 °C
(91% yield, >20:1 dr)
Me
Me
241 273
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13C NMR (101 MHz, CDCl3) δ 148.1, 140.6, 114.6, 110.5, 73.1, 49.0, 48.0, 45.0, 37.6, 
34.6, 34.3, 33.9, 32.8, 30.1, 23.8, 22.7, 17.8. 
FTIR (NaCl, thin film) 3601, 3452 (br), 3077, 2996, 2950, 2932, 2865, 1635, 1459, 
1441, 1413, 1380, 1367, 1343, 1291, 1275, 1250, 1200, 1170, 1081, 1058, 994, 974, 909, 
858, 846, 666 cm.-1  
HRMS (ESI) calc’d for C17H27 [M–OH]+ 231.2107, found 231.2101. 
 
Preparation of allylic alcohol 240.  
 
A 50 mL round-bottom flask containing divinyl alcohol 273 (88.0 mg, 0.355 
mmol) was pumped into a N2-filled glovebox where Hoveyda–Grubbs second-generation 
catalyst (22.2 mg, 0.035 mmol, 0.100 equiv) was added. The flask was sealed under 
nitrogen, removed from the glovebox and dry benzene (17.7 mL) was added via syringe. 
The green reaction mixture was heated to 80 °C for 3.5 hours, then cooled to room 
temperature. Ethyl vinyl ether was added to inactivate the catalyst and stirred for 15 
minutes before the reaction mixture was concentrated in vacuo. The crude residue was 
purified by silica gel flash chromatography (isocratic: 30% Et2O/hexane) to afford allylic 
alcohol 240 (72.5 mg, 93% yield) as a pale yellow oil and a single diastereomer at C1: [𝛼]!!".! = –62.9° (c = 2.67, CHCl3). 
 
Me
OH
H
H
Me
Me
Me
H
OH
HG-II (10 mol%)
PhH, 80 °C
(93% yield)
Me
Me
273 240
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1H NMR (400 MHz, CDCl3) δ 5.84 (dd, J = 10.9, 2.5 Hz, 1H), 5.15 (ddd, J = 11.0, 2.9, 
2.2 Hz, 1H), 2.41 (dt, J = 11.6, 2.7 Hz, 1H), 2.09 (td, J = 11.5, 10.7, 7.9 Hz, 2H), 1.69 
(ddd, J = 13.0, 3.2, 1.1 Hz, 1H), 1.64 (s, 1H), 1.63 – 1.56 (m, 2H), 1.54 – 1.41 (m, 2H), 
1.34 – 1.25 (m, 2H), 1.15 (dd, J = 12.8, 2.2 Hz, 1H), 1.12 – 1.06 (m, 1H), 1.05 (s, 3H), 
1.03 (s, 3H), 0.87 (s, 3H).   
 
13C NMR (101 MHz, CDCl3) δ 134.1, 132.5, 75.1, 49.9, 45.3, 43.9, 39.0, 38.1, 37.8, 
35.0, 32.6, 30.9, 26.9, 21.3, 20.2. 
 
FTIR (NaCl, thin film) 3350 (br), 3004, 2948, 2930, 2866, 1460, 1443, 1369, 1380, 
1366, 1329, 1270, 1256, 1238, 1175, 1106, 1044, 1030, 999, 973, 958, 925, 875, 864, 
766, 723 cm.-1 
 
HRMS (MM) calc’d for C15H23 [M–OH]+ 203.1794, found 203.1790. 
 
Preparation of tertiary alcohol 274.  
 
 To a 100 mL round-bottom flask were added allylic alcohol 240 (107 mg, 0.486 
mmol) and Pd/C (103 mg, 10% by weight, 0.097 mmol, 0.200 equiv). The flask was 
fitted with a septum and the atmosphere exchanged 1x for N2. MeOH (9.7 mL) was then 
added via syringe and the reaction placed under a balloon atmosphere of H2 (purged 
through a needle for 30 seconds). The reaction was stirred vigorously at room 
temperature for 2.5 hours, at which time the atmosphere was purged with argon. The 
Me
OH
H
H
Me
Me
H2, Pd/C
MeOH, rt
(94% yield)
274
Me
OH
H
H
Me
Me
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reaction mixture was filtered over celite, washed thoroughly with Et2O, and the filtrate 
concentrated in vacuo. The crude residue was purified by silica gel flash chromatography 
(isocratic: 40% Et2O/pentane) to afford 274 (101 mg, 94% yield) as a colorless oil: [𝛼]!!".! = +6.37° (c = 0.800, CHCl3). 
 
1H NMR (400 MHz, CDCl3) δ 1.97 (ddd, J = 11.8, 10.7, 7.9 Hz, 1H), 1.86 – 1.78 (m, 
1H), 1.78 – 1.68 (m, 3H), 1.67 (d, J = 0.8 Hz, 3H), 1.51 – 1.39 (m, 2H), 1.34 (dt, J = 3.5, 
2.0 Hz, 1H), 1.33 – 1.22 (m, 4H), 1.15 – 1.04 (m, 1H), 1.02 (d, J = 12.8 Hz, 1H), 0.97 (s, 
3H), 0.96 (s, 3H), 0.80 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 74.0, 50.2, 46.3, 40.3, 40.1, 39.7, 38.2, 36.4, 34.6, 32.8, 
30.7, 27.1, 22.7, 20.9, 20.7. 
 
FTIR (NaCl, thin film) 3368 (br), 2948, 2927, 2863, 1460, 1443, 1384, 1364, 1332, 
1288, 1249, 1217, 1183, 1124, 1102, 1050, 1022, 993, 976, 936, 918, 873, 862 cm.-1 
 
HRMS (ESI) calc’d for C15H25 [M–OH]+ 205.1951, found 205.1951. 
 
Preparation of benzophenone 239.39  
 
 Inside a N2-filled glovebox, to a 1 dram vial containing tertiary alcohol 274 (14.4 
mg, 0.065 mmol) were added Pd(OAc)2 (4.36 mg, 0.019 mmol, 0.300 equiv), dppf (21.6 
mg, 0.039 mmol, 0.600 equiv), and NaH (95%, 3.11 mg, 0.130 mmol, 2.00 equiv). PhMe 
Me
OH
H
H
Me
Me
Br OMe
OMe
Pd(OAc)2 (15 mol %)
dppf (30 mol %)
+
Ph
O NaH, PhMe, 110 °C
(45% yield)
Me
O
H
H
Me
Me
PhO
OMe
OMe239274 275 
(1.1 equiv)
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(650 μL) was then added and the orange reaction mixture stirred at room temperature for 
5 minutes before aryl bromide 27514 (22.8 mg, 0.071 mmol, 1.10 equiv) was added as a 
solid in one portion. The reaction was sealed with a Teflon cap and heated to 110 °C in a 
preheated aluminum block inside the glovebox. After 13.5 hours, the reaction was cooled 
to room temperature, diluted with EtOAc and saturated aqueous Na2HPO4 was added. 
The layers were separated and the aqueous layer was extracted with EtOAc until the 
organic layer was colorless. The combined organics were filtered over a plug of celite 
and Na2SO4. The filtrate was concentrated in vacuo and the crude residue purified by 
silica gel flash chromatography (isocratic: 30% hexane/CH2Cl2 + 1% EtOAc) to afford 
239 (13.4 mg, 45% yield) as a milky white gum: [𝛼]!!".! = +1.27° (c = 0.345, CHCl3). 
  
1H NMR (400 MHz, CDCl3) δ 7.86 – 7.76 (m, 2H), 7.51 (tt, J = 7.5, 2.7 Hz, 1H), 7.44 – 
7.35 (m, 2H), 6.29 (d, J = 2.1 Hz, 1H), 6.23 (d, J = 2.1 Hz, 1H), 3.83 (s, 3H), 3.70 (s, 
3H), 1.90 (ddd, J = 12.0, 10.7, 7.9 Hz, 1H), 1.78 (d, J = 2.3 Hz, 1H), 1.73 (t, J = 6.5 Hz, 
2H), 1.68 (dt, J = 13.0, 2.3 Hz, 1H), 1.65 – 1.57 (m, 1H), 1.55 – 1.45 (m, 2H), 1.45 – 1.35 
(m, 3H), 1.27 – 1.23 (m, 2H), 1.22 – 1.11 (m, 2H), 1.04 (d, J = 12.9 Hz, 1H), 0.92 (s, 
3H), 0.91 (s, 3H), 0.69 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 196.0, 161.3, 158.7, 155.2, 138.8, 132.8, 129.6, 128.3, 
116.8, 100.3, 92.5, 86.9, 55.9, 55.6, 47.6, 45.6, 39.7, 37.5, 36.8, 36.2, 36.1, 34.6, 32.7, 
30.7, 27.1, 22.5, 20.9, 20.5. 
 
FTIR (NaCl, thin film) 3059, 2948, 2930, 2861, 1671, 1601, 1582, 1458, 1451, 1438, 
1420, 1364, 1335, 1312, 1266, 1216, 1199, 1157, 1138, 1107, 1052, 1015, 998, 948, 917, 
843, 819, 802, 721, 702, 689 cm.-1 
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HRMS (MM) calc’d for C30H38NaO4 [M+Na]+ 485.2662, found 485.2672. 
 
Preparation of Norrish–Yang product 276.  
 
 To a 13 x 100 quartz test tube was added benzophenone 239 (15.5 mg, 0.034 
mmol). The tube was fitted with a 19/38 rubber septum and the atmosphere was 
exchanged 3 x for N2. Rigorously degassed dioxane (4.70 mL, freeze-pump-thawed 3x) 
was then added via syringe and the tube was sealed with electrical tape. The reaction was 
then placed in a bottomless test tube rack in front of a Honeywell 254 nm lamp and 
irradiated for 1 hour at room temperature. The reaction mixture was transferred to a cone-
bottom flask and concentrated in vacuo. The crude residue was purified by preparative 
thin-layer chromatography (30% hexane/CH2Cl2 + 1% EtOAc) to afford 27815 (2.4 mg, 
28% yield) as a white solid and 276 (1.00 mg, 6.5% yield) as a colorless oil: [𝛼]!!".! = 
+13.8° (c = 0.050, CHCl3). Note: an additional ~18% yield of a complex mixture of 
products is also isolated as a single band. Although this mixture generally appears similar 
to 276 by 1H NMR, definitive characterization was not achieved.  
 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.26 (m, 1H), 7.24 – 7.09 (m, 4H), 6.11 (dd, J = 
2.5, 1.1 Hz, 1H), 6.01 (dd, J = 2.4, 1.2 Hz, 1H), 3.95 (d, J = 1.1 Hz, 1H), 3.78 (d, J = 1.2 
Hz, 3H), 3.35 (d, J = 1.1 Hz, 3H), 2.65 (dd, J = 12.7, 3.5 Hz, 1H), 2.62 – 2.52 (m, 1H), 
2.40 (t, J = 14.4 Hz, 1H), 2.26 (q, J = 10.4 Hz, 1H), 2.11 – 1.90 (m, 1H), 1.86 (d, J = 13.0 
hν (254 nm)
dioxane, rt, 1 h
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Hz, 1H), 1.83 – 1.72 (m, 1H), 1.69 – 1.57 (m, 1H), 1.43 – 1.34 (m, 2H), 1.30 – 1.09 (m, 
4H), 0.80 (s, 3H), 0.78 (s, 3H), 0.75 (s, 3H), 0.50 (dt, J = 14.5, 4.2 Hz, 1H). 
 
13C NMR (101 MHz, CDCl3) δ 160.5, 158.8, 154.3, 149.3, 127.4, 126.1, 125.8, 111.4, 
94.2, 93.5, 80.6, 74.6, 55.6, 55.4, 48.5, 48.1, 44.0, 37.3, 36.8, 35.7, 35.5, 34.6, 33.2, 30.5, 
26.4, 25.0, 20.6, 20.4. 
 
FTIR (NaCl, thin film) 3542 (br), 3312, 3187 (br), 2960, 2924, 2854, 1738, 1726, 1710, 
1666, 1614, 1592, 1492, 1462, 1453, 1445, 1423, 1376, 1366, 1351, 1332, 1261, 1215, 
1203, 1150, 1112, 1045, 1020, 865, 800, 736, 702, 664 cm.-1 
 
HRMS (MM) calc’d for C30H37O3 [M–OH]+ 445.2737, found 445.2729. 
 
Preparation of exo-enone 283. 
 
To a 200 mL round-bottom flask were added vinyl ketone 241 (884 mg, 4.01 
mmol), aryl aldehyde 28216 (1.08 g, 4.41 mmol, 1.10 equiv), and KOH (1.13 g, 20.1 
mmol, 5.00 equiv). Freshly distilled MeOH (40.1 mL) was then added, the flask fitted 
with a reflux condenser under ambient conditions and heated to 80 °C for 12 hours. At 
completion, the volume of MeOH was reduced in vacuo and the reaction quenched with a 
saturated solution of aqueous NH4Cl. Et2O was added and the layers were separated. The 
aqueous layer was extracted twice with Et2O and the combined organic layers were dried 
Me
H
O KOH (5 equiv)+
O
H
Br OMe
OMe
241 282
Me
H
MeO Br
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O
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MeOH, 80 °C
(92% yield)
Me
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over MgSO4, filtered, and concentrated in vacuo. The crude residue was purified by silica 
gel flash chromatography (isocratic: 20% Et2O/hexane) to afford exo-enone 283 (1.66 g, 
92% yield) as an off-white solid: [𝛼]!!".! = +11.4° (c = 1.08, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.11 (t, J = 2.0 Hz, 1H), 6.75 (d, J = 2.3 Hz, 1H), 6.40 (d, 
J = 2.3 Hz, 1H), 5.74 (ddd, J = 17.1, 10.3, 8.6 Hz, 1H), 4.95 (ddd, J = 24.7, 2.1, 0.8 Hz, 
1H), 4.94 (td, J = 2.3, 0.8 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 2.44 – 2.20 (m, 5H), 2.12 
(td, J = 10.0, 8.5 Hz, 1H), 1.55 (ddd, J = 13.3, 10.3, 6.0 Hz, 1H), 1.50 (ddd, J = 10.7, 8.4, 
0.6 Hz, 1H), 1.45 (d, J = 10.4 Hz, 1H), 1.38 (dtd, J = 11.0, 5.0, 2.1 Hz, 1H), 0.99 (s, 3H), 
0.98 (s, 3H), 0.93 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 202.2, 160.8, 158.6, 139.6, 139.2, 130.5, 125.1, 118.7, 
115.3, 109.0, 98.1, 55.8, 55.7, 50.3, 49.4, 45.0, 36.5, 34.9, 33.2, 32.5, 30.1, 24.7, 23.7, 
22.6. 
FTIR (NaCl, thin film) 3073, 3000, 2952, 2863, 1686, 1599, 1558, 1482, 1461, 1435, 
1407, 1381, 1367, 1303, 1259, 1214, 1153, 1051, 1035, 996, 938, 911, 960, 831, 795 cm.-
1 
HRMS (MM) calc’d for C24H32BrO3 [M+H]+ 447.1529, found 447.1520. 
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Preparation of allylic alcohols 286 and 287.  
 
 A 100 mL round-bottom flask was flame dried under vacuum and backfilled with 
N2. Dry THF (21.2 mL) was then added, followed by freshly prepared vinyllithium as a 
solution in THF (8.42 mL, 0.756 M, 3.00 equiv). The solution was cooled to –78 °C and 
exo-enone 283 (928 mg, 2.07 mmol) was taken up in 5.0 mL THF and added dropwise 
over 5 minutes. After 40 minutes, the reaction was quenched with a saturated solution of 
NH4Cl and warmed to room temperature. The mixture was diluted with Et2O and the 
layers were separated. The aqueous layer was extracted twice with Et2O and the 
combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. The 
crude residue was purified by silica gel flash chromatography (30% hexane/CH2Cl2 + 1% 
EtOAc until unreacted 283 and 287 elute, then 5% EtOAc/CH2Cl2) to afford 286 (536 
mg, 54%), 287 (260 mg, 26%), and recovered 283 (164 mg, 18%). 
Preparation of vinyllithium:  
 THF (38.0 mL) was added to a flame-dried 200 mL round-bottom flask under N2, 
followed by tetravinyl tin (2.10 mL, 11.5 mmol). The solution was cooled to –78 °C and 
n-BuLi (17.3 mL, 2.5 M in hexanes, 43.3 mmol, 3.76 equiv) was added dropwise. The 
reaction was stirred for 20 minutes at  –78 °C, then lifted out of the ice bath and allowed 
to warm to room temperature. The reaction was allowed to stir at room temperature for at 
least 2 hours before use, and provides a ~0.756 M solution of vinyllithium (note: highest 
(3 equiv)
Me
H
MeO Br
OMe
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(80% total yield, 2:1 dr)
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yields for 1,2-addition are obtained after stirring for 6 hours, at which time the mixture 
should be slightly milky grey in appearance).  
Data for 286 (major diastereomer, peak 2): [𝛼]!!".! = –23.8° (c = 1.07, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.73 (d, J = 2.3 Hz, 1H), 6.40 (d, J = 2.3 Hz, 1H), 6.19 
(dd, J = 17.2, 10.6 Hz, 1H), 6.04 (d, J = 1.5 Hz, 1H), 5.77 (ddd, J = 17.1, 10.2, 8.9 Hz, 
1H), 5.46 (dd, J = 17.3, 1.6 Hz, 1H), 5.21 (dd, J = 10.6, 1.5 Hz, 1H), 4.92 (dddd, J = 
17.0, 14.0, 2.2, 0.8 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 2.40 – 2.22 (m, 2H), 2.07 (q, J = 
9.6 Hz, 1H), 1.92 (dt, J = 14.3, 4.5 Hz, 1H), 1.51 (q, J = 14.0, 13.3 Hz, 2H), 1.44 (d, J = 
12.7 Hz, 1H), 1.41 (d, J = 9.4 Hz, 2H), 1.35 – 1.17 (m, 2H), 1.12 (s, 3H), 0.97 (d, J = 1.2 
Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 159.7, 158.3, 146.6, 145.3, 140.5, 125.3, 120.4, 119.7, 
114.8, 112.9, 108.5, 98.1, 76.1, 55.8, 55.7, 49.3, 47.0, 46.1, 34.7, 34.6, 34.4, 33.1, 30.0, 
23.8, 23.4, 22.9. 
FTIR (NaCl, thin film) 3424 (br) 3001, 2950, 2930, 2858, 2832, 1599, 1560, 1483, 1459, 
1434, 1406, 1379, 1366, 1301, 1268, 1210, 1145, 1053, 1037, 994, 910, 879, 830, 811 
cm.-1 
HRMS (MM) calc’d for C26H34BrO2 [M–OH]+ 457.1742, found 457.1744. 
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Data for 287 (minor diastereomer, peak 1): [𝛼]!!".! = –34.2° (c = 1.03, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.75 (d, J = 2.4 Hz, 1H), 6.42 (d, J = 2.3 Hz, 1H), 6.23 (d, 
J = 1.4 Hz, 1H), 6.09 (dd, J = 17.4, 10.3 Hz, 1H), 5.77 (ddd, J = 17.2, 10.2, 8.7 Hz, 1H), 
5.48 (dd, J = 17.4, 1.5 Hz, 1H), 5.16 (dd, J = 10.3, 1.5 Hz, 1H), 4.93 (dddd, J = 18.0, 
15.2, 2.2, 0.8 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 3H), 2.35 (t, J = 9.3 Hz, 1H), 2.15 – 2.02 (m, 
2H), 1.90 (dddd, J = 14.3, 12.8, 4.4, 1.6 Hz, 1H), 1.77 – 1.65 (m, 2H), 1.59 (d, J = 13.2 
Hz, 1H), 1.49 – 1.41 (m, 2H), 1.34 (td, J = 12.8, 4.3 Hz, 1H), 1.11 (dtd, J = 12.6, 4.0, 1.9 
Hz, 1H), 0.97 (d, J = 1.1 Hz, 6H), 0.89 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.6, 158.4, 146.2, 144.9, 140.6, 125.4, 120.9, 117.9, 
115.6, 114.8, 108.4, 98.1, 75.8, 55.8, 55.7, 49.6, 49.1, 46.5, 35.6, 34.9, 34.5, 33.1, 30.1, 
25.0, 23.8, 22.3. 
FTIR (NaCl, thin film) 3451 (br) 3073, 2998, 2951, 2934, 2858, 1630, 1560, 1560, 1482, 
1461, 1434, 1406, 1380, 1366, 1301, 1266, 1211, 1150, 1038, 996, 936, 909, 884, 830, 
813 cm.-1  
HRMS (MM) calc’d for C26H34BrO2 [M–OH]+ 457.1742, found 457.1744. 
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Preparation of aryl bromide 281.  
 
A 250 mL round-bottom flask containing allylic alcohol 286 (807 mg, 1.70 mmol) 
was pumped into a N2-filled glovebox where Hoveyda–Grubbs second-generation 
catalyst (106 mg, 0.170 mmol, 0.100 equiv) and 1,4-benzoquinone (18.4 mg, 0.170 
mmol, 0.100 equiv) were added. The flask was sealed under nitrogen, removed from the 
glovebox and dry benzene (85.0 mL) was added via syringe. The green reaction mixture 
was heated to 80 °C for 12 hours, then cooled to room temperature. Ethyl vinyl ether was 
added to inactivate the catalyst and stirred for 15 minutes before the reaction mixture was 
concentrated in vacuo. The crude residue was purified by silica gel flash chromatography 
(20–30% Et2O/hexane) to afford aryl bromide 281 (704 mg, 93%) as a white foam and a 
single diastereomer at C1: [𝛼]!!".! = +95.5° (c = 0.815, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.74 (d, J = 2.4 Hz, 1H), 6.41 (d, J = 2.4 Hz, 1H), 6.32 (d, 
J = 1.7 Hz, 1H), 5.84 (dd, J = 10.8, 2.4 Hz, 1H), 5.34 (ddd, J = 10.8, 2.8, 2.1 Hz, 1H), 
3.79 (s, 3H), 3.74 (s, 3H), 2.53 (dt, J = 11.6, 2.6 Hz, 1H), 2.37 (td, J = 11.2, 7.9 Hz, 1H), 
2.28 (dd, J = 12.8, 2.3 Hz, 1H), 2.18 (dddd, J = 15.1, 11.0, 6.0, 1.9 Hz, 1H), 2.08 (ddd, J 
= 15.1, 5.2, 3.6 Hz, 1H), 1.75 (s, 1H), 1.60 – 1.46 (m, 2H), 1.41 (dd, J = 12.9, 2.2 Hz, 
1H), 1.37 – 1.22 (m, 2H), 1.08 (s, 3H), 1.06 (s, 3H), 0.90 (s, 3H). 
Me
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MeO Br
OMe
286
OH
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13C NMR (101 MHz, CDCl3) δ 159.6, 158.5, 147.7, 134.6, 131.6, 125.5, 120.8, 116.3, 
108.5, 98.2, 76.7, 55.9, 55.7, 50.9, 45.4, 43.4, 38.3, 37.5, 35.1, 32.3, 30.9, 26.2, 24.5, 
21.5. 
FTIR (NaCl, thin film) 3422 (br) 3002, 2949, 2930, 2862, 1599, 1562, 1481, 1462, 1455, 
1434, 1405, 1366, 1302, 1267, 1211, 1149, 1037, 1015, 979, 938, 870, 858, 830, 813, 
772, 755 cm.-1 
HRMS (MM) calc’d for C24H30BrO2 [M–OH]+ 429.1429, found 429.1429. 
 
Preparation of tertiary alcohols 288 and 296.  
 
 Inside a N2-filled glovebox, Crabtree’s catalyst (59.6 mg, 
0.074 mmol, 0.05 equiv) was added to a 100 mL round-bottom 
flask containing bromide 281 (663 mg, 1.48 mmol). CH2Cl2 (14.8 
mL) was added and the flask was placed inside a steel bomb, which 
was closed under nitrogen and brought out of the glovebox. The 
pressure gauge was quickly attached and all bolts on the bomb 
tightened with a wrench. The bomb was connected to a H2 inlet and 
the vessel purged with 250 psi H2 three times before being charged 
281
H2 (500 psi), CH2Cl2
(95% total yield, 16:1 dr)
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to 500 psi. The reaction was stirred at room temperature for 3 hours, at which time H2 
was vented from the reaction. The solvent was removed in vacuo and the crude residue 
purified by silica gel flash chromatography (isocratic: 40% Et2O/hexane) to afford 
tertiary alcohols 288 (599 mg, 90%) and 296 (37.4 mg, 5%) as white, crystalline solids. 
Data for 288 (major diastereomer, peak 2): [𝛼]!!".! = –20.5° (c = 0.900, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.70 (d, J = 2.4 Hz, 1H), 6.40 (d, J = 2.4 Hz, 1H), 3.79 (s, 
3H), 3.77 (s, 3H), 3.03 (dd, J = 13.2, 2.7 Hz, 1H), 2.61 (dd, J = 13.2, 10.0 Hz, 1H), 2.08 
(ddd, J = 11.9, 10.6, 7.9 Hz, 1H), 1.95 (ddd, J = 13.8, 10.4, 3.6 Hz, 1H), 1.83 (dd, J = 
12.8, 2.6 Hz, 1H), 1.78 – 1.57 (m, 4H), 1.57 – 1.34 (m, 5H), 1.34 – 1.23 (m, 2H), 1.01 (s, 
3H), 0.99 (s, 3H), 0.96 (dd, J = 12.9, 5.6 Hz, 2H), 0.77 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 158.9, 158.9, 125.9, 122.8, 108.9, 98.4, 76.2, 55.9, 55.6, 
51.7, 50.1, 45.4, 38.7, 38.0, 36.0, 35.0, 33.9, 33.3, 30.8, 28.5, 26.6, 26.3, 21.3, 21.0. 
FTIR (NaCl, thin film) 3474 (br), 3000, 2946, 2930, 2862, 1603, 1568, 1482, 1461, 
1435, 1410, 1294, 1272, 1212, 1198, 1151, 1130, 1054, 1038, 999, 937, 926, 876, 831, 
756 cm.-1  
HRMS (MM) calc’d for C24H34BrO2 [M–OH]+ 433.1737, found 433.1685. 
Data for 296 (minor diastereomer, peak 1): [𝛼]!!".! = –27.7° (c = 0.950, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.72 (d, J = 2.5 Hz, 1H), 6.40 (d, J = 2.4 Hz, 1H), 3.80 (s, 
3H), 3.78 (s, 3H), 2.85 (dd, J = 13.6, 5.8 Hz, 1H), 2.59 (dd, J = 13.6, 8.1 Hz, 1H), 2.29 
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(dddd, J = 11.4, 8.0, 5.8, 3.5 Hz, 1H), 1.98 (ddd, J = 11.0, 9.4, 6.7 Hz, 2H), 1.80 – 1.52 
(m, 4H), 1.52 – 1.37 (m, 4H), 1.37 – 1.26 (m, 4H), 1.25 (s, 1H), 0.94 (s, 6H), 0.78 (s, 
3H). 
13C NMR (101 MHz, CDCl3) δ 158.9, 158.5, 126.1, 123.0, 109.2, 98.3, 75.2, 55.8, 55.7, 
49.3, 46.4, 45.4, 41.0, 38.5, 36.9, 36.6, 33.8, 30.5, 30.4, 29.2, 27.6, 24.2, 24.1, 21.5. 
FTIR (NaCl, thin film) 3482 (br), 2998, 2945, 2928, 2859, 1690, 1648, 1602, 1567, 
1482, 1459, 1435, 1409, 1381, 1364, 1294, 1273, 1211, 1198, 1154, 1134, 1051, 1039, 
973, 937, 830, 809, 756. 
 
HRMS (MM) calc’d for C24H35BrO3Na [M+Na]+ 475.1818, found 475.1858. 
 
Preparation of pentacycle 280.  
 
 Aryl bromide 288 (274 mg, 0.607 mmol) was added to each of two 20 mL 
scintillation vials and pumped inside a N2-filled glovebox, where CuI (23.1 mg, 0.121 
mmol, 0.200 equiv), 2,2’-bipyridine (18.9, 0.121 mmol, 0.200 equiv), and KOt-Bu (204, 
1.82 mmol, 3.00 equiv) were added as solids to each. Dry DMF (6.10 mL) was then 
added, the reaction sealed under N2 with a Teflon screw-cap and heated to 120 °C in a 
pre-heated aluminum block inside the glovebox for 3.5 hours. After cooling to room 
temperature, the reaction mixtures were combined and loaded directly onto a short silica 
288
KOt-Bu, DMF, 120 °C
(75% yield)
CuI (20 mol %)
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gel column, pre-equilibrated with 5% Et2O/hexane. The column was eluted with 5% 
Et2O/hexane (isocratic) to afford pentacycle 280 (339 mg, 75%) as a white solid:      [𝛼]!!".! = +42.4° (c = 1.08, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.02 (d, J = 2.4 Hz, 1H), 6.00 (d, J = 2.4 Hz, 1H), 3.77 (s, 
3H), 3.74 (s, 3H), 2.55 (dd, J = 16.6, 4.0 Hz, 1H), 2.20 – 2.03 (m, 2H), 1.97 (dd, J = 12.6, 
2.3 Hz, 1H), 1.77 (dddd, J = 18.7, 9.0, 7.4, 4.8 Hz, 2H), 1.69 – 1.55 (m, 4H), 1.52 – 1.41 
(m, 3H), 1.32 (t, J = 10.7, 9.6 Hz, 2H), 1.32 – 1.20 (m, 1H), 1.17 (dd, J = 12.6, 1.1 Hz, 
1H), 0.99 (s, 3H), 0.97 (s, 3H), 0.86 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 159.5, 158.3, 154.4, 104.5, 94.2, 90.8, 79.9, 55.5, 55.4, 
48.0, 44.3, 40.9, 38.0, 36.9, 35.6, 35.1, 33.5, 30.8, 28.4, 27.1, 26.5, 22.8, 20.9, 19.9. 
FTIR (NaCl, thin film) 2995, 2945, 2928, 2862, 2843, 1617, 1589, 1494, 1460, 1420, 
1363, 1288, 1215, 1201, 1186, 1164, 1145, 1108, 1074, 1054, 1033, 1008, 942, 928, 810 
cm.-1 
HRMS (MM) calc’d for C24H35O3 [M+H]+ 371.2581, found 371.2578. 
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Preparation of benzylic ethers 290 and 291.40 
 
To a flame-dried 25 mL round-bottom flask was added pentacycle 280 (80.0 mg, 
0.216 mmol) and the atmosphere exchanged three times for argon. A 1:1 mixture of dry 
MeCN/CH2Cl2 (6.40 mL) was then added, followed by ethoxyethanol (1.54 mL) via 
syringe and the solution cooled to 0 °C. A previously prepared stock solution of DDQ in 
dry MeCN (0.860 mL, 0.508 M, 2.00 equiv) was then added dropwise. The reaction 
turned grey/blue immediately upon addition of DDQ and slowly turned green-blue by the 
end of addition. Once the addition was complete, the reaction was lifted from the ice bath 
and gradually warmed to room temperature. The color became an olive green-brown after 
1 hour, indicating the reaction had stalled at ~50% conversion (as judged by TLC). At 
this point, the reaction was quenched with a saturated solution of aqueous NaHCO3 and 
stirred vigorously for 10 minutes before the layers were separated. The aqueous layer was 
extracted twice more with CH2Cl2 and the combined organic layers were washed with one 
portion of DI H2O, dried over Na2SO4, filtered, and concentrated in vacuo. The crude 
residue was purified by silica gel flash chromatography: SiO2 was first deactivated by 
applying a few drops of aqueous NH4OH (28%) to the top of a dry column and 
equilibrating with 100 mL of 5% Et2O/hexane. The crude residue was then applied and 
eluted with fresh 5% Et2O/hexane until unreacted 280 elutes completely, then 20% 
Et2O/hexane until complete elution of second diastereomer to afford a mixture of 290 and 
1:1 CH2Cl2/MeCN
0 °C to rt
(60% yield, 2 cycles, 4.8:1 dr)
DDQ (2 equiv)
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291 (41.0 mg, 41% yield), and recovered starting material 280 (40.8 mg, 51%). The 
recovered starting material was re-subjected to the reaction conditions described above to 
afford additional 290 and 291 (18.8 mg, 60% total over 2 cycles) and 2 (15.2 mg, 74% 
overall brsm). Analytically pure samples of 290 and 291 were obtained by preparative 
TLC (30% Et2O, 1% Et3N/hexane) and a representative spectrum of the mixture as used 
in the next step is also provided.  
Data for 290 (major diastereomer, peak 1): [𝛼]!!".! = +43.5° (c = 0.815, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.01 (d, J = 2.4 Hz, 1H), 5.94 (d, J = 2.3 Hz, 1H), 4.27 (d, 
J = 3.3 Hz, 1H), 3.98 (dt, J = 9.8, 4.9 Hz, 1H), 3.81 (dd, J = 10.9, 5.1 Hz, 1H), 3.79 (s, 
3H), 3.73 (s, 3H), 3.58 (dd, J = 5.9, 4.9 Hz, 2H), 3.53 (q, J = 7.0 Hz, 2H), 2.48 – 2.36 (m, 
1H), 2.21 (qd, J = 14.4, 4.1 Hz, 1H), 2.10 (ddd, J = 12.2, 10.7, 7.9 Hz, 1H), 2.00 (dd, J = 
12.7, 2.3 Hz, 1H), 1.79 – 1.61 (m, 3H), 1.59 – 1.41 (m, 4H), 1.42 – 1.20 (m, 4H), 1.20 (t, 
J = 7.0 Hz, 3H), 0.99 (s, 3H), 0.98 (s, 3H), 0.86 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 161.1, 159.7, 154.7, 106.6, 93.8, 91.2, 80.5, 72.1, 71.4, 
70.5, 66.7, 55.4, 55.4, 49.3, 47.6, 46.1, 39.4, 39.3, 36.3, 34.8, 33.5, 32.4, 30.8, 26.8, 23.1, 
22.3, 20.8, 15.4. 
FTIR (NaCl, thin film) 2948, 2930, 2864, 1614, 1589, 1491,1462, 1438, 1424, 1365, 
1353, 1332, 1320, 1287, 1215, 1202, 1189, 1166, 1148, 1109, 1053, 1033, 1005, 951, 
921, 866, 811, 731, 638 cm.-1 
HRMS (MM) calc’d for C24H33O3 [M–O(CH2)2OEt]+ 369.2424, found 369.2430. 
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Data for 291 (minor diastereomer, peak 2): [𝛼]!!".! = +29.6° (c = 0.230, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 6.02 (d, J = 2.4 Hz, 1H), 5.92 (d, J = 2.4 Hz, 1H), 4.30 (d, 
J = 10.4 Hz, 1H), 3.78 (s, 3H), 3.75 (ddd, J = 9.1, 3.0, 1.3 Hz, 1H), 3.73 (s, 3H), 3.58 – 
3.45 (m, 5H), 2.24 – 2.04 (m, 2H), 1.92 (ddt, J = 14.7, 9.9, 3.2 Hz, 2H), 1.80 – 1.64 (m, 
2H), 1.65 – 1.40 (m, 5H), 1.36 – 1.19 (m, 4H), 1.19 (t, J = 7.0 Hz, 3H), 0.97 (s, 3H), 0.96 
(s, 3H), 0.86 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 161.0, 160.0, 155.9, 105.8, 94.2, 91.7, 81.7, 73.4, 70.5, 
67.8, 66.7, 55.5, 55.4, 48.2, 47.2, 44.4, 37.8, 37.2, 35.6, 35.1, 33.2, 30.8, 28.4, 26.4, 23.7, 
20.9, 20.4, 15.4. 
FTIR (NaCl, thin film) 2947, 2934, 2864, 1613, 1587, 1490, 1459, 1438, 1421, 1364, 
1349, 1312, 1288, 1267, 1245, 1216, 1202, 1147, 1107, 1054, 1034, 1002, 973, 943, 868. 
812, 736, 636 cm.-1 
HRMS (MM) calc’d for C24H33O3 [M–O(CH2)2OEt]+ 369.2424, found 369.2427. 
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Preparation of diarylmethanes 279 and 293.  
 
 A 10 mL round-bottom flask containing CuCN (11.9 mg, 0.133 mmol, 2.05 
equiv) was flame-dried under vacuum. After cooling to room temperature, the flask was 
backfilled with argon and dry Et2O (2.70 mL) was added via syringe. The suspension was 
cooled to –78 °C under argon and PhLi (0.140 mL, 1.9 M in dibutyl ether, 0.266 mmol, 
4.09 equiv) was added dropwise. After stirring at –78 °C for 5 minutes, the reaction was 
warmed to 0 °C and stirred for an additional 30 minutes. The higher-order cuprate was 
then cooled back to –78 °C and the 4.8:1 mixture of benzylic ethers 290 and 291 (30.0 
mg, 0.065 mmol) was as a solution in Et2O (1.00 mL). The reaction was stirred for 1-2 
minutes before BF3•OEt2 (0.160 mL, 1.30 mmol, 20.0 equiv) was added dropwise via 
syringe. The reaction was stirred at –78 °C  for 10 minutes, then quickly transferred to a 
pre-equilibrated bath at –55 °C, which was allowed to –50 °C over 5 minutes, then 
maintained at or just below –45 °C for another 30 minutes. The reaction was checked for 
completion by TLC, then quenched with aqueous NaHCO3 and warmed to room 
temperature. The layers were separated and the aqueous layer extracted twice with Et2O. 
The combined organic layers were dried over MgSO4, filtered, and concentrated in vacuo. 
The crude residue was purified by silica gel flash chromatography (isocratic: 5% 
Et2O/hexane) to afford diarylmethanes 279 and 293 (26.3 mg, 90%) as a 2:1 inseparable 
mixture, white solid: [𝛼]!!".! = +2.08° (c = 1.23, CHCl3). 
279
Me
H
H
Me
Me
O OMe
OMe
H
Me
H
H
Me
Me
O OMe
OMe
H
Ph
Ph2Cu(CN)Li2
BF3•OEt2, Et2O
–78 °C to –45 °C
(90% yield, 2:1 dr)O
OEt
293
Me
H
H
Me
Me
O OMe
OMe
H
Ph
290 and 291
(4.8:1 mixture)
+
Chapter 3 – Revised Strategies for the Enantioselective Synthesis (+)-Psiguadial B  251 
1H NMR (2:1 dr, asterisk denotes minor diastereomer, 400 MHz, CDCl3) δ 7.24 – 6.96 
(m, 5H), 6.10* (d, J = 2.4 Hz, 1H), 6.07 (d, J = 2.5 Hz, 1H), 6.03* (d, J = 2.4 Hz, 1H), 
5.93 (d, J = 2.4 Hz, 1H), 4.10* (d, J = 6.4 Hz, 1H), 3.79* (s, 3H), 3.76 (s, 3H), 3.46* (s, 
3H), 3.47 (d, J = 11.3 Hz, 1H), 3.20 (s, 3H), 2.23 – 2.06 (m, 1H), 2.00 (dd, J = 12.7, 2.4 
Hz, 1H), 1.93* (dd, J = 12.6, 2.5 Hz, 1H), 1.88 – 1.73 (m, 2H), 1.73 – 1.60 (m, 3H), 1.55 
– 1.41 (m, 4H), 1.39 – 1.26 (m, 5H), 1.20 (q, J = 13.1, 12.1 Hz, 1H), 1.00 (s, 3H), 0.99 (s, 
3H), 0.92* (s, 3H), 0.83 (s, 3H), 0.82* (s, 3H), 0.74* (s, 3H). 
13C NMR (279, major diastereomer, 101 MHz, CDCl3) δ 160.0, 159.2, 155.2, 146.7, 
129.8, 127.7, 125.4, 109.2, 94.5, 92.7, 80.4, 55.3, 55.2, 50.7, 48.1, 44.3, 41.9, 37.9, 36.9, 
35.6, 35.1, 33.3, 30.8, 28.2, 26.3, 24.3, 20.9, 20.2. 
 
13C NMR (293, minor diastereomer 101 MHz, CDCl3) δ 160.1, 159.2, 155.1, 141.5, 
128.9, 127.0, 125.5, 106.4, 94.1, 91.5, 80.7, 55.6, 55.4, 50.0, 45.8, 44.3, 39.3, 38.5, 36.7, 
35.5, 35.0, 33.2, 32.7, 30.8, 26.2, 25.8, 20.9, 20.4. 
 
FTIR (NaCl, thin film) 3081, 3059, 3025, 2998, 2948, 2934, 2864, 2843, 1614, 1588, 
1490,1460, 1454, 1440, 1420, 1364, 1307, 1288, 1274, 1249, 1216, 1202, 1166, 1148, 
1123, 1105, 1076, 1054, 1033, 1005, 943, 870, 811, 759, 740, 701 cm.-1 
 
HRMS (MM) calc’d for C30H39O3 [M+H]+ 447.2894, found 447.2905.  
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Preparation of resorcinols 294 and 297.  
 
 Solid pyridine•HCl (1.44 g, 12.5 mmol, 307 equiv) was weighed into each of two 
2-dram vials, containing a 2:1 mixture of diarylmethanes 279 and 293 (18.2 mg, 0.041 
mmol). The vials were sealed with a Teflon screw cap under a stream of argon and heated 
to 200 °C in a pre-heated aluminum block for 2.5 hours. (Note: it is important to choose a 
vial/heating block combination that will cover the entire volume of the solid to ensure 
that it stays completely melted during the course of the reaction). The reactions were 
cooled to room temperature, during which time the mixture solidified. The crude solids 
were dissolved in DI H2O, and combined by pipetting dropwise into an Erlenmeyer flask 
containing a saturated solution of aqueous NaHCO3. EtOAc was then added and the 
layers were separated. The aqueous layer was extracted three times with EtOAc and the 
combined organic layers were dried over MgSO4 and concentrated in vacuo. The crude 
residue was purified by silica gel flash chromatography (isocratic: 10% EtOAc, 1% 
AcOH/hexane) to separate resorcinols 294 and 297. The concentrated fractions for each 
diastereomer (initially a pale orange oil) were each passed through another short plug of 
silica gel (eluting with 20% EtOAc/heaxnes) to remove residual AcOH and remaining 
trace impurities to afford 294 (21.3 mg, 62%) and 297 (10.3 mg, 30%) as white solids.  
Data for 294 (major diastereomer, peak 1): [𝛼]!!".! = –28.2° (c = 0.475, CHCl3). 
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1H NMR (400 MHz, CDCl3) δ 7.44 – 7.26 (m, 5H), 6.00 (d, J = 2.6 Hz, 1H), 5.88 (d, J = 
2.6 Hz, 1H), 4.73 (s, 1H), 4.46 (s, 1H), 3.49 (d, J = 11.4 Hz, 1H), 2.16 (ddd, J = 12.3, 
10.4, 7.9 Hz, 1H), 2.01 (dd, J = 12.8, 2.3 Hz, 1H), 1.85 – 1.58 (m, 4H), 1.54 – 1.44 (m, 
2H), 1.44 – 1.30 (m, 4H), 1.28 (m, 1H), 1.18 (d, J = 12.9 Hz, 1H), 1.10 – 1.03 (m, 1H), 
1.00 (s, 3H), 0.99 (s, 3H), 0.85 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.1, 155.8, 155.4, 142.3, 128.0, 106.3, 97.7, 96.8, 80.1, 
50.5, 48.1, 44.2, 41.8, 37.8, 36.9, 35.6, 35.2, 33.3, 30.8, 28.6, 26.3, 24.0, 20.9, 20.0. 
FTIR (NaCl, thin film) 3511 (br), 3386 (br), 3060, 3024, 2948, 2928, 2863, 1702, 1627, 
1598, 1509, 1492, 1459, 1364, 1349, 1320, 1272, 1248, 1228, 1166, 1138, 1087, 1072, 
1057, 1034, 1014, 925, 869, 831, 761, 738, 703, 667, 638, 571, 516 cm.-1 
HRMS (MM) calc’d for C28H35O3 [M+H]+ 419.2581, found 419.2591. 
Data for 297 (minor diastereomer, peak 2): [𝛼]!!".! = +26.7° (c = 0.180, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.21 (m, 5H), 6.02 (d, J = 2.5 Hz, 1H), 5.96 (d, J = 
2.5 Hz, 1H), 4.73 (s, 1H), 4.30 (s, 1H), 4.00 (d, J = 7.0 Hz, 1H), 2.16 (ddd, J = 12.5, 7.0, 
3.9 Hz, 1H), 1.93 (dd, J = 12.7, 2.3 Hz, 2H), 1.79 (ddd, J = 12.3, 10.3, 7.8 Hz, 1H), 1.66 
(ddd, J = 12.4, 8.7, 5.4 Hz, 1H), 1.57 – 1.43 (m, 5H), 1.39 – 1.28 (m, 4H), 1.23 – 1.12 
(m, 3H), 1.09 – 0.95 (m, 2H), 0.91 (s, 3H), 0.82 (s, 3H), 0.75 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 156.2, 155.7, 155.4, 138.6, 127.4, 104.8, 97.6, 95.9, 80.4, 
49.7, 45.6, 44.2, 39.6, 38.3, 36.6, 35.4, 35.1, 33.2, 32.0, 30.8, 29.9, 26.1, 25.4, 20.8, 20.3. 
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FTIR (NaCl, thin film) 3385 (br), 3027, 2949, 2925, 2857, 1624, 1600, 1508, 1493, 
1459, 1452, 1377, 1364, 1247, 1190, 1163, 1143, 1086, 1055, 1034, 1015, 925, 826, 761, 
721, 701 cm.-1 
HRMS (MM) calc’d for C28H35O3 [M+H]+ 419.2581, 419.2595. 
 
Preparation of (+)-psiguadial B (56).  
 
 To a 2-dram vial was added resorcinol 294 (15.4 mg, 0.037 mmol) and the 
atmosphere exchanged three times for N2. CH2Cl2 (1.30 mL) was then added via syringe, 
followed by dichloromethyl methyl ether (0.083 mL, 0.920 mmol, 25.0 equiv). The 
solution was cooled to –78 °C and a freshly prepared stock solution of TiCl4 (0.190 mL, 
0.912 M in CH2Cl2, 0.173 mmol, 4.68 equiv) was added dropwise. The reaction 
immediately turns dark red. The reaction was stirred at –78 °C for 5 minutes, then 
warmed to room temperature and stirred for an additional 3 hours and 40 minutes. DI 
H2O (2.00 mL) was then added via syringe and the reaction stirred vigorously for 15 
minutes before the layers were separated. The aqueous layer was extracted five times 
with CH2Cl2 and the combined organic layers were filtered over a plug of Na2SO4 and 
concentrated in vacuo. The crude residue was purified by silica gel flash chromatography 
(isocratic: 2% EtOAc, 1% AcOH/hexane) to afford (+)-psiguadial B (56) (8.7 mg, 50%) 
as an ivory solid. Note: 56 is streaky on SiO2 and after an initial concentrated band elutes, 
Me
H
H
Me
Me
O OH
OH
H
Ph
DCM, –78 °C to rt;
then, H2O
(50% yield)
294
Me
H
H
Me
Me
O OH
OH
H
Ph
CHO
CHO
(+)-psiguadial B (56)
HepG2 IC50 = 46 nM
Cl Cl
OMe
,  TiCl4
Chapter 3 – Revised Strategies for the Enantioselective Synthesis (+)-Psiguadial B  255 
approximately 12% of the product is contained in the following very dilute fractions. The 
natural product is weakly UV active, but can also be visualized by TLC using 2,4-
dinitrophenylhydrazine stain. [𝛼]!!".! = +94.0° (c = 0.265, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 13.51 (s, 1H), 13.04 (s, 1H), 10.07 (s, 2H), 7.26 (dd, J = 
14.6, 1.5 Hz, 2H), 7.23 – 7.17 (m, 1H), 7.10 (br s, 2H), 3.49 (d, J = 11.5 Hz, 1H), 2.20 – 
2.12 (m, 1H), 2.09 (dd, J = 12.7, 2.4 Hz, 1H), 1.92 (ddd, J = 14.9, 12.8, 4.2 Hz, 1H), 1.82 
(ddd, J = 12.3, 8.8, 5.6 Hz, 1H), 1.73 – 1.59 (m, 3H), 1.53 – 1.44 (m, 1H), 1.49 (ddd, J = 
11.6, 8.1, 2.9 Hz, 2H), 1.44 – 1.29 (m, 4H), 1.05 (dd, J = 7.6, 5.8 Hz, 1H), 1.02 (s, 3H), 
1.00 (s, 3H), 0.85 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 192.3, 191.5, 169.6, 168.5, 163.5, 143.4, 128.2, 126.2, 
105.7, 104.6, 104.1, 84.1, 50.0, 47.4, 44.0, 40.4, 37.6, 36.9, 35.4, 35.1, 33.4, 30.6, 29.3, 
26.1, 23.9, 20.7, 20.1. 
FTIR (NaCl, thin film) 3026, 2945, 2926, 2864, 2720, 1633, 1603, 1493, 1437, 1382, 
1363, 1300, 1270, 1251, 1231, 1184, 1154, 1143, 1031, 1006, 976, 926, 917, 875, 851, 
840, 824, 768, 701, 636, 618, 606, 564 cm.-1 
HRMS (MM) calc’d for C30H35O5 [M+H]+ 475.2479, found 475.2487. 
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Comparison of 1H NMR data for natural and synthetic (+)-psiguadial B (56).  
carbon 
number 
Natural (+)-psiguadial B41 
1H NMR, 500 MHz, CDCl3 
Synthetic (+)-psiguadial B 
1H NMR, 400 MHz, CDCl3 
5'-OH δ 13.51 (s, 1H) δ 13.51 (s, 1H) 
7'-OH 13.04 (s, 1H) 13.04 (s, 1H) 
14', 15' 10.08 (s, 2H) 10.07 (s, 2H) 
9', 13'42 7.23 (2H) 7.26 (dd, J = 14.6, 1.5 Hz, 2H) 
11' 7.18 (3H) 7.23 – 7.17 (m, 1H) 
10', 12’ – 7.10 (br m, 2H) 
1' 3.49 (d, J = 11.5 Hz, 1H) 3.49 (d, J = 11.5 Hz, 1H) 
2 2.16 (1H) 2.20 – 2.12 (m, 1H) 
12 2.08 (1H) 2.09 (dd, J = 12.7, 2.4 Hz, 1H) 
7 1.93 (1H) 1.92 (ddd, J = 14.9, 12.8, 4.2 Hz, 1H) 
5 1.82 (m, 1H) 1.82 (ddd, J = 12.3, 8.8, 5.6 Hz, 1H) 
9 1.68 (1H) 1.73 – 1.59 (m, 3H) 
6 1.65 (1H) – 
7 1.58 (m, 1H) – 
3 1.52 (1H) 1.53 – 1.44 (m, 1H) 
10 1.49 (m, 2H) 1.49 (ddd, J = 11.6, 8.1, 2.9 Hz, 2H) 
6, 11 1.41 (2H) – 
3 1.37 (1H) 1.44 – 1.29 (m, 4H) 
12 1.29 (1H)  – 
11 1.10 (1H) 1.05 (dd, J = 7.6, 5.8 Hz, 1H) 
13 1.02 (s, 3H) 1.02 (s, 3H) 
14 1.01 (s, 3H) 1.00 (s, 3H) 
15 0.86 (s, 3H) 0.85 (s, 3H) 
(+)-psiguadial B (56) carbon numbering as reported by Shao et al.41 
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Comparison of 13C NMR data for natural and synthetic (+)-psiguadial B (56). 
carbon 
number 
Natural (+)-psiguadial B41 
13C NMR, 125 MHz, CDCl3 
Synthetic (+)-psiguadial B43 
13C NMR, 101 MHz, CDCl3 
Δ 
(ppm) 
15' 192.3 192.3 0.0 
14' 191.4 191.5 0.1 
7' 169.6 169.6 0.0 
5' 168.5 168.5 0.0 
3' 163.5 163.5 0.0 
8' 143.4 143.4 0.0 
9', 11', 13’ 128.2 128.2 0.0 
10', 12' 126.2 126.2 0.0 
2' 105.7 105.7 0.0 
4' 104.6 104.6 0.0 
6' 104.2 104.1 -0.1 
8 84.1 84.1 0.0 
9 50.0 50.0 0.0 
12 47.5 47.4 -0.1 
5 44.1 44.0 -0.1 
1' 40.4 40.4 0.0 
11 37.6 37.6 0.0 
2 37.0 36.9 -0.1 
3 35.5 35.4 -0.1 
4 35.1 35.1 0.0 
1 33.4 33.4 0.0 
13 30.6 30.6 0.0 
7 29.4 29.3 -0.1 
15 26.1 26.1 0.0 
10 23.9 23.9 0.0 
14 20.7 20.7 0.0 
6 20.1 20.1 0.0 
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1H NMR spectral comparison of natural and synthetic (+)-psiguadial B (56). 
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.511.011.512.012.513.013.514.014.515.0 f1 (ppm)
LMC-04-214-flash.2.fid
3.3
9
3.2
3
2.9
5
1.0
8
4.1
3
3.1
9
3.4
5
1.1
7
1.0
7
2.0
7
1.0
0
2.0
0
1.0
5
3.0
7
2.0
2
0.9
6
0.9
6
Parameter Value
Data File Name / Volumes/ nmrdata/ lchapman/ nmr/ LMC-04-214-flash/ 2/ fid
Title LMC-04-214-flash.2.fid
Comment
Origin Bruker BioSpin GmbH
Spectrometer spect
Solvent CDCl3
Temperature 295.0
Pulse Sequence zg30
Experiment 1D
Number of Scans 16
Receiver Gain 143
Relaxation Delay 10.0000
Pulse Width 11.7000
Acquisition Time 4.0894
Acquisition Date 2016-07-02T16:29:45
Spectrometer Frequency 400.13
Spectral Width 8012.8
Nucleus 1H
Acquired Size 32768
Spectral Size 65536
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13C NMR spectral comparison of natural and synthetic (+)-psiguadial B (56). 
 
 
 
102030405060708090100110120130140150160170180190200210 f1 (ppm)
LMC-04-214-flash.3.fid
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.08
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.74
23
.88
26
.07
29
.34
30
.61
33
.44
35
.07
35
.40
36
.89
37
.57
40
.36
44
.00
47
.42
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.99
84
.10
10
4.1
2
10
4.6
1
10
5.6
9
12
6.2
0
12
8.1
5
14
3.3
8
16
3.4
7
16
8.5
0
16
9.6
2
19
1.5
0
19
2.3
3
Parameter Value
Data File Name / Volumes/ nmrdata/ lchapman/ nmr/ LMC-04-214-flash/ 3/ fid
Title LMC-04-214-flash.3.fid
Comment
Origin Bruker BioSpin GmbH
Spectrometer spect
Solvent CDCl3
Temperature 294.9
Pulse Sequence zgpg30
Experiment 1D
Number of Scans 1024
Receiver Gain 72
Relaxation Delay 2.0000
Pulse Width 10.0000
Acquisition Time 1.3631
Acquisition Date 2016-07-02T17:28:52
Spectrometer Frequency 100.62
Spectral Width 24038.5
Nucleus 13C
Acquired Size 32768
Spectral Size 65536
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The remaining three aromatic proton signals are adjusted accordingly in the 
comparison list. 
(43)  Center peak of CDCl3 is referenced to 76.999 ppm, as shown in the Shao et al.  
report, see 13C spectral comparison. 
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Appendix 4 
Progress Toward a Concise Total Synthesis of (+)-Rumphellaone A 
 
4.1 INTRODUCTION 
4.1.1 Isolation and Biosynthetic Origins 
A variety of β-caryophyllene-derived natural products, such as 298–300, have been 
isolated from the gorgonian coral, Rumphella antipathies (Figure 4.1).1 In 2010, Chung 
and coworkers reported the discovery of (+)-rumphellaone A (302), which was found to 
exhibit cytotoxicity against a human T-cell acute lymphoblastic leukemia tumor cell line 
(CCRF-CEM IC50 = 12.6 µg/mL). From a structural standpoint, 302 is a novel 4,5-seco-
caryophyllane sesquiterpenoid; although several C4-C5 oxidative cleavage products of β-
caryophyllene (21) have been reported previously (e.g. 301), 2  302 possesses an 
unprecedented γ-butyrolactone.3 Two additional members of this family, rumphellaones 
B and C (303 and 304), were isolated from the same marine invertebrate several years 
later and were shown to possess anti-inflammatory activity.4  
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Figure 4.1. Rumphellaone A and related β-caryophyllene-derived natural products 
 
Biosynthetically, 302 is proposed to originate from β-caryophyllene (21) by 
double epoxidation, followed by reduction to give diol 306 (Scheme 4.1).2 Oxidation of 
the secondary alcohol at C5 affords ketone 307, which may undergo Baeyer–Villager 
oxidative ring expansion to produce 308. Hydrolysis of this 10-membered lactone gives 
rise to 4,5-seco-caryophyllane 309, a possible precursor for other members of this family 
(e.g. 301, Figure 4.1). Lactonization of 309 and a final oxidation then provides the natural 
product,  (+)-rumphellaone A (302). 
Scheme 4.1. Proposed biosynthesis of (+)-rumphellaone A  
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4.2 PREVIOUS TOTAL SYNTHESES OF (+)-RUMPHELLAONE A 
4.2.1 Kuwahara’s Enantioselective Synthesis 
The first enantioselective total synthesis of (+)-rumphellaone A (302) was 
achieved by Kuwahara and coworkers in 2012 (Scheme 4.2).5 Nitrile 312 was obtained in 
6 steps from methyl isobutylate (310) and allyl bromide (311). Chemoselective reduction 
of the ester in 312 using DIBAL gave an allylic alcohol that was used to effect a 
Sharpless asymmetric epoxidation, furnishing 313 in 92% ee and 64% yield, over the two 
steps. Following protection of the primary alcohol, the cyclobutane ring was formed via a 
key epoxy nitrile cyclization,6 providing trans-cyclobutane 314 in excellent yield and 
diastereoselectivity. Initial efforts to develop this transformation provided mixtures of cis 
and trans cyclobutanes; however, the use of excess base at elevated temperatures was 
found to be crucial for complete conversion to the thermodynamic trans product.  
Reduction of nitrile 314 to aldehyde 315 then facilitated installation of 
rumphellaone’s “northern” methyl ketone via homologation with Wittig reagent 316. The 
remaining carbons were introduced using a Horner–Wadsworth–Emmons reaction to 
Scheme 4.2. Kuwahara’s enantioselective total synthesis of (+)-rumphellaone A 
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afford 318 after 3 steps. Global hydrogenation and a final lactonization then furnished 
(+)-302 in 18 steps from commercially available starting materials.  
 
4.2.2 Echavarren’s Asymmetric Synthesis 
Four years after Kuwahara’s initial disclosure, Echavarren and coworkers 
reported a markedly different strategy toward 3027 that highlights the utility of their 
previously developed gold(I)-catalyzed [2+2] cycloaddition of 1,10-enynes8 (Scheme 
4.3). The key cycloaddition substrate 320 was accessed in short order from 
enantioenriched alcohol 319 via O-benzylation and a Sonogoshira reaction. Treatment of 
320 with 5 mol % of gold catalyst 323 provided macrocyclic cyclobutene 321 in 75% 
yield and 9:1 dr. Hydrogenolysis of the benzyl ether in 321, followed by oxidative 
cleavage of the aryl group gave carboxylic acid 322. A 4-step sequence involving base-
mediated epimerization of an ester generated in situ provided trans-ketone 324, which 
was subjected to an asymmetric allylation reaction, delivering tertiary alcohol 325 in 80% 
yield and 9:1 dr. Finally, a one-pot procedure9 converted the homoallylic alcohol in 325 
into the γ-butyrolactone with concominant deprotection to afford 302 in 12 total steps.  
Scheme 4.3. Echavarren’s asymmetric total synthesis of (+)-rumphellaone A 
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4.3 RETROSYNTHETIC ANALYSIS 
Having developed an enantioselective total synthesis of (+)-psiguadial B (56), we 
sought to apply the key strategy concepts in the context of other bioactive, trans-
cyclobutane-containing natural products, such as (+)-rumphellaone A (302). We reasoned 
that 302 could be obtained through a late-stage Wittig reaction with trans-aldehyde 326, 
using the reaction conditions developed by Kuwahara.5 In turn, trans-aldehyde 326 would 
be accessed using the Schwartz reduction/epimerization sequence previously developed 
for the synthesis of 56. Construction of the γ-butyrolactone was envisioned to be enabled 
by hydration of the vinyl group in 327, which would be the direct product of a C(sp3)–H 
alkenylation reaction between cyclobutane (–)-89 and vinyl iodide 328. Thus, our studies 
commenced by determining the feasibility of joining these two fragments.  
Figure 4.2. Retrosynthetic analysis for (+)-rumphellaone A 
 
 
4.4 FORWARD SYNTHETIC EFFORTS 
Vinyl iodide 328 was easily prepared via ketalization of the corresponding known 
aldehyde.10 Subjection of (–)-89 and 3 equiv 328 to the standard Pd-catalyzed C(sp3)–H 
alkenylation reaction conditions resulted in formation of the expected product, 327 as a 
single diastereomer, albeit in only 11% yield (Table 4.1, entry 1). The reaction profile 
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was quite clean and analysis of the crude mixture by TLC and 1H NMR revealed that the 
low yield resulted from poor conversion of the starting materials, both of which remained 
intact. Given that solvent choice proved critical in the optimization of this transformation 
for the synthesis of 147 (see Chapter 2, Table 2.1), both toluene and dioxane were 
investigated (entries 2 and 3), but each gave similarly disappointing results. A more 
thorough survey of reaction parameters is currently ongoing with parallel efforts to 
identify alternative iodides that might react more efficiently than 328.  
Table 4.1. Preliminary solvent screen for C(sp3)–H alkenylation with iodide 328 
 
With modest quantities of 327 in hand, Markovnikov hydration of the 1,1-
disubstituted olefin was accomplished using Mukaiyama’s protocol.11 Exposure of 327 to 
20 mol % Co(acac)2 and phenyl silane under a balloon atmosphere of O2 effected slow 
conversion to 329 and 330, as well as peroxide 331, each as a ~1:1 mixture of 
diastereomers at C8 (Table 4.2, entry 1). Increasing the catalyst loading to 40 mol % 
significantly reduced reaction time, and the addition of 2 equiv triphenylphosphine after 
workup led to the disappearance of 331, allowing isolation of 329 and 330 as the sole 
products in a combined 44% yield (entry 2). Formation of peroxide 331 was not observed 
when triphenylphosphine was present during the reaction,12 though a more complex 
reaction profile and lower overall yield was observed with the use of 1 equiv Co(acac)2 
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(entry 3). Although 329 and 330 could be separated using preparative TLC, determination 
of the configuration at C8 could not be established by 2D NMR spectroscopy.13 
Table 4.2. Mukaiyama hydration of terminal olefin 327 
 
Deprotection of the dimethylacetal in 329 was accomplished using aqueous HCl 
in THF and the crude mixture of diastereomeric lactols (332) was subjected to standard 
Ley oxidation conditions, which smoothly afforded γ-butyrolactone 333 in 74% yield, 
over the two steps (Scheme 4.4a). However, no reaction was observed when 333 was 
exposed to 2 equiv Schwartz’s reagent—a result that was quite surprising.14 Upon the 
addition of excess reagent, the reaction profile became complex. Although Georg has 
reported several examples of chemoselective reduction of amides over esters using 
Schwartz’s reagent,15 analysis of the crude reaction mixture by 1H NMR showed only the 
formation of lactol 332, with no evidence of aminoquinoline cleavage.   
Discouraged by the inability to achieve a chemoselective amide reduction in the 
presence of the lactone, attention turned to reduction at an earlier stage. Unfortunately, 
attempted Schwartz reduction of 330 also resulted in no reaction; in this case, adding 
another portion of Schwartz reagent resulted in only recovered starting material (Scheme 
4.4b). Likewise, an attempt to employ a stronger reducing agent was unsuccessful; 
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treatment of 329 with excess LiAlH4 in refluxing THF led to isolation of secondary aryl 
amine 336 in 37% yield without any evidence that the desired alcohol 337 had formed.  
Scheme 4.4. Construction of γ-butyrolactone and attempted Schwartz reduction 
 
Since these initial attempts to remove the aminoquinoline auxiliary were met 
without success, we considered that a survey of other reducing agents, or conversion to a 
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members of the broader 4,5-seco-caryophyllane sesquiterpenoid family (i.e. 301 and 
342–344, see Scheme 4.5). Thus, investigation of this route was pursued.   
Gratifyingly, smooth reductive cleavage of the aminoquinoline auxiliary was 
observed upon exposure of amide 327 to Schwartz reagent, delivering cis-aldehyde 338 
in 30% yield (Scheme 4.5). Notably, side products resulting from hydrozirconation were 
not observed, and the low yield obtained from this experiment is attributed to incomplete 
conversion of starting material, as well as the dilute reaction concentration used on small 
scale.14 Subjection of 338 to the standard epimerization protocol gave trans-aldehyde 
339, which was telescoped through a Wittig olefination with phosphonate 3165 to furnish 
enone 340 in 85% yield over the 2 steps. An initial attempt to apply the previously 
established conditions for Mukaiyama hydration of the 1,1-disubstituted olefin in 340 
Scheme 4.5. Preliminary synthetic studies toward (+)-rumphellaones A and B 
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led to the detection of new products by mass spectrometry with the desired molecular 
weight of 341; however, the structure of these (presumably) diastereomeric products 
could not be definitively confirmed by 1H NMR, due to the small scale (0.7 mg) on which 
this preliminary experiment was conducted.  Efforts to reproduce this synthetic sequence 
and confirm that Mukaiyama hydration of 340 indeed affords the desired tertiary alcohol 
341 are currently underway.  
 
4.5 CONCLUDING REMARKS AND FUTURE DIRECTIONS 
In summary, initial studies are disclosed toward a concise synthesis of the 
bioactive trans-cyclobutane-containing natural product, (+)-rumphellaone A (302). 
Although the preliminary results reveal that considerable optimization will be required to 
obtain synthetically useful yields of 327, a C(sp3)–H alkenylation reaction between (–)-89 
and vinyl iodide 328 has been realized. Moreover, a Mukaiyama hydration reaction was 
successfully employed to transform 327 into tertiary alcohol 329, which was used to 
complete the γ-butyrolactone ring of the natural product.  
Ultimately, a chemoselective reduction of the aminoquinoline auxiliary in 327 
was achieved and the corresponding aldehyde was elaborated to enone 340, which may 
serve as a precursor to a variety of naturally occurring 4,5-seco-caryophyllane 
sesquiterpenoids. Current efforts are directed toward utilizing this intermediate to 
confirm the structure of tertiary alcohol 341, which would require only a remaining 2 or 3 
steps to access (+)-rumphellaone B, and (+)-rumphellaone A, respectively. If successful, 
the implementation of this synthetic strategy would constitute the shortest route to (+)-
rumphellaone A reported to date.  
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4.6 EXPERIMENTAL SECTION 
4.6.1 Materials and Methods 
General Procedures. Unless otherwise stated, reactions were performed under a 
nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene 
chloride (CH2Cl2), tert-butyl methyl ether (TBME), toluene (PhMe), and dioxane were 
dried by passing through activated alumina columns. Methanol (MeOH) was distilled 
over calcium hydride prior to use. Unless otherwise stated, chemicals and reagents were 
used as received. All reactions were monitored by thin-layer chromatography using 
EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and were visualized by UV, 
p-anisaldehyde staining. Flash column chromatography was performed either as 
described by Still et al.17 using silica gel (particle size 0.032-0.063) purchased from 
Silicycle or using pre-packaged RediSep®Rf columns on a CombiFlash Rf system 
(Teledyne ISCO Inc.). 1H and 13C NMR spectra were recorded on a Bruker Avance III 
HD with Prodigy cryoprobe (at 400 MHz and 101 MHz respectively), a Varian 400 MR 
(at 400 MHz and 101 MHz, respectively), a Varian Inova 500 (at 500 MHz and 126 
MHz, respectively), or a Varian Inova 600 (at 600 MHz and 150 MHz, respectively), and 
are reported relative to internal CHCl3 (1H, δ = 7.26) and CDCl3 (13C, δ = 77.1). Data for 
1H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling 
constant (Hz), integration). Multiplicity and qualifier abbreviations are as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR 
spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in 
frequency of absorption (cm–1). HRMS were acquired using an Agilent 6200 Series TOF 
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with an Agilent G1978A Multimode source in electrospray ionization (ESI), or mixed 
(MM) ionization mode. 
 
4.6.2 Preparative Procedures and Spectroscopic Data 
Preparation of vinyl iodide 328.  
 
To a flame-dried 15 mL flask were added aldehyde 34110 (371 mg, 1.77 mmol) 
and freshly distilled MeOH (5.00 mL). Trimethylorthoformate (966 μL, 8.83 mmol, 5.00 
equiv) was then added, followed by p-toluenesulfonic acid monohydrate (16.8 mg, 0.088 
mmol, 0.05 equiv). The reaction was allowed to stir at room temperature for 20 minutes, 
at which time the reaction was determined complete by TLC analysis. The reaction was 
quenched with saturated aqueous NaHCO3, diluted with Et2O and the layers were 
separated. The aqueous layer was extracted with Et2O (3 x 5 mL), and the combined 
organics were dried over MgSO4, filtered, and concentrated in vacuo. The crude residue 
was purified by silica gel flash chromatography (isocratic: 6% Et2O/pentane) to afford 
328 (348 mg, 77% yield) as a colorless oil.  
 
1H NMR (400 MHz, CDCl3) δ 6.05 (q, J = 1.4 Hz, 1H), 5.70 (dd, J = 1.5, 0.7 Hz, 1H), 
4.37 (t, J = 5.7 Hz, 1H), 3.33 (s, 6H), 2.52 – 2.40 (m, 2H), 1.87 – 1.76 (m, 2H). 
 
 
 
O
I
p-TsOH•H2O
CH(OMe)3 (5 equiv)
MeOH, rt
(77% yield)
341
OMe
I
OMe328H
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Preparation of vinyl acetal 327.  
 
To each of 3x flame-dried 1 dram vials were added (–)-89 (30.0 mg, 0.118 mmol), 
328 (90.6 mg, 0.354 mmol, 3.00 equiv), Pd(OAc)2 (3.97 mg, 0.018 mmol, 0.150 equiv), 
and Ag2CO3 (32.5 mg, 0.118 mmol, 1.00 equiv). TBME, PhMe, or dioxane (590 μL) was 
then added and the vials were sealed with a Teflon screw cap under ambient conditions 
and heated to 90 °C in a preheated aluminum block for 18 hours. The reactions were then 
cooled to room temperature and each was filtered through a small plug of celite and 
washed with EtOAc until the filtrate runs colorless. The filtrates were concentrated in 
vacuo and 1,2,4,5-tetrachloro-3-nitrobenzene (5.90 mg, 0.023 mmol) was added as an 
internal standard to determine the respective yields of 327 as indicated in Table 4.1 by 1H 
NMR analysis. The reaction mixtures were then combined and purified by silica gel flash 
chromatography (10–20% EtOAc/hexane) to afford 327 (17.3 mg, 13% yield) as an 
amorphous white residue. 
 
1H NMR (400 MHz, CDCl3) δ 9.79 (s, 1H), 8.83 (dd, J = 7.1, 2.0 Hz, 1H), 8.79 (dd, J = 
4.2, 1.7 Hz, 1H), 8.14 (dd, J = 8.3, 1.7 Hz, 1H), 7.54 – 7.46 (m, 2H), 7.44 (dd, J = 8.3, 
4.2 Hz, 1H), 5.01 (dd, J = 2.1, 1.3 Hz, 1H), 4.94 (dd, J = 2.2, 1.2 Hz, 1H), 4.26 (t, J = 5.7 
Hz, 1H), 3.38 – 3.28 (m, 1H), 3.18 (s, 3H), 3.15 (s, 3H), 3.11 (ddd, J = 8.6, 2.9, 0.7 Hz, 
1H), 2.49 (t, J = 10.8 Hz, 1H), 2.10 – 1.95 (m, 2H), 1.96 – 1.89 (m, 1H), 1.82 – 1.62 (m, 
2H), 1.43 (s, 3H), 1.13 (s, 3H). 
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13C NMR (101 MHz, CDCl3) δ 171.1, 148.3, 148.1, 138.7, 136.4, 134.9, 128.0, 127.6, 
121.6, 121.3, 116.7, 109.6, 104.1, 56.3, 52.9, 52.4, 37.3, 37.0, 35.3, 30.6, 30.2, 29.3, 25.2. 
FTIR (NaCl, thin film) 3359, 3047, 2952, 2928, 2866, 2829, 1688, 1670, 1523, 1485, 
1460, 1424, 1386, 1324, 1258, 1193, 1160, 1127, 1077, 1059, 903, 826, 792 cm.-1 
HRMS (MM) calc’d for C23H31N2O3 [M+H]+ 383.2329, found 383.2340. 
 
Preparation of hydration products 329 and 330.  
 
 To a 1 dram vial containing 327 (7.40 mg, 0.019 mmol) was added dioxane (500 
μL) and O2 was bubbled through the resulting solution for 15 minutes before stock 
solutions of Co(acac)2 (80.0 μL, 0.100M, 0.008 mmol, 0.414 equiv) and PhSiH3 (100 μL, 
0.582M, 0.058 mmol, 3.00 equiv) were added successively via syringe.  The reaction was 
stirred vigorously at room temperature for 2 hours, then quenched with saturated aqueous 
Na2S2O4 and diluted with Et2O. The aqueous layer was extracted 5x with Et2O and the 
organics filtered through a small plug of Na2SO4 and concentrated in vacuo. The crude 
residue was taken up in CH2Cl2 (500 μL) and solid PPh3 (10.1 mg, 0.039 mmol, 2.00 
equiv) was added. The reaction was stirred for 1 hour, at which point analysis by LC/MS 
had indicated the disappearance of peroxide 331. The reaction mixture was concentrated 
and purified by silica gel preparative thin-layer chromatography (50% EtOAc/hexane) to 
O2, Co(acac)2,
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afford 329 (1.90 mg, 25% yield) and 330 (1.50 mg, 19% yield) each as colorless residues. 
Note: the stereochemical configuration at C8 is arbitrarily assigned.  
 
Data for 329 (major diastereomer):  
 
1H NMR (400 MHz, CDCl3) δ 9.81 (s, 1H), 8.81 (dd, J = 4.3, 1.7 Hz, 2H), 8.17 (dd, J = 
8.2, 1.7 Hz, 1H), 7.55 (d, J = 3.4 Hz, 2H), 7.54 (s, 1H), 7.47 (dd, J = 8.3, 4.2 Hz, 1H), 
6.18 (s, 1H), 4.35 (t, J = 5.7 Hz, 1H), 3.33 (s, 3H), 3.33 (s, 3H), 3.13 (ddd, J = 8.9, 2.3, 
0.9 Hz, 1H), 2.67 (dt, J = 11.1, 9.0 Hz, 1H), 2.46 (t, J = 11.1 Hz, 1H), 1.79 (ddd, J = 11.2, 
9.1, 2.3 Hz, 1H), 1.75 – 1.62 (m, 2H), 1.49 (ddd, J = 13.4, 11.6, 5.4 Hz, 1H), 1.42 (s, 3H), 
1.37 – 1.28 (m, 1H), 1.15 (s, 3H), 1.10 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 174.2, 148.3, 138.4, 136.5, 134.0, 127.9, 127.4, 122.0, 
121.7, 116.9, 105.3, 70.4, 56.1, 52.9, 52.8, 41.4, 35.8, 35.5, 34.5, 30.6, 27.2, 25.1, 24.8. 
 
Data for 330 (minor diastereomer):  
 
1H NMR (600 MHz, CDCl3) δ 9.79 (s, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.77 (dd, J = 
6.6, 2.2 Hz, 1H), 8.17 (dd, J = 8.3, 1.7 Hz, 1H), 7.58 – 7.51 (m, 2H), 7.47 (dd, J = 8.2, 
4.2 Hz, 1H), 5.99 (s, 1H), 4.28 (t, J = 5.7 Hz, 1H), 3.38 – 3.28 (m, 2H), 3.22 (d, J = 1.1 
Hz, 3H), 3.19 (s, 3H), 3.11 (dd, J = 8.9, 2.1 Hz, 1H), 2.67 (q, J = 9.5 Hz, 1H), 2.49 (t, J = 
11.2 Hz, 1H), 1.91 – 1.77 (m, 2H), 1.66 – 1.60 (m, 1H), 1.43 (s, 3H), 1.11 (s, 3H), 1.03 
(s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 174.3, 148.4, 138.5, 136.6, 134.1, 128.1, 127.5, 122.1, 
121.8, 117.0, 105.0, 70.9, 56.0, 53.0, 52.4, 41.4, 35.8, 35.2, 34.0, 30.7, 27.5, 25.0, 24.4.  
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Preparation of γ-butyrolactone 333.  
 
To a 2 dram vial containing 329 (1.70 mg, 0.004 mmol) was added a 1:1 mixture 
of THF/5M HCl (500 μL). The reaction was stirred at room temperature for 2.5 hours, 
then quenched with saturated aqueous NaHCO3 and diluted with Et2O. The aqueous layer 
was extracted 5x with Et2O and the organics filtered through a small plug of Na2SO4 and 
concentrated in vacuo. The crude lactol 332 was analyzed by 1H NMR, then concentrated 
into another 2 dram vial and dried under high vacuum. N-methylmorpholine N-oxide 
(1.13 mg, 0.010 mmol, 2.27 equiv) and previously flame-dried, activated 4Å mol sieves 
were quickly added to the vial as a solid and the atmosphere exchanged for N2 1x. CH2Cl2 
(500 μL) was then added via syringe, followed by TPAP (1.7 mg, 0.005 mmol, 1.14 
equiv) as a solid in one portion. The reaction immediately turns yellow, then brown, and 
was stirred at room temperature. Analysis of an aliquot of the reaction mixture by LC/MS 
indicated full conversion of starting material after 1 hour, at which time the reaction was 
diluted with CH2Cl2, filtered through a plug of silica gel, and concentrated to afford 333 
(1.10 mg, 74% yield) as a colorless residue that was used directly in the next step.  
 
Data for intermediate lactol 332 (mixture of diastereomers): 
 
1H NMR (500 MHz, CDCl3) δ 11.43 (s, 1H), 9.80 (s, 1H), 9.11 – 8.64 (m, 2H), 8.19 (ddt, 
J = 14.3, 6.2, 3.0 Hz, 1H), 7.59 – 7.49 (m, 2H), 7.47 (dd, J = 8.4, 4.3 Hz, 1H), 3.25 – 3.05 
O
N
H N
Me
Me
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OMeH
Me OH
5M HCl
Me
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O
O
Me
Me
O
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H N
4Å MS, CH2Cl2Me
H
O
OH
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Me
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H N
THF, rt
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(m, 1H), 2.95 – 2.43 (m, 2H), 2.14 (td, J = 11.6, 8.1 Hz, 3H), 1.67 (ddd, J = 11.8, 7.9, 2.3 
Hz, 1H), 1.42 (s, 3H), 1.26 (s, 3H), 1.23 – 1.19 (m, 1H), 1.12 (s, 3H). 
 
Data for γ-butyrolactone 333: 
 
1H NMR (600 MHz, CDCl3) δ 9.79 (s, 1H), 8.81 (dd, J = 4.2, 1.7 Hz, 1H), 8.77 (dd, J = 
7.3, 1.7 Hz, 1H), 8.15 (dd, J = 8.2, 1.7 Hz, 1H), 7.56 – 7.48 (m, 2H), 7.45 (dd, J = 8.2, 
4.2 Hz, 1H), 3.14 (dd, J = 9.4, 2.6 Hz, 1H), 3.06 (dt, J = 11.1, 9.1 Hz, 1H), 2.62 – 2.55 
(m, 1H), 2.53 (dd, J = 9.4, 3.7 Hz, 1H), 2.51 – 2.45 (m, 1H), 2.37 (t, J = 11.0 Hz, 1H), 
1.94 (ddd, J = 13.1, 9.6, 3.0 Hz, 1H), 1.88 (ddd, J = 11.1, 8.8, 2.6 Hz, 1H), 1.54 (s, 3H), 
1.42 (s, 3H), 1.23 (s, 4H). 
 
Attempted preparation of aldehyde 334.  
 
Inside a N2-filled glovebox, Schwartz reagent (1.60 mg, 0.006 mmol, 2.00 equiv) 
was added to an oven-dried vial. The vial was sealed under N2 and brought out of the 
box, where THF (250 μL) was added via syringe. To the resulting suspension was added 
333 (1.10 mg, 0.003 mmol) as a solution in 300 μL THF in a quick drip. The reaction was 
stirred at room temperature for 1 hour, at which time TLC analysis indicated that no 
reaction had occurred. The vial was sealed under a stream of N2 with a Teflon screw cap 
and pumped into the glovebox where additional Schwartz reagent (2.40 mg, 0.010 mmol, 
Me
H
O
O
Me
Me
O
N
H N
Me
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O
O
Me
Me
O
H
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then, + 3 equiv: messy333
Me
H
O
OH
Me
Me
O
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H N
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3.00 equiv) was added as a solid in one portion. The reaction was allowed to stir for an 
additional 2.5 hours, then quenched with aqueous NaHCO3 and diluted with Et2O. The 
aqueous layer was extracted 5x with Et2O and the organics filtered through a small plug 
of Na2SO4 and concentrated in vacuo. Analysis of the crude reaction mixture by TLC and 
1H NMR showed a complex mixture including 332 as the major, discernable product. 
 
Attempted preparation of aldehyde 335.  
 
Inside a N2-filled glovebox, Schwartz reagent (1.93 mg, 0.008 mmol, 2.00 equiv) 
was added to an oven-dried vial. The vial was sealed under N2 and brought out of the 
box, where THF (250 μL) was added via syringe. To the resulting suspension was added 
330 (1.50 mg, 0.004 mmol) as a solution in 300 μL THF in a quick drip. The reaction was 
stirred at room temperature for 2 hours, at which time TLC analysis indicated that no 
reaction had occurred. The vial was sealed under a stream of N2 with a Teflon screw cap 
and pumped into the glovebox where additional Schwartz reagent (3.48 mg, 0.013 mmol, 
3.60 equiv) was added as a solid in one portion. The reaction was allowed to stir for >24 
hours, then quenched with aqueous NaHCO3 and diluted with Et2O. The aqueous layer 
was extracted 5x with Et2O and the organics filtered through a small plug of Na2SO4 and 
concentrated in vacuo. Analysis of the crude reaction mixture by TLC and 1H NMR 
showed no evidence of 335, with only 330 remaining.  
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THF, rt
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w/ up to 5.6 equiv
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Preparation of aryl amine 336. 
 
The atmosphere inside a ½ dram vial containing alcohol 329 (1.40 mg, 0.003 
mmol) was exchanged for N2 3x, and THF (200 μL) was added via syringe, followed by a 
commercial solution of LiAlH4 (1M in THF, 17μL, 0.017 mmol, 5.00 equiv) at room 
temperature. The reaction turned yellow upon addition of LiAlH4. The vial was sealed 
under a stream of N2 with a Teflon screw cap and electrical tape, then heated to 65 °C in 
a preheated aluminum block for 2 hours. The reaction turns orange in the first 15 minutes 
of heating, then back to a bright yellow by the end of the reaction. Note: reaction turns 
orange/red upon exposure to ambient conditions for TLC. The reaction was then cooled 
to 0 °C, carefully quenched with a saturated aqueous solution of Rochelle’s salt, and 
diluted with Et2O. The aqueous layer was extracted 5x with Et2O and the organics filtered 
through a small plug of Na2SO4 and concentrated in vacuo. The crude yellow residue was 
purified by silica gel preparative thin-layer chromatography (50% EtOAc/hexane) to 
afford 336 (0.500 mg, 37% yield) as a yellow residue. Note: several other bands on the 
TLC plate were collected, but none contained any spectroscopic evidence of 337.  
 
1H NMR (600 MHz, CDCl3) δ 8.70 (dd, J = 4.1, 1.7 Hz, 1H), 8.04 (dd, J = 8.2, 1.7 Hz, 
1H), 7.38 (t, J = 7.9 Hz, 1H), 7.35 (dd, J = 8.2, 4.2 Hz, 1H), 7.06 (dd, J = 8.1, 1.2 Hz, 
1H), 6.76 (d, J = 7.7 Hz, 1H), 6.04 (s, 1H), 4.31 (t, J = 5.6 Hz, 1H), 3.80 (dt, J = 13.1, 7.0 
Hz, 1H), 3.47 – 3.40 (m, 1H), 3.31 (s, 3H), 3.30 (s, 3H), 2.53 (ddt, J = 18.7, 7.4, 3.5 Hz, 
LiAlH4 (5 equiv)
THF, 65 °C
OH
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Me
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Me OH
337
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3H), 1.98 (t, J = 10.8 Hz, 1H), 1.65 (ddddd, J = 30.5, 19.2, 13.7, 11.1, 5.4 Hz, 3H), 1.48 – 
1.40 (m, 1H), 1.35 (ddd, J = 13.7, 11.4, 5.4 Hz, 1H), 1.28 (s, 3H), 1.28 (s, 3H), 1.09 (s, 
3H). 
 
Preparation of cis-aldehyde 338.  
 
Inside a N2-filled glovebox, Schwartz reagent (5.50 mg, 0.021 mmol, 2.18 equiv) 
was added to an oven-dried vial. The vial was sealed under N2 and brought out of the 
box, where THF (200 μL) was added via syringe. To the resulting suspension was added 
a previously prepared stock solution of 327 (100 μL, 0.049 M in THF, 3.74 mg, 0.010 
mmol) in a quick drip. The reaction was stirred at room temperature for 1 hour, then 
quenched with aqueous NaHCO3 and diluted with Et2O. The aqueous layer was extracted 
5x with Et2O and the organics filtered through a small plug of Na2SO4 and concentrated 
in vacuo. The crude residue was purified by silica gel preparative thin-layer 
chromatography (30% EtOAc/hexane) to afford 338 (0.70 mg, 30% yield) as a pale 
yellow residue. 
 
1H NMR (600 MHz, CDCl3) δ 9.80 (d, J = 6.4 Hz, 1H), 4.95 (s, 1H), 4.86 (s, 1H), 4.33 
(t, J = 5.7 Hz, 1H), 3.31 (dd, J = 3.2, 0.8 Hz, 7H), 3.25 (q, J = 9.2 Hz, 1H), 2.69 – 2.59 
(m, 1H), 2.38 (t, J = 11.0 Hz, 1H), 2.06 (ddd, J = 11.3, 8.4, 3.3 Hz, 1H), 1.95 (dd, J = 
10.2, 6.0 Hz, 1H), 1.88 (dd, J = 10.4, 5.2 Hz, 1H), 1.79 – 1.71 (m, 1H), 1.67 (ddd, J = 
16.0, 11.8, 5.7 Hz, 1H), 1.31 (s, 4H), 1.08 (s, 3H). 
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Preparation of trans-enone 340.  
 
 
To a 2 dram vial containing cis-aldehyde 338 (0.700 mg, 0.003 mmol) were added 
KOH (3.30 mg, 0.059 mmol, 20.2 equiv), and wet methanol (300 μL). The vial was 
sealed under ambient conditions with a Teflon screw cap and allowed to stir vigorously at 
room temperature for 14 hours. The reaction was then quenched with pH 7 buffer, 
followed by a saturated aqueous solution of NH4Cl. The mixture was stirred vigorously 
for 30 seconds before being diluted with Et2O. The aqueous layer was extracted 6x with 
Et2O, and the organics filtered through a small plug of Na2SO4 and concentrated in vacuo. 
The crude trans-aldehyde 339 (0.800 mg, quantitative yield) was analyzed by 1H NMR, 
then concentrated into a 1 dram vial. The atmosphere inside the vial was exchanged 3x 
for N2, and a previously prepared stock slurry of Wittig ylide (see below: 300 μL, 0.054 
mmol, 18.6 equiv) was added using an wide-bore, 18G needle. The reaction was stirred at 
room temperature for 6.5 hours, then quenched with a saturated aqueous solution of 
NH4Cl. The reaction mixture was diluted with Et2O. The aqueous layer was extracted 6x 
with Et2O, and the organics filtered through a small plug of Na2SO4 and concentrated in 
vacuo to afford trans-enone 340 (0.700 mg, 85% yield, 2 steps) as a colorless residue. 
Analysis by 1H NMR indicated that the material was of sufficient purity to use in the next 
step without further manipulation.  
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Data for crude trans-aldehyde 339: 
 
1H NMR (600 MHz, CDCl3) δ 9.78 (d, J = 2.0 Hz, 1H), 4.83 – 4.76 (m, 1H), 4.69 (d, J = 
1.5 Hz, 1H), 4.35 (t, J = 5.7 Hz, 1H), 3.32 (s, 3H), 3.32 (s, 3H), 3.24 (q, J = 9.6 Hz, 1H), 
2.77 (dt, J = 9.4, 1.2 Hz, 1H), 2.38 – 2.30 (m, 1H), 1.98 (t, J = 8.4 Hz, 2H), 1.92 – 1.84 
(m, 1H), 1.75 – 1.72 (m, 2H), 1.27 (s, 3H), 1.16 (s, 3H). 
 
Data for crude trans-enone 340: 
 
1H NMR (600 MHz, CDCl3) δ 6.80 (dd, J = 15.9, 7.7 Hz, 1H), 6.05 (dd, J = 16.0, 1.2 Hz, 
1H), 4.75 (t, J = 1.4 Hz, 1H), 4.70 (s, 1H), 4.34 (t, J = 5.6 Hz, 1H), 3.31 (s, 6H), 2.82 (q, 
J = 9.4 Hz, 1H), 2.63 (t, J = 8.7 Hz, 1H), 1.99 (t, J = 8.2, 7.4 Hz, 2H), 1.90 (td, J = 8.8, 
8.5, 1.7 Hz, 1H), 1.75 – 1.67 (m, 2H), 1.64 (t, J = 10.4 Hz, 1H), 1.10 (s, 3H), 1.07 (s, 
3H). 
 
Preparation of Wittig ylide:5  
Inside a N2-filled glovebox, sodium hydride (95%, 10.0 mg, 0.417 mmol) and dry 
DME (1.00 mL) were added to a 1 dram vial and sealed with a septum under nitrogen. 
The vial was brought out of the box and dimethyl (2-oxopropyl)phosphonate 316 (50.0 
μL, 0.362 mmol) was added via syringe (note: gas bubbles form immediately upon 
addition). The reaction was allowed to stir at room temperature for 1 hour before another 
1.0 mL DME was added to dilute the resulting thick, white slurry (~0.181 M ylide), 
which was used directly for the methylenation of crude trans-aldehyde 339.  
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Attempted preparation of tertiary alcohol 341.  
 
 To a 1 dram vial containing 340 (0.700 mg, 0.003 mmol) were successively added 
stock solutions of Co(acac)2 (300.0 μL, 0.003 M, 0.001 mmol, 0.400 equiv) and PhSiH3 
(100 μL, 0.075 M, 0.008 mmol, 2.67 equiv), which were each prepared in dioxane and 
sparged with O2 for 15 minutes prior to use. The reaction was stirred vigorously at room 
temperature under an atmosphere of O2 for 3 hours, then quenched with saturated 
aqueous Na2S2O4 and stirred for 20 minutes before Et2O was added. The aqueous layer 
was extracted 5x with Et2O and the organics filtered through a small plug of Na2SO4 and 
concentrated in vacuo. Analysis of the crude residue by LC/MS-TOF revealed several 
peaks in the chromatogram corresponding to the expected mass of 341; however, the 
amount of material obtained was insufficient to give discernable 1H NMR signals needed 
to confirm the structure.   
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